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 i 
Abstract 
 
Germinal centres (GCs) are the sites where V-gene hypermutation and B cell selection are taking 
place. Testing specificity and affinity of GC B cell receptor by interaction with antigen on 
follicular dendritic cells (FDCs) may be an important selection process to select high affinity B 
cell clone. As antigen on FDC is present in the form of antigen-antibody immune complex, GC B 
cells are expected to have to compete with antibody to get access antigen. Initially this antibody 
will be of low affinity. However, during the course of an immune response, this affinity may 
increase. 
 
We have tested this competitive selection model by following the replacement of antibodies in 
the GC over the course of an immune response. The speed of this replacement is dependent on 
affinity. Antibody added during an ongoing GC reaction can replace antibody in the GC, but 
only, if it is of high enough affinity. Presence of high or low affinity antibodies on FDC 
influences centrocyte selection, leading to variations in apoptosis within the GC, serum affinity, 
and plasma cell output. Parallel in silico experiments support the idea that a dynamic GC 
selection threshold, dependent on the affinity of GC output cells increases affinity maturation, 
because it enhances selection efficiency over a longer period during the course of a GC reaction. 
A dynamic selection threshold may explain the termination of the GC reaction, when affinity of 
new B cell variants is not sufficient to overcome the affinity of antibodies produced outside the 
GC. 
 
IRF4 is essential for the plasma cell differentiation and Ig class switch. IRF4 mRNA and protein 
rapidly upregulate within one hour after naive B cells get stimulation with NP-Ficoll in 
QM×C57BL/6 mice, and then activated B blasts expressing intermediate level of IRF4 either go 
into the red pulp to form the early extrafollicular response by upregulating high level of IRF4, or 
travel into the follicle to differentiate into GC founding cells. IRF4 completely shuts down when 
 ii 
cells becomes proliferating centrocytes. But IRF4 expresses again in centorcytes, which have 
been committed to differentiate into the plasmablasts. Its high level expression shows the GC 
emigrants. Here IRF4 is selected as the marker for the early plasmablats appearance on the GC-T 
zone interface at the beginning of the GC reaction. And further experiments by using cytokines 
such as IL-6, IL-10, IL-21, costimulatory signals OX40, CD30 deficient mice show that these 
signals can affect the development of these early IRF4+ plasmablasts on the GC-T zone interface 
in the TD antigen response. 
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Chapter One Introduction 
1.1 Overview 
Vaccination is designed to induce the rapid production of high affinity antibodies in 
response to infection. Antibody has two important protective functions. One is the 
opsonization of microorganisms leading to their destruction by phagocytes such as 
macrophages. Another is neutralization in which antibody blocks the molecular 
interactions required for toxins and viruses to enter the body’s cells (Janeway CA 2005). 
Antibody responses derive from antigen-driven proliferation of B lymphocytes and their 
subsequent differentiation into antibody secreting cells. High affinity antibody responses 
develop via an immunoglobulin (Ig) hypermutation process that randomly generates 
antigen receptors of higher or lower affinity.   
 
In T cell dependent antibody responses, germinal centres (GCs) are the sites where B cell 
proliferation, Ig V-gene hypermutation, and B cell selection are taking place (MacLennan 
1994; Liu YJ 1997a). B cell maturation in GCs also involves Ig class switching (Liu YJ 
1996b). This thesis is concerned with the development of antibody responses in lymphoid 
tissues, focusing on the identity and the role of signals during the germinal centre 
reaction. 
 
Mutated GC B cells have to go through a Darwinian selection process in order to increase 
the affinity of their mutated B cell receptor. They test the specificity of their antigen- 
receptor by scanning over the surfaces of follicular dendritic cells (FDC), where antigen 
is held in the form of immune complex: complexes of antigen and antibodies formed 
during the response. We hypothesize that B cells receive positive selection signals during 
this interaction only if the affinity of their own antigen cell receptor can compete with the 
affinity of the antibodies in the immune complex. This may be a major mechanism, by 
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which high affinity antibody responses evolve. My first aim was to test whether antibody 
competition may act as a selection threshold mechanism for B cell selection in germinal 
centres. As antibody affinity will increase during the germinal centre reaction, higher 
affinity antibody will provide a positive feedback loop for the induction of high affinity 
GC selection. 
  
IRF4, transcription factor, is essential for plasma cell differentiation and Ig class switch 
(Klein U 2006; Sciammas R 2006). In Chapter 4, IRF4 is used as a marker for the 
germinal centre selection and plasma cell output. This shows an early appearance of 
selected germinal centre emigrants at the GC-T zone interface. Furthermore, I am 
showing results on signals for the early exit of IRF4+ plasmablasts from germinal centres. 
For this, mice deficient for cytokines and costimulatory molecules possibly involved in 
germinal centre B cell selection are used to follow plasmablasts exiting from germinal 
centres. With a combination of histology, microdissection and RT-PCR I am trying to 
define these signals and locate the site of their production. 
 
1.2 The structure and function of murine spleen 
Lymphoid organs are organized, compartmentalized cellular structures. In these organs, 
interactions between lymphocytes and with non-lymphoid cells are important for 
lymphocyte development, initiation of the adaptive immune responses, and their survival 
maintenance. The primary lymphoid organs are the bone marrow where B lymphocytes 
mature, and the thymus where precursor T lymphocytes originating in bone marrow 
undergo their maturation (Janeway CA 2005). Secondary lymphoid organs (such as the 
lymph nodes and spleen) and mucosal-associated lymphoid tissues are discrete sites 
where lymphocytes are maintained and encounter antigens to generate adaptive responses. 
Immature lymphocytes leave primary lymphoid organs where they mature in secondary 
lymphoid tissues. Mature lymphocytes recirculate through the blood and secondary 
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lymphoid tissues where foreign antigen and antigen-presenting cells can efficiently 
concentrate and activate a small number of antigen specific lymphocytes during an 
immune response (Janeway CA 2005; Bergstrom CT 2006)  
  
This thesis investigates the signals for B cell differentiation during the development of 
high affinity antibody responses in murine spleens. The spleen is central in the defence 
against blood-borne immunogens, such as foreign antigens, old or damaged cells, and 
contributes most significantly to defence against bacterial pathogesn (e.g. Salmonella 
(Brendolan A 2007) (Fig 1.1). In essence, the spleen is comprised of two functionally and 
morphologically distinct compartments: the red pulp and the white pulp (Janeway CA 
2005). The red pulp consists of a three dimensional meshwork of splenic cords and 
venous sinuses. The splenic cords compose fibroblasts, reticular fibers, and are associated 
with macrophages. This specialized structure provides an area with the unique capacity to 
filter blood and remove foreign material and old erythrocytes. The spleniccords in the 
murine red pulp are associated with are haematopoietic cells (Johnson 1975), 
lymphocytes, as well as plasma cells and plasmablasts that migrate from the follicle and 
outer T zones after antigen induced activation (Wolber FM 2002; Mebius RE 2005). 
Plasmablasts are attracted to the extrafollicular foci. Within the red pulp, it has been 
found that CD11chigh dendritic cells (DCs) which are associated with plasmablasts have a 
role in plasma cell survival (de Vinuesa CG 1999; Vinuesa CG 2000). In addition, the red 
pulp contains poorly-characterized niches that may sustain plasma cell survival (Sze DM 
2000). 
 
Bridging channels are less defined, at moment known as small areas where the follicles 
surround the T zone, enabling the T zone to makes direct contact with the red pulp. 
Bridging channels are the exits for recirculating B cells and T cells from the white pulp 
(Bajenoff M 2008) and also an exit point for plasmablasts generated in extrafollicular foci 
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in the adjacent red pulp (Jacob J 1991; Liu YJ 1991; Toellner KM 1996). Antibody 
forming cells temporarily reside in these channels after antigen challenge (Leenen PJ 
1998).  
1.2.1 T zone 
The T zone lies at the centre of each white pulp, surrounding the central arteriole. It 
largely contains T cells, but also comprises interdigitating DCs, and B cells after 
activation. The boundary of the T zone and the follicle (also called the outer T zone) is 
the site of interaction between activated B cells with primed T cells (Toellner KM 1996; 
Garside P 1998). Recirculating T cells in the blood travel though the marginal zone (MZ) 
into the T zone, and then test their T cell receptor (TCR) against the antigen presented in 
the context of MHC class I or II molecules or CD1d by DCs, this initiates the process of 
T cell priming (Austyn JM 1988; Stoll S 2002; Mempel TR 2004). These T cells enter 
cell cycle and then migrate to the outer T zone by co-expressing CCR7 and CXCR5 
(Hardtke S 2005). They interact with primed B cells that have taken up and processed 
antigen via their BCR at the boundary of the T zone and the follicle (Toellner KM 1996; 
Okada T 2005). B cells are induced to migrate to these areas in both TI and TD responses 
(de Vinuesa CG 1999b; Okada T 2005; Hsu MC 2006)  
 
1.2.2. The follicles  
The follicles (B cell areas) surrounding the T zone are found at bifurcation sites of the 
central arterioles (Ward JM 1999). They are predominantly composed of recirculating B 
cells with few follicular dendritic cells (FDC) and CD4+ T cells (van Rees 1996; Tew JG 
1997). Characteristically, recirculating B cells are IgDhigh, IgM+, CD23high, CD21+, 
B220high (Coffman RL 1981; Gray D 1984; Grey HM 1984; Ling NR 1987). They are 
found throughout primary follicles and are in a constant state of migration between the 
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follicles of secondary lymphoid tissues (Nieuwenhuis P 1976). Primary follicles contain 
naïve recirculating B cells, the FDC network, and no germinal centres (GC) whilst 
secondary follicles contain GCs, which form upon antigenic stimulation. Germinal 
centres contain activated GC B cells, FDCs, tingible body macrophages, T cells and 
apoptotic B cells. GCs are the sites of somatic hypermutation and Ig class switching 
(MacLennan 1994).  
  
Recent evidence indicates that in lymph nodes recirculating B cells (naive B cells) can 
take up antigen from macrophages and FDCs in the first few days following antigen 
administration (Phan TG 2007; Suzuki K 2009). FDCs have been considered to be 
responsible for antigen presentation to B cells in secondary lymphoid organs. They can 
retain the extracellular antigen in a plasma membrane-associated form in the follicles for 
months after immunization (Nossal G 1968; Batista FD 2009). Furthermore, it is known 
that FDCs in follicles can mediate the retention of antigen in the form of immune 
complex (Mandel T 1980; Tew JG 1980) through complement receptors (Chen 1978; Tew 
JG 1997) and Fc receptors (Yoshida 1993; Qin D 2000). The special arrangement of 
immune complex on FDCs has been found to promote B cell somatic hypermutation in 
vitro and vivo (Song H 1998; Sukumar 2008; Wu Y 2008). Also, FDC are considered to 
be potent accessory cells during B cell activation, possibly secreting chemokines and/or 
FcγRIIB (Tew JG 1980; Tew JG 2001). The detail about the role of FDCs derived 
immune complex on somatic hypermutation and antibody production will be further 
discussed in Chapter 3.  
 
The importance of CD3–CD4+ adult lymphoid tissue inducer cells (LTi cells) in 
organising the development and perhaps the maintenance of secondary lymphoid organs 
has been highlighted (Mebius 2003; Lane PJ 2005). Signals from LTi cells are sufficient 
to regulate T cell organisation and the expression of podoplanin and CCL21 on T zone 
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stoma (Withers DR 2007). Furthermore, adult LTi cells may have a role for high quality 
memory B cell responses ((Lane PJ 2005) and papers from Lane group). Adult LTi cells 
associate closely with VACM+ FDCs in follicles where they foster the survival of 
follicular T helper cells in GCs, as well as with the VACM+ stroma population within the 
B-T zone interface where LTi cells foster the survival of memory T cells (Kim MY 2007).   
 
1.2.3. The marginal zone 
The marginal zone (MZ) is a unique region of the spleen that is situated at the interface of 
the red pulp and white pulp (the T zone and B cell follicles) (Cesta 2006). The MZ 
contains reticular fibroblasts, B cells, marginal zone macrophages and dendritic cells 
(Martin F 2002; Mebius RE 2005; Cesta 2006). Marginal zone macrophages form the 
outer ring of macrophages, characterised by expression of the C-type lectin SIGNR1, the 
receptor for blood-borne antigen (Geijtenbeek 2002; Kang YS 2003; Karlsson MC 2003), 
and the type 1 scavenger receptor MARCO that is important for the uptake of various 
bacteria (Elomaa O 1995). Marginal zone metallophilic macrophages form an inner ring 
of the marginal zone adjacent to the follicles and T zone (Munday J 1999). The inner 
limit of the MZ blood sinusoids and peripheral to marginal zone metallophilic 
macrophages is the marginal sinus (MS). It is continuous with vessels that feed the 
capillary beds of the white pulp (Mebius RE 2005; Cesta 2006). The cells in the MZ 
come into contact with the blood from the MS (Schmidt EE 1988). Therefore, the MZ is 
considered to screen the systemic circulation for antigens and pathogens, having an 
important role in antigen processing. The MS is the transit area at which both 
recirculating T and B cells leave the bloodstream and enter the white pulp (Mebius RE 
2005) (Fig 1.1). MZ B cells are a unique subset, and are distinct from follicular B cell 
(discussed in detail in section 1.3.3).  
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Figure 1.1: The structure of the white pulp of the murine spleen 
The murine white pulp mainly consists of the T zone and the B cell rich follicles. T zones 
are surrounded by follicles. The follicles are separated from the marginal zone (MZ) by 
the marginal sinus (MS). Extra follicular plasma cell foci (EF) are formed at the bridging 
channels where the red pulp abuts the T zone early during antibody responses. Germinal 
centres (GC) form in the follicle after antigen stimulation.  
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1.3 B cell subsets 
B cells develop from pluripotent haemopoietic stem cells in the liver during mid-to-late 
fetal development, and in the bone marrow after birth. They can provide humoral 
immunity by producing soluble immunoglobulin against free antigen in solution (Stites 
DP 1994). B cells are divided into distinct subsets: B-1, recirculating B2 and MZ B cells. 
Additionally, in the mouse B-1 cells are subdivided into B-1a which express CD5, so 
called CD5+ B cells, and B-1b, which do not express CD5. B-1 are a minority subset of B 
cells comprising about 5 % of all B cells in adult mice and humans (Janeway CA 2005). 
B-1a, B-1b, and recirculating B2 cells undergo distinct developmental pathways. 
(Montecino-Rodriguez E 2006; Tung JW 2006), and MZ B cells can originate from all 
three kinds of cells. However, all B cells follow a common initial developmental pathway, 
originating from haematopoietic B cell precursors (Hardy RR 2001; Tung JW 2006). This 
thesis mainly focuses on recirculating B2 cells, also called recirculating follicular B cells. 
 
1.3.1 Recirculating B2 cells and their development 
B2 cells represent the major B cell population in the body. Their Ig repertoire is diverse 
with random VDJ segment usage and extensive N-additions (Feeney 1990). During adult 
life there is a continued low level input of newly formed B cells into the recirculating 
pool. Recirculating B2 cells have a limited capacity to respond to TI antigens (Lane PJ 
1986). The rearrangement of V, D, and J Ig genes is a fate decision step for developing B 
cell in the bone marrow, which is initiated during the intermediate pro-B stage, termed 
antigen independent diversification. This, unlike class switching, is not dependent on 
antigen activation. The rearrangement process is not analogous to that of Ig class switch 
recombination (CSR), however, both involve somatic DNA recombination to improve the 
antibody repertoire.  
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Once a functional and fully formed IgM molecule composed of a successfully rearranged 
H and L chain, is expressed on the cell, the cell immediately becomes an immature B cell, 
whilst highly self-reacting newly-formed B cells are induced to die. However, some 
immature B cells which have autoreactive BCR can be eliminated to become tolerant or 
anergic (Rolink A 1994). Immature B cells leave the bone marrow to undergo further 
differentiation to become mature B cells that co-express IgD, which is accomplished by 
alternative mRNA splicing (Janeway CA 2005). 
 
Immature B cells can enter the circulation and then T zone of the spleen (MacLennan IC 
1986). A proportion of these cells are selected either to mature and become recirculating 
B2 cells that enter the follicles, or to become MZ B cells (Bazin H 1987). The precise 
mechanism by which this selection occurs is only partially understood, but it appears to 
involve a process that at least in part, BCR specificity (Cariappa A 2002), non-specific 
factors, such as B cell-activating factor (BAFF), are also necessary for B2 cell maturation 
and survival (Schiemann B 2001). Some polyreactivity, including self-reactivity of BCR 
may drive B cells to become MZ B cells or B-1 cells (Kanayama N 2005; Xing Y 2009). 
Most of the immature B cells (about 90%) die within 1-3 days upon arrival in the spleen 
if they are not selected to mature in the periphery (Chan EY 1993). While the life span of 
mature recirculating B2 cells is five to six weeks (Calame KL 2003), the life span of MZ 
B cells is probably in the range of months (Carvalho TL 2001). 
 
1.3.2 B-1 cells 
The B-1 pool is largely found in the peritoneal, pleural cavities and lamina propria, with 
only a few B-1a cells residing in the spleen and lymph nodes (Hardy RR 1994; Hsu MC 
2006). They mainly derive from foetal liver and omentum (i.e. B-1a) in the mouse, 
although small number of cells can be produced in adult life (Wortis HH 2001). The B-1 
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cells do not, or express a low levels of CD45RA compared to B2 cells which express 
higher level (Montecino-Rodriguez E 2006). In addition, the phenotype of B-1 cells 
shares some phenotypic features with that of MZ B cells; they are both IgMhiIgDlow/- and 
CD21+CD23low/- (Janeway CA 2005). Mouse peritoneal B-1 cells additionally express 
CD11b, which is down-regulated in splenic B-1 cells (Martin F 2001b). Within this 
population, cells not expressing CD5 are referred to as B1b cells as opposed to CD5+ 
B-1a cells (Hardy RR 2001).  
 
B-1 cells, unlike B2 cells arise from a development pathway independent of IL-7 
signalling but dependent on CD19 expression (Carvalho TL 2001). The possible reason is 
that in mature mice B-1 cell numbers are maintained by self-renewal by ubiquitous self 
and environmental antigens, rather than from haemopoiesis. In addition, Esplin (2009) 
found that B1 cells could be derived from both early lymphoid and common lymphoid 
progenitors (Esplin BL 2009). The expression of CD19 affects the fate of B-1a and B-1b 
cells. For example, overexpression of CD19 during mouse development produces more 
B1a than B1b cells, and the opposite effect is observed in CD19 knock-out mice (Haas 
KM 2005). CD19 and CD21 are important in synergising the BCR signal transduction, 
whilst CD5 may inhibit BCR signalling via SHP-1 (Sen G 1999).  
 
B-1 cells have a low threshold of activation compared to B2 cells (Fagarasan S 2000). 
They can form plasmablasts in extrafollicular foci, and differentiate into plasma cells in 
the spleen (Hsu MC 2006) omentum (Ha JP 2006) and lamina propria of the gut (Rosado 
MM 2009). B-1 cells can produce natural antibody (Hardy RR 2001), largely composed 
of IgM or secretory IgA. They may promote TD contact sensitivity responses when they 
move into the spleen within 24 hours to secrete IgM (Itakura A 2005). B-1a cells can 
respond to TI antigens (i.e. polysaccharide antigens, NP-Ficoll) (Hsu MC 2006), which 
engage their BCR. Recently they were found to be responsible for the early response to 
 17
Salmonella Typhimurium (Gil-Cruz C 2009).  
 
The BCR repertoire of B-1 cells is limited, with no N-nucleotide additions in VH-D or 
D-JH joints, possibly because B-1 cells develop early (when TdT is not expressed). 
Consequently, this restricts the range of VH regions used and antigen-binding specificities 
(Feeney A J 2000). Therefore B-1 cells carry out a more primitive, less adaptive, immune 
response than conventional B2 cells.  
 
1.3.3 Marginal Zone B cells 
Marginal zone B cells usually reside in the marginal zone of the white pulp. They appear 
to be resting mature B cells but they express different surface proteins from follicular B 
cells. Phenotypically they are characterised by the following expression profile: 
IgMhighIgDlow/- and CD21highCD23low/-, and do not express CD5 or CD11b in mice, unlike 
B1a cells (Balazs M 2002; Hsu MC 2006). However, some MZ cells are switched and do 
not express IgM or IgD (Pape KA 2003). 
 
Margnal zone B cells have several origins: immature B2 cells can be recruited directly 
into the MZ B cell pool (Balazs M 2002), and recirculating B cells can be recruited to 
become MZ B cells (Kumararatne DS 1981; Vinuesa CG 2003). B-1 cells might also be 
recruited into the MZ pool (Martin F 2000; Pillai S 2005). Furthermore, memory B cells 
colonize the MZ B cell population (Liu YJ 1988; Toellner KM 1996) and are known as 
MZ memory B cells, which are largely derived from the GC (Dunn-Walters DK 1995). 
 
Marginal zone B cells are ideally located to respond blood-borne pathogens. They leave 
the MZ stroma on activation. Both TD and TI-2 antigen activation can promote their 
movement into the out T zone (Liu YJ 1988; Vinuesa CG 2001). MZ B cells actively 
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transport antigen-antibody complexes to FDCs via their CR1/CR2 receptors (Gray D 
1984; Molina H 1996). In addition, activation with LPS (Pettersen JC 1967) or via their 
Fc receptors (Brown JC 1970) induces the migration of MZ B cells to follicles.  
 
Marginal zone B cells continuously shuttle back and forth between the MZ and the 
follicles (Cinamon G 2008). The movement of MZ B cells to the follicle is mainly 
dependent upon the up-regulation of CXCR5 which enables migration towards CXCL13, 
produced by FDCs in the follicles, whereas return to the marginal zone requires the 
sphingosine 1-phosphate receptor (S1P1) and to some extent S1P3 present in the blood in 
the MZ sinusoids (Lu TT 2002; Cinamon G 2004; Cinamon G 2008). 
 
Marginal zone B cells are very easily activated (Oliver AM 1997), and in particular are 
rapidly recruited into both TD and TI extrafollicular antibody responses (Liu YJ 1991; 
Toellner KM 1996). They can produce natural antibodies together with B1 cells as the 
main source of natural antibody (Pillai S 2005). Their high expression of complement 
coreceptor CD21 enables them to respond actively to TI-2 antigens (Zandvoort A 2002), 
some of which fix complement and bind C3d without the requirement for prior 
interaction with soluble Ig. They also have the capacity to form GCs (Song H 2003).   
 
1.4 B cell activation 
1.4.1 T cell dependent activation  
Most of B cell responses considered are dependent upon T cell help and are thus known 
as thymus dependent (TD) antibody responses. There are two separate stages in the 
process by which T cells help B cells to make antibody. The first step requires physical 
contact between the B and T cell, and specific recognition of peptide presented by the B 
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cell in association with its class II MHC molecules, and co-stimulation via B7.1 or B7.2 
molecules on B cells and CD28 on T cells. Once activated through physical interaction 
with a T cell, B cells can respond in a non-cognate fashion to molecules that are produced 
and released from T cells or other cells (Janeway CA 2005). 
 
Naïve T cells are unable to provide help for B cells until they become primed by antigen 
presenting cells, including B cells or dendritic cells (DCs). The later are found in the T 
cell rich areas of secondary lymphoid organs. In vivo studies demonstrated that 
antigen-charged B cells focus on interacting with T cells activated by DCs (Toellner KM 
1998). It takes at least 2 days before sufficient numbers of primed T cells are available in 
T zone (PALS) to activate B cells (Hodgkin PD 1996). 
 
When the primed T cell recognizes antigen presented by the B cell, it provides signals 
such as OX40 and CD40-Ligand that result in the local growth of both cell populations 
(MacLennan IC 2003). By day 4 after immunization, activated B cells proliferate and 
differentiate along two divergent pathways (Shih TA 2002a). After two cell cycles, B cells 
are induced to become plasmablasts, migrating from the out T zone to the local site of 
extrafollicular growth (the extrafollicular antibody response): the red pulp of the spleen, 
and the medullary cords in lymph nodes, and they then differentiation into early plasma 
cells which characteristically produce non-mutated low affinity antibody. Expression of 
the chemokine receptor CXCR4 by plasmablasts may be responsible for the migration of 
plasmablasts to extrafollicular foci (MacLennan IC 2003). Plasmablasts proliferate 
extensively for 3 days in extrafollicular foci before they differentiate into plasma cells 
(Sze DM 2000). Non-dividing plasma cells synthesize and secrete large amounts of Ig. 
Most plasma cells lost from the spleen after 2-3 days and only a minority of cells 
surviving as long-lived plasma cells (Smith KG 1996; Sze DM 2000). The other activated 
B cells travel to follicles and begin proliferating to form germinal centres by day 7 after 
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primary immunization (known as the follicular response) (Toellner KM 1996). (The basic 
pathways of B cell migration after stimulation see Fig 1.2) 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: B cell activation 
The primed T cells help B cell activation, and then activated B cells travel to the outer T 
zone, some differentiate into the early plasmablasts in extrafollicular foci, and others go 
to the follicle to form germinal centres (BC: B cell, TC: T cell, PC: Plasma cell) (Taken 
from Dr. K-M. Toellner) 
 
Mice that are primed with antigen and are then challenged with the same antigen some 
weeks later undergo a secondary immune response. The onset of B cell proliferation in 
this response is shortened to less than 12 hours, as T cell help is readily available due to 
memory through previous antigen encounter (Toellner KM 1996; Sze DM 2000). The 
extrafollicular plasmablast response is seen between 2 and 3 days when those B cells that 
have moved into the red pulp begin to divide exponentially. By day 4 most of these cells 
have left cell cycle and become terminally differentiated plasma cells. GCs are seen by 
day 3 after immunization, but these are smaller than those formed during the primary 
response (Toellner KM 1996). This is probably due to the fact that memory B cells are 
more likely to differentiate into plasma cells, whilst naïve B cells prefer the germinal 
centre pathway (Arpin C 1997). 
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1.4.2 T cell independent activation 
B cells can be activated by some antigens without T cell help. These antigens are 
characterized by their ability to induce immune responses in nude, athymic mice (Vinuesa 
CG 2000) and fall into two main classes: T independent type 1 (TI-1) antigens such as 
lipopolysaccharide (LPS) which is associated with the outer layer of the cell membrane of 
Gram-negative bacteria. LPS can stimulate responses not only in mature B cells but also 
in neonatal B cells. TI-1 responses exhibit little evidence of memory. These antigens are 
recognized by innate B cell surface receptors such as TLR4 and CD21 that can deliver 
costimulatory signals to B cells (Shih TA 2002b).  
 
TI-2 antigens possess characteristics embodied by polysaccharide antigens. These 
antigens cannot evoke antibody responses in humans until several months after birth, and 
full adult responses to them do not develop until 5 years old (Murray CJ 1997). They do 
not elicit strong memory responses (Mond JJ 1995), although some development of 
memory B cell-like cells has been described (Obukhanych TV 2006). Due to their 
presence of repeating epitopes, these antigens have the capacity to induce a substantial 
amount of surface Ig cross-linking between B cells that provides a strong signal of 
activation (Vinuesa CG 2001). 
1.4.3 Haptens 
Hapten molecules have been used to study antigen and their interaction with antibody, 
because they are small defined structures that are good B cell antigens. They are unable to 
induce antibody responses on their own, and have to be conjugated to immunogenic 
proteins. Carrier proteins (such as Chicken Gamma Globulin, CGG) can induce T cell 
help, resulting in the induction of hapten specific antibody responses. The same haptens 
can also be conjugated to TI carriers (e.g. Ficoll) making it possible to study TI responses. 
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Therefore, it is possible to produce transgenic mice that have hapten-specific BCR to 
both types of responses (Janeway CA 2005). 
 
The hapten 4-hydroxy-3-nitrophenol (NP) conjugated to a variety of carriers has been 
used for several decades to provoke a restricted immune response in mice. It has the 
attraction of inducing a canonical response which is highly biased towards Igλ light chain 
and the IgH chain V segment-V186.2-DFL16.1-Jh2 (Bothwell AL 1981). Therefore, it 
has been used to study somatic hypermutation (SHM) and affinity maturation when it is 
conjugated as immunogens such as NP-CGG and NP-Ficoll (Bothwell AL 1981; Azuma 
T 1987; Maizels N 1988). 
 
1.5 B cell responses in Germinal Centres  
1.5.1 T cell dependent immunization 
Within 3 days of immunization naïve T cells are primed on interdigitating dendritic cells 
in the T zone (Luther SA 1997; Toellner KM 1998). B cells that have interacted with 
primed T cells in the outer T zone migrate into follicles, where they form GCs, which are 
a hallmark of the TD adaptive immune response. In GCs B cells proliferate and undergo 
SHM of their Ig genes, after which mutant clones that have acquired increased affinity for 
antigen (affinity maturation) are selected. These high-affinity cells form the progenitors 
of both the long-lived antibody-secreting plasma cells and the memory B cells that 
sustain serological immunity after infection (MacLennan 1994).  
 
As the GC expands non-responding IgD+ B cells are displaced and form the follicular 
mantle. B blasts proliferate and within about 4 days the GC reaches peak size (Liu YJ 
1991). During this time the mature GC segregates into distinct dark and light zones (Liu 
YJ 1992; Camacho SA 1998). Earlier studies showed that molecules such as chemokines 
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CXCR4 and CXCR5 are very important for GC organization (Allen CD 2004), however, 
the details of GC organization still remain unclear. The GC light zone can be 
differentiated into the inner and the outer light zone. While the inner light zone is 
abundant in FDCs, the outer light zone, which is adjacent to the follicular mantle, is rich 
in T helper cells (MacLennan 1994).  
 
The dark zone (DZ) contains the bulk of proliferating centroblasts. Centroblasts were 
named for their appearance as large mitotically active cells that lack surface Ig. The 
prevailing view is that SHM and class switch recombination takes place in the DZ 
(MacLennan IC 2003). This represents the first step in affinity maturation, and since base 
changes are introduced stochastically, it results in Ig with a wide range of affinities for the 
immunizing antigens. The light zone (LZ) is located distal to the T cell-rich area adjacent 
to the primary follicle. This is where FDCs, T cells and centrocytes differentiated from 
centroblasts, are located. FDCs have the unique capacity to present antigen to centrocytes 
in the form of antigen-antibody complexes containing various Ig isotypes with different 
affinities (Kosco-Vilbois 2003). 
 
Antigen in immune complex that is bound by antigen-specific GC B cells may be taken 
up, processed and presented to antigen-specific follicular helper T cells (TFH) to raise T 
cell help (MacLennan 1994; Liu YJ 1996a). Centrocytes test their new surface Ig antigen 
receptors against antigen displayed on FDCs. Interaction with TFH may lead to migration 
back to the DZ which may result in further proliferation, SHM and selection, leading to a 
further improvement of antigen receptor affinity (MacLennan 1994; Liu YJ 1997a; 
Camacho SA 1998). Finally centrocytes expressing high-affinity and non-self-reactive 
antibody may be positively selected to differentiate into long-lived plasma cells or 
memory B cells. This most likely occurs in the LZ (Cattoretti G 2006a). By contrast, low 
affinity or self reactive centrocytes undergo apoptosis, either because they are not 
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stimulated through their B cell receptors, or because they do not find self-antigen specific 
T cells to interact with (Shokat KM 1995; Shih TA 2002a). Thus centrocyte selection 
mediated by TFH cells within GC provides the basis for affinity maturation of the 
antibody response and B cell memory formation. The signals that initiate centrocyte 
differentiation into either memory cells or plasma cells are poorly understood. 
 
1.5.1.1 Somatic Hypermutation and Class switch recombination 
Centroblasts undergo SHM of their BCR V, D, and J genes in the GC, which leads to 
refinement and changes in the specificity of the humoral immune response. SHM is a 
mutational process used to create additional diversity after functional Ig genes have been 
assembled. High rates of point mutations are randomly introduced into the H and L chain 
V-region exon, leading to either an increase or decrease in the affinity of the resulting Ig 
for its target antigen, known as “affinity maturation” (Stites DP 1994; Jacobs H 2001; 
Kenter AL 2004). Activation-induced cytidine deaminase (AID) is the first of a complex 
series of proteins that initiate SHM of the antibody V region that encodes the 
antigen-binding site (Review on (Peled JU 2008)). 
 
Class switch recombination (CSR) is the mechanism by which the IgV regions are 
recombined with different heavy chain genes, to produce other classes beyond IgM. This 
alters the effector function of the antibody, but not the specificity. CSR can be activated 
by T cell dependent signals, i.e. CD40 ligation, together with T cell derived cytokine 
signals. For example, in mice, CD40 ligation with IL-4 production, characteristic of Th2 
responses, classically induces switching to IgG1 and IgE. In contrast CD40 ligation with 
IFNγ (Th1 response) is associated with switching to IgG2a (Toellner KM 1998). CSR can 
also occur in TI extrafollicular responses. For instance, TI-1 antigens in mice induce 
mainly IgG2b production, while TI-2 antigens induce switching predominantly to IgG3 
(Perlmutter RM 1978). 
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Recent studies demonstrated that commonly CSR results from the fusion of an upstream 
switch (S) region to a downstream S region with the deletion of intervening DNA on 
heavy chains (Fig1.3). Recombination of DNA occurs in the switch region and depends 
on the inducer (I) exon, a small exon upstream of the switch region, and the switch region 
that precedes the heavy chain constant region (Harriman GR 1996; Manis JP 2002). 
Transcription from the І promoter can result in the production of a sterile germline heavy 
chain transcript (Stavnezer-Nordgren J 1986). CSR will only occur if this transcript is 
produced and spliced (Lorenz M 1995; Hein K 1998).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: The mechanism of CSR illustrated by the switching to IgG1 
Transcription occurs from Iγ1 locus and a germline switch transcript is produced. This is 
spliced and switching occurs via the looping out of the intervening DNA. This results in a 
switch circle and a rearranged heavy chain transcript. (Taken from Dr. K-M Toellner) 
 
+
Iγ3
Cμ
Cδ
Sγ3
Cγ3
Iγ1
SμSγ1
switch
circle
Iμ Cγ1
Sγ1V    DJ Iμ Sμ
Cγ1
μ-γ1 switched transcript
IgG1 switched DNA
V    DJ Iμ Sμ Cμ Cδ Iγ3 Sγ3 Cγ3 Iγ1 Sγ1 Cγ1
transcription
Iγ1
Iγ1 Sγ1 Cγ1
Cγ1
IgG1 switch transcript
SμV    DJ Iμ Sγ1
Cγ1
Iγ3
Cμ
Cδ
Sγ3
Cγ3
Iγ1
 26
AID is also required in this process, this enzyme converts cytosines in both S regions, 
inducing breaks in the DNA. This allow the excision of the intervening regions and the 
production of a switch circle (Schrader CE 2005). As a consequence of this process, a 
U:G mismatch in the Ig locus may be repaired through uracil removal by uracil-N- 
glycosylase (UNG) or by base-excision repair and mismatch repair (de Yebenes VG 
2006). Mutations in the AID gene lead to deficits in CSR, SHM and gene conversion of 
IgV genes (Muramatsu M 2000; Kenter 2005). Mice deficient in AID have a form of 
hyper IgM syndrome type 2, characterized by the presence of large TD GC, but with 
minimal hypermutation and class switching (Revy P 2000). AID expression is restricted 
to GC B cells, and its expression and activity are highly regulated even though it is 
unclear as to how AID is targeted to the Ig locus (Review on (Stavnezer J 2008). For 
example, miRNA 155 has been shown to downregulate AID expression (Dorsett Y 2008; 
Teng G 2008) whilst miR-181b could inhibit AID expression and subsequently CSR to γ1 
(de Yebenes VG 2008). IL-4 and anti-CD40 stimulation could activate AID expression, 
possibly through binding signal transducer and activator of transcription (STAT6) and 
nuclear factor kappa light polypeptide gene enhancer in B-cells (NF-κB) to the 5’ 
promoter region (Dedeoglu F 2004). Transcription factors including E proteins (Sayegh 
CE 2003), Pax5 (Gonda H 2003), IRF8 (Lee CH 2006) and IRF4 (Sciammas R 2006) 
may have a role for AID expression. Furthermore, the activity of AID requires replication 
protein A (RPA) (Chaudhuri J 2003) and phosphorylation by protein kinase A (PKA) 
(Basu U 2005; Pasqualucci L 2006). 
 
1.5.2 TI immunization resulting in germinal centre formation 
We have previously observed that GCs can also be induced by the TI-2 antigen NP-Ficoll, 
when high frequencies of B cells contain an antigen-specific B cell receptor, for example 
in quasimonoclonal (QM) mice (Vinuesa CG 2000). Extrafollicular foci develop within 3 
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days as in a wild-type the response to NP-CGG. GCs are easily detected 3 days after 
immunization, with the similar kinetics as in the secondary TD immune responses 
(Vinuesa CG 2000; Lentz VM 2001; Toellner KM 2002). But unlike the GC induced by 
TD antigen, TI GC does not contain T cells and spontaneously abort by 5 days 
post-immunization. Extrafollicular plasma cells and GC cells produced have been found 
to undergo a very limited mutation, but significant amount of Ig V-region recombination. 
The predominant antibodies produced are IgM and IgG3 (Toellner KM 2002). This also 
suggested that GC B cell survival, selection and differentiation all require T cell help. 
Germinal centre B cells in the TI response, like their TD counterparts also express the 
known GC B cell markers such as PNA, GL-7, Fas, and have downregulated IgD 
(Vinuesa CG 2002). 
 
1.5.3 B cell lymphoma 6 (Bcl-6) 
The Bcl-6 proto-oncogene encodes a nuclear transcriptional repressor, with pivotal roles 
in the GC formation as well as the regulation of lymphocyte function, differentiation, and 
survival (Jardin F 2007). Bcl6-deficient mice display normal B cell development but lack 
germinal centre development and affinity maturation (Dent AL 1997; Ye BH 1997). The 
Bcl-6 is protein highly expressed on germinal centre B cells. Naïve B cells also contain 
Bcl-6 mRNA and but do not produce detectable amounts of the protein, indicating that 
Bcl-6 expression is regulated at the post-transcriptional or post-translational level 
(Allman D 1996). 
 
Bcl-6 has some important functions for GC B cells, including promoting cell cycle 
progression and inhibiting differentiation (Tarlinton D 2008b). Firstly, Bcl-6 suppresses 
apoptosis and cell cycle arrest via suppression of the p53 and p21, associating with 
N-CoR SMRT or B-CoR together to transcriptionally repress of genes (i.e. ATR). This 
 28
suppression could enable GC B cells to undergo vigorous proliferation while undergoing 
genetic remodelling by SHM and CSR without eliciting the growth-arrest and apoptotic 
responses seen in other cell types (Ranuncolo SM 2007; Ranuncolo SM 2007). Secondly, 
Bcl-6 inhibits the expression of genes involved in B cell activation such as CD69, CD44, 
STAT1 (Shaffer AL 2000) and CD80 (Niu H 2003). This serves to prevent premature 
activation of B cells before they have completed proliferation and SHM. Thirdly, Bcl-6 
may inhibit the differentiation of GC B cells into plasma cells (Falini B 2000; Basso K 
2004) and differentiation into memory B cells (Kuo TC 2007).  
 
1.5.4 Migration within the Germinal Centre 
The dynamic model of GC B cell development described above has been termed the 
“Cyclic-re-entry” model (Brink 2007). Recently, Haberman et al (2003) proposed a dark 
zone selection model in which recognition of soluble antigen within the DZ may permit B 
cell selection and proliferation, and movement into the LZ resulting in B cell 
differentiation (Haberman AM 2003). Some cell types (e.g. proliferating and apoptotic B 
cells and tingible-body macrophages) proposed to be required for selection are accessible 
in the DZ, at either the DZ periphery or at the follicle-T zone interface (Camacho SA 
1998; Haberman AM 2003; Hauser AE 2007a). In mature GCs, portions of the DZ base 
are in direct contact with the adjacent T zone which contains activated T cells and DCs 
during the TD response (Grouard G 1996; Pape KA 2003; Okada T 2005). Houser et al 
(2007b) suggests that DCs in the T-B zone interface are theoretically capable of providing 
some signals similar to those thought to be provided by FDCs, including presentation of 
retained, intact antigen (Wykes M 1998; Bergtold A 2005; Qi H 2006). 
 
The recent development of intravital multiphoton microscopy has allowed visualization 
of immune cells (e.g. antigen specific GC B cells, naïve resting B cells, and FDCs) when 
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they move through living lymphoid tissues. These powerful techniques (combining 
genetic and physical labelling techniques) can provide valuable insight into some of the 
GC development processes largely derived from histology. Three independent studies 
reveal consistent findings that alter the conventional picture of GC B cell behaviour 
(Schwickert TA 2007; Allen CD 2007a; Hauser AE 2007b). Although there are some 
debates, their observations all suggest that at least in mice, the phenotypes of GC B cells 
in these LZ and DZ may not be as different as what was previously thought (Fig 1.4). The 
studies by Allen and Hauser show that GC B cell proliferation occurs in both LZ and DZ. 
Allen (2007a) proposes that B cells may compete not only for antigen but also for T cell 
help. Migration of B cells between the LZ and DZ can occur at relatively low frequencies, 
but can also be quite extensive (Schwickert TA 2007). Therefore, Hause et al (2007b) 
revised the classic GC migration “cyclic re-entry model”, and suggested an “intra-zonal 
circulation model” (Figure 1.4) (Detailed review regarding in vivo imaging of GC 
development see (Allen CD 2007b; Hauser AE 2007b). Currently germinal centre B cells 
can be observed by intra-vital microscopy only for very short time-spans, these 
observations are still controversial, and further studies are needed (Allen CD 2007b). 
Reanalysis of the intravital data using computer modelling further suggests that current 
observation times are too short to provide significant data on recirculation, and the data 
currently available are still compatible with the traditional ‘cyclic re-entry model’ (Figge 
MT 2008; Meyer-Hermann ME 2009).  
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Figure 1.4: Conventional and revised views of germinal centre B cell morphology 
and migration 
Germinal centers (GCs) form within the primary B cell follicle and consist of light zone 
(LZ) and dark zone (DZ), which are distal and proximal to the T cell zone, respectively. 
Follicular dendritic cells (FDCs) and T follicular helper cells (TFH) localize within LZ. 
A: The conventional view of the GC is that LZ B cells (centrocytes) are nonproliferating 
and relatively small, whereas DZ B cells (centroblasts) are large, dividing cells. 
According to the cyclic-re-entry model, there is a frequent passage of B cells between the 
LZ and DZ.  B: The results of Hauser et al (2007b), Allen (2007a) and Schwickert (2007) 
indicate a modified picture of the GC in which B cells migrate extensively inside either 
the LZ or DZ, and can divide within either zone. Migration of B cells between the LZ and 
DZ can occur at relatively low frequencies, but can also be quite extensive (Taken from 
Bring 2007). 
 
1.6 Plasmacytic differentiation  
Exposure of B cells to TI antigens activates proliferation and formation of the 
extrafollicular foci of antibody-forming cells (AFC) (MacLennan IC 2003). These 
short-lived plasma cells secrete antibodies with relatively low affinity for antigen, usually 
of the IgM class and have no IgV region gene hypermutation, though a small amount of 
mutation may occur (Toellner KM 2002). Following exposure to TD antigens, one 
pathway of B cell differentiation is rapid clonal expansion of activated B cells, which 
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form the short-lived AFCs in splenic extrafollicular foci and lymph node medulla. This is 
homologous to the main B cell differentiation in the TI responses, providing rapid 
antibody production followed by fast antigen clearance (Manz RA 2002).  
 
Several transcription factors have been found to be crucial for plasma cell commitment 
and differentiation. Pax5, a transcriptional repressor is essential for maintaining the 
phenotype of mature B cells, including naive, GC and memory B cells (Cobaleda C 
2007). It has been shown that downregulation of Pax5 in mature B cells results in plasma 
cell differentiation (Delogu A 2006; Nera KP 2006). Inhibition of Pax5 may represent the 
initial step in plasma cell differentiation, resulting in the establishment of a 
'pre-plasmablast' that secretes low amounts of antibodies. The pre-plasmablast is 
characterised by expression of Flt3 and Embigin genes which are otherwise repressed by 
Pax5 (Kallies A 2007b). This distinct stage is then followed by the upregulation of 
several genes that promote development into mature plasma cells.  
 
The second crucial event is the downregulation of Bcl-6 (Falini B 2000; Basso K 2004), 
which allows GC B cells to differentiate into memory B cells or plasma cells. Bcl-6 stops 
the repression of Blimp1, which facilitates plasma cell differentiation (Shaffer AL 2000; 
Vasanwala FH 2002; Tunyaplin C 2004; Parekh S 2007). Combined BCR- and 
CD40-triggering is known to inhibit Bcl-6 expression in centrocytes.  
 
Blimp-1 in the present study is used as a marker for terminal differentiation of B blasts 
into plasma cells. Blimp-1 knock-out studies show that GC detection and extrafollicular 
response occurs, but no plasma cells are produced (Shapiro-Shelef M 2003). Blimp-1 acts 
upstream of X-box binding protein 1 (XBP-1), a transcription factor that is required for 
the secretory phenotype of plasma cells (Reimold AM 2001; Iwakoshi 2003; Shaffer AL. 
2004). Blimp-1 is capable of repressing the expression of genes that maintain B cell 
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identity, gene, such as Pax5 and CTIIA, and others that promote GC B cell proliferation 
such as Bcl-6 and c-myc (Shapiro-Shelef M 2005).  
 
The transcription factor Interferon-Regulatory Factor 4 (IRF4) has been suggested to act 
upstream of (Sciammas R 2006), or in parallel to (Klein U 2006), Blimp-1 in the 
generation of plasma cells and isotype switching . IRF4 could inhibit Bcl-6 and induce 
Prdm1 which encodes Blimp-1 (Sciammas R 2006). Immunofluorescence studies have 
shown reciprocal expression patterns of IRF4 and Bcl-6 in GC B cells. The B cell subset 
expressing IRF4 is Bcl-6-negative, and the subset that expresses Blimp-1 is IRF4-positive 
(Cattoretti G 2006a). Recent work suggests that the expression of Blimp1, IRF4 and 
XBP-1 are independently regulated, but all three are required for the development of 
terminally differentiated plasma cells and/or initiation of plasma-cell differentiation 
(Reimold AM 2001; Klein U 2006; Sciammas R 2006; Kallies A 2007a). IRF4 is 
expressed in immature B cells in the bone marrow (Lu TT 2002) and has a biphasic 
pattern of expression in B cells. It is strongly induced within hours of B cell activation via 
T-independent stimuli. IRF4 protein expression can be seen during the transit of activated 
B blasts through the T zone. Although IRF4 is seen as a plasma cell differentiation related 
gene, rapid IRF4 expression is found in plasmablast as well as germinal centre B cell 
precursors. IRF4 expression is lost when B blasts move to follicles and differentiate into 
proliferating centroblasts (Marshall, Zhang et al submitted for publication, Caoretti 
2006a). 
 
Another transcription factor STAT3 may affect plasma cells differentiation (Fornek JL 
2006). IL21 can induce Blimp-1 expression via activation of STAT3 (Ozaki K 2004). 
IL21 and STAT3 promote B cell differentiation in vitro (Ettinger R 2005; Good KL 2006), 
and are required for plasma cell development in vivo (Ozaki K 2002). 
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1.7 Memory B cell development 
Memory B cells provide a rapid strong response, and produce antibodies of a greater 
affinity against recurrent antigens in comparison to those produced by the naive B cells 
(Toellner KM 1996; Anderson SM 2007; Tangye SG 2009). The formation and 
maintenance of memory lymphocytes are critically important for the design of vaccines 
and the treatment of immunodeficiency diseases, but the current knowledge of signals 
leading to memory B cell differentiation is less well defined than for plasma cell 
differentiation (Tarlinton 2006). Studies have defined that memory B cells (i.e. in 
serological memory) develop from GCs, and frequently, but not always, express switched 
antibody isotypes (Coico RF 1983). In mice, after TD antigen immunisation, memory B 
cells express class-switched antibody, CD38 and B220, present somatically mutant Ig V 
genes, and in addition, constitutively express co-stimulatory molecules CD80 and CD86 
(Tarlinton 2006; Anderson SM 2007). In mice CD80+ memory B cells are found in the 
blood, MZ and the follicle (Anderson SM 2007), and the spleen has been found to be the 
predominant site for the localisation of the long-lived memory B cells (Tangye SG 2009). 
Recent studies in mice have described that B-1b cells can form long-lasting memory cells 
in response to TI-2 antigen, and these memory cells express large amount of IgM, CD19 
and CD11b, but little B220 and IgD (Alugupalli KR 2004). In humans the phenotype of 
memory B cells is less controversial than in mice (Liu YJ 1988; Dunn-Walters DK 1995). 
CD27, a marker associated with switched and mutated cells (Maurer D 1992; Klein U 
1998), is found on B cells in the blood (Agematsu 1997). Some memory B cell subsets 
have been identified, such as IgM+/IgM-CD27+, and CD27+/CD27-IgG+. CD27- memory 
B cells express the inhibitory receptor Fc-receptor like 4 (FCRL4) (Ehrhardt GR 2005; 
Tangye SG 2006). IgM+CD27+ B cells were found in a patient, lacking GC, although 
there were fewer of these cells compared with the normal controls. These studies 
demonstrated that IgM+CD27+ memory B cells formation is dependent on GC.   
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Phosphorylated STAT5 may mediate human memory cell differentiation as opposed to 
plasma cell differentiation by controlling expression of Bcl-6 (Scheeren FA 2005). A role 
for Bcl-6 has also been suggested in memory B-cell development (Reljic R 2000). 
However, Bcl-6 deficient mice develop cells with a memory B cell-like phenotype 
(Toyama 2002), and in vitro experiments have shown Bcl-6 to inhibit the human memory 
B cell formation (Kuo TC 2007). The role of STAT5 in memory B-cell differentiation 
remains to be clarified. BAFF may have some roles for the survival of memory B cells, 
since memory B cells express BAFF-R and TACI, two receptors for BAFF (Tangye SG 
2006). However, studies in mice demonstrated no effect on the memory B cells 
compartments after inhibiting BAFF signalling (Benson MJ 2008). Even though IRF4 is 
not required for memory cell formation, but it is essential for both induction of AID and 
hence CSR, and the production of plasma cells from naïve and memory B cells (Klein U 
2006).  
 
CD40 signalling may have an important role for memory B cell differentiation (Arpin C 
1995). In vitro experiments show that human GC B cells cultured on CD40 ligand 
(CD154) expressing fibroblasts with IL-2 and IL-10 were found to generate a memory B 
cell phenotype, while the removal of CD154 from the system resulted in differentiation of 
the cells into plasmablasts (Arpin C 1995). It remains to be determined whether 
continued stimulation through CD40 directs the centrocytes towards the memory B cell 
pathway, whereas the release of CD40 signalling is a prerequisite for their differentiation 
into plasma cells in vivo. In addition, BCR signalling may regulate the activity of 
centrocytes. Some studies have suggested that low affinity B cells form GCs, and then 
become memory B cells (Smith KG 1997; Dal Porto JM 2002; Shih TA 2002a; Paus D 
2006). 
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Chapter 2 Materials and Methods 
2.1 Animals 
Female and male mice of different strains and origins (Table 2.1) at the age of 6-16 weeks 
were maintained in specific-pathogen-free units at the Biomedical Services Unit (BMSU), 
University of Birmingham. All procedures were approved by the University Ethics 
Committee. The F1 heterozygotes from QM x C57BL/6, and Cg1-Cre x ROSA26-eYFP 
were identified using PCR-typing (Section 2.10).  
 
2.2.1 QM mice 
Quasi monoclonal mice (QM) have a rearrangement in their V(D)J segments at the Ig 
heavy chain locus, and JH sequence is replaced by the VHDJH 17.2.25 segment. This 
introduced segment was taken from an affinity mature NP-specific BALB/c hybridoma. 
The mouse also has a targeted deletion of the κ light chain allele. When paired with any λ 
light chain, 17.2.25 is specific for the hapten NP (Cascalho M 1996). This mouse was 
designed to be ‘monoclonal’, however, only 60% of B cells respond to NP. Some are 
combining with a λ light chain that is not specific for NP. Furthermore, there are 
secondary rearrangements from recombination signal sequence that is present in the 
rearranged 17.2.25. Hence this mouse is called ‘quasi monoclonal’.  
 
QM×C57BL/6 F1 hybrid mice have one copy of rearrangement VDJ heavy chain genes 
and normal κ light chains. These mice have just around 5% of B cells that are NP-specific, 
because most B cells express κ genes (Marshall JL 2009, Thesis UoB). The response to 
NP-Ficoll in QM×B6 mice induces GCs and plasmablasts with similar kinetics to 
immunization with TD antigens if immediate T cell help is available (Vinuesa CG 2000). 
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Table 2.1: Animal used 
Mouse strain Source Reference 
C57BL/6 Harlan, U.K  
BABL/c Harlan, U.K   
QMNP/NP x κ-/-  Prof. Matthias Wabl Cascalho M (Science 1996)
QMNP/—x C57BL/6 F1 
(B6NP/WT)  
Bred in BMSU, University 
of Birmingham, U.K. 
Vinuessa CG (JEM 2000) 
B1-8 x κ-/- Prof. Michael Reth 
MPI of Immunology 
Shih TA Y  
(Nat Immunol 2002) 
B1-8high x κ-/- Prof. Michael Reth 
MPI of Immunology 
Shih TA Y 
(Nat Immunol 2002) 
ROSA26eYFP Jackson Lab Soriano P.  
(Nature Genetics 1999) 
Cγ1-Cre Dr. Stefano Casola (IFOM, 
Milan)  
Casola S (PNAS 2006) 
Cγ1-Crex 
ROSA26eYFP 
Bred in BMSU 
University of Birmingham  
 
IL-4 deficient 
(BALB/c background) 
Charles River Laboratories  
France 
Kuhn R (Science 1991) 
IL-4Rα deficient  
(BALB/c background) 
Prof. James Alexander 
(University of Strathclyde) 
Mohrs M  
(J. Immunol. 1999) 
IL-6 deficient Charles River Laboratories  
France 
Kopf M (Nature 1994) 
IL-10 deficient Charles River Laboratories  
France 
Kuhn R (Cell 1993) 
IL-13 deficient 
(BALB/c background) 
Charles River Laboratories  
France 
McKenzie GJ  
(Immunity 1998a) 
IL-22 deficient 
(BALB/c background) 
Prof. Chris Bukley 
(University of Birmingham) 
Zheng Y  
(Nat Immunol 2008) 
CD28 deficient 
(BALB/c background) 
Prof. Granham Anderson 
(University of Birmingham) 
Shahinian A  
(Science 1993) 
CD30 deficient Prof. Peter Lane 
(University of Birmingham) 
Piggig SD 
(J. Immunol 1999) 
OX40 deficient Prof Peter Lane 
(University of Birmingham) 
Amakawa R (Cell1996) 
CD30OX40 double 
deficient 
Bred in BMSU  
University of Birmingham 
Gaspal F (JEM, 2005) 
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2.2.2 B1-8 and B1-8 high mice 
The B1-8 mouse is also a powerful model to investigate the TI-2 (NP-Ficoll) immune 
response. It is designed on C57BL/6 mouse background, and contains VH 
186.2-DFL16.1-Jh2 derived from NP-binding antibody B1-8 (Bothwell AL 1981; Reth M 
1986; Zou YR 1993), and λ1 only light chain by mice homozygous for the (Cκ) mutation 
(Zou YR 1993). This kind of light chain can provide an efficient way to quantitate 
VHB1-8 expression in the B cell population (Sonoda E 1997). Mutation of TrpÆ Leu at 
codon 33 of B1-8 increases the affinity for NP by a factor of 10 (B1-8 high), whereas the 
four amino acid changes found in hybridoma 3C52 decreases NP-binding by a factor of 
four (B1-8 low) (Allen D 1986). For both B1-8high and B1-8low genes, an additional silent 
TGTÆ TGC mutation was introduced at codon 96 to avoid VH replacement (Reth M 
1986). These antibody genes are expressed in the endogenous locus and are therefore 
subject to physiologic regulation, including switch recombination. Furthermore, these 
gene recombinations do not affect the populations of pro-, pre-, immature, transitional, 
follicular and MZ B cells in bone marrow and spleen (Shih TA 2002b). 
 
2.2.3 Cγ1-Cre × ROSA eYFP mouse 
Cγ1-Cre mouse 
Cre/loxP-mediated conditional gene targeting is an approach to tackle proliferation, 
differentiation and selection of GC B cells in vivo. Cγ1 (IgG1 constant region locus)-Cre 
mice were developed on the C57BL/6 genetic background. An internal ribosome entry 
site (IRES) followed by the Cre-coding sequence in 129-derived ES cells was inserted 
into the 3’ region of the Cγ1 locus between the last membrane-coding exon and its 
polyadenylation sits (Fig 2.1A). This approach allows for the expression from the Cγ1 
locus of a bicistronic mRNA consisting of the Cγ1 and the Cre transcript, respectively 
(Casola S 2006) (Casola S 2004). This mouse strain promotes conditional gene targeting 
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in the majority of GC B cells generated, IgG1 memory cells and plasma cells in response 
to immunization with TD antigens. Driving Cre expression from the Cγ1 locus allows to 
track the fate of B cells undergoing sterile Cγ1 transcription and thus to investigate to 
what extent this process controls the targeting of CSR in vivo (Casola S 2006). 
 
Rosa26-eYFP reporter stain 
This transgenic mouse model based on C57BL/6 background, is designed mainly by 
using Cre-loxP system as well. Firstly a Cre-dependent LacZ reporter strains is produced 
by targeted insertion of a LacZ gene, proceeded by a loxP- flanked (floxed) strong 
transcriptional termination sequence (tpA), into the ubiquitously expressed ROSA26 
locus (Soriano 1999). When the mice are crossed with Cre-expressing transgenic mice, 
the Cre-mediated excision of the floxed termination sequence leads to constitutive lacZ 
expression. In these doubly transgenic animals, a lacZ gene is turned on in cells 
expressing Cre recombinase, as well as daughter cells. These mice are useful for cell 
lineage tracing experiments as well as for monitoring the expression of Cre transgenes, 
but lacZ expression cannot easily be detected in living tissue. EYFP (enhanced yellow 
fluorescent protein) as a report offers an advantage for monitoring the expression of Cre 
and tracing the lineage of these cells and their descendants in living tissue (Soriano 1999; 
Mao X 2001; Srinivas S 2001). EYFP as report was inserted into the ROSA26 locus, 
preceded by a loxP-flanked stop sequence, in a genetic targeting vector (Fig 2.1B), and 
then this targeting vector was then electroporated into the ES cell. The mouse strain was 
tested by crossing with Cre-expressing transgenic mice, and the Cre-mediated excision of 
the floxed termination sequence leads to constitutive eYFP expression. If mice have a 
silencer surrounded by two loxP sites and the colour marker, eYFP is only expressed in 
the cells that express Cre. Casola (2006) studied the efficiency of Cre-recombination in 
vivo at the single cell level, Cγ1-Cre mice were crossed with a ROSA26eYFP reporter 
strain (Cγ1-Cre×ROSA eYFP), and finally showed that eYFP expressed essentially in all 
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B cells after T help type 2 like activation (Fig 2.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Gene map of Cγ1-Cre×ROSA26-eYFP mice 
A: the basic gene map of Cγ1-Cre knockin mouse strain. B: gene map of ROSA26-eYFP 
report strain. When Cγ1-Cre mice are bred to the R26-eYFP, Cγ1 transcription expression 
will induce Cre, Cre recombinase has to induce excision of loxP flanked reporter 
expression, and finally reporter expression will be detected.  
 
2.2 Antigens and Immunizations 
For immunization, (4-hydroxy-3-nitrophenyl)-acetyl-CGG (NP-CGG) was used at 
250µg/ml suspended in sterile phosphate buffered saline (PBS) (Sigma UK) and injected 
intraperitonally (i.p.). NP-CGG, a conjugated protein, was prepared using NP-OSu 
(Cambridge Research Biochemicals, UK) dissolved in dimethylformamide (DMF) 
(Sigma, Poole, UK) at 200 mg/ml. CGG (Sigma) was dissolved in PBS at 5 mg/ml. 200 
μl of NP was added to 1 ml of the protein solution and incubated for 2 hours at room 
temperature on a rotating mixer, then extensively dialysed against PBS pH 7.4. The final 
conjugation ration is NP18-CGG, a kind gift from Ms Chandra Raykundalia. 
NP-CGG/CGG was precipitated in 9% aluminium potassium sulphate (in H2O, sterile) 
for primary immunization (Nossal GJ 1990). The alum precipitate was made with 1 part 
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NP-CGG/CGG (5mg/ml) to 1 part Alum. This is made up to 500 µl with sterile PBS and 
the pH adjusted to 6.5. This was kept in the dark in room temperature for 1 hour, and was 
then washed twice in PBS. The pellet was resuspended in 50µg /200µl PBS per mouse 
and if required 107 Bordetella pertussis (LEE laboratories, BD, USA) was added per 
mouse. For footpad injection, 20µg/20µl NP-CGG +5×108 B.p. is given per pad.  
 
Sterile NP-Ficoll (Biosearch Technologies, CA) was diluted in sterile PBS during studies 
on B cell response in QM×B6 mice or B1-8/B1-8high mice, and usually 30µg/200µl of 
NP-Ficoll was given to each mouse via i.p.. NP-Ficoll immune complex preparations  
were based on a ratio of hapten /antibody antigen-binding site of 1:1. One part of 
NP28-Ficoll (6µg) and 5 part of anti-IgD or anti-IgM (30µg) were mixed in 200µl of PBS 
just before i.v.injection.  
 
Some mice were injected intravenously (i.v.) 2×108/200µl sheep red blood cells (SRBC, 
TCS Biosciences). SRBC were prepared by washing three times, followed by 
centrifugation and resuspending in PBS.  
 
2.3 Anti-NP antibody production 
2.3.1 Anti-NP antibody production 
We developed a number of hybridoma cell lines to produce large amounts of anti-NP 
antibodies with different affinity/avidity and isotypes in a large amount. This project was 
in collaboration with Dr Margaret Goodall. B cells were removed from the spleen of 
B1-8/B1-8high (IgHa allotype) mouse at day 4 after immunized with 30µg/200µl of 
NP-Ficoll via i.p.. Using polyethylene glycol B cells are then fused with myeloma tumor 
cells, which can grow rapidly and indefinitely in culture, and produce large amount of 
antibodies. Viable hybridomas are selected and screened for NP-specific antibodies by 
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ELISA. The single antibody secreting hybridomas with the highest absorbance are 
selected and grown. Other hybridomas are frozen down at a concentration of 1.0×107 
cells/ml for long term storage and one is selected for cloning by limiting dilution to 
generate a stable and generation cell line. Wells with growing cells following cloning 
antibody secretion are screened by ELISA again. Isotyping of the positive hybridomas 
will be included. Supernatant from a specific hybridoma will be grown up to 
approximately 500 ml. Antibody was affinity purified from supernatant according to 
specific isotype, and then extensively dialysed against PBS pH 7.4. The antibody purity 
was simply checked by running on SDS-PAGC gel (PIERCE). Some antibody (i.e. IgM) 
with low purity was further purified by affinity chromatography using specific 
monoclonal antibody. On rate, off rate, and avidity of all antibodies for binding antigen 
(NP) have been checked by BioCore (BiaCore 3000 GE), and the data was analyzed by 
the related software. All hybridoma have been frozen down for long term storage after get 
amount of antibodies. Hybridomas we produced at moment and imported from Cologne 
(Klaus Rajewsky lab) are listed below.  
 
Table 2.2: Anti-NP hybridoma list 
 Name Isotype Affinity Specificity Allotype origin 
1 Clone 82 IgMa 2.5×10-6 Anti-NP QM (IgHa) 
2 NP2.315 IgMa 2×10-6 Anti-NP B1-8 (IgHa) 
3 NP2.248 IgMa 2×10-6 Anti-NP B1-8 (IgHa) 
4 NP1.197 IgMa 2×10-7 Anti-NP B1-8hi (IgHa) 
5 NP1.298 IgMa 2×10-7 Anti-NP B1-8hi (IgHa) 
6 231 IgG3a 2×10-7 Anti-NP B1-8hi (IgHa) 
7 240 IgG2a+ba 2×10-7 Anti-NP B1-8hi (IgHa) 
8 18-01-16 IgG1a  Anti-NP BALB/c (IgHa) 
9 B1-8 IgD IgDb 2×10-6 Anti-NP C57BL/6 (IgHb) 
10 B1-8 IgM IgMb 2×10-6 Anti-NP C57BL/6 (IgHb) 
11 S8 IgG2ab 5.8×10-9 Anti-NP C57BL/6 (IgHb) 
12 S43-10 IgG2ab 2.4×10-8 Anti-NP C57BL/6 (IgHb) 
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2.3.2 BiaCore for checking antibody avidity 
For analysis of antibody affinity, we employed the BiaCore system, which utilizes surface 
plasmon resonanace (SPR) as a means of detection, to measure the real-time interaction 
between NP protein conjugates and anti-NP antibodies. NP15-BSA was covalently 
attached to the sensor chip via the amine coupling method. Carboxyl groups on the 
surface of the sensor chip are activated with a mixture of EDC and NHS (BiaCore 
location) to give reactive succinimide esters. The ligand is then passed over the surface 
and the esters react with primary amine groups and other nucleophilic groups to link the 
ligand covalently to the dextran matrix. Ethanolamine is then passed over the chip to 
deactivate excess reactive groups (the detail methods according to manufacture’s 
instructions). Ligand was prepared in acetate buffer (pH 4) and run at a flow rate of 
5µl/min for 30 min at 25°C. Antibodies were diluted to various concentrations (from 
15.625µM to 2mM) in degassed PBS. Each antibody dilution was run for a period of 
1800 seconds at a flow rate of 5µl/second. All experiments were performed at 38°C. Data 
was analysed on the BIAevaluation software (BIAevaluation 3.2RC1) and the 
background was measured by passing the analyte through a flow cell containing BSA 
immobilised to the chip. This background response was then subtracted from the 
sensorgram before analysis. 
Table 2.3: Reagents required for BIAcore surface plasmon resonance 
Solution  
EDC 0.4M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide in water 
NHS 0.1M N-hydroxysuccinimide in water 
Ethanolamine 1M ethanolamine-HCL pH 8.5 
 
2.4 Tissue section for experiment 
2.4.1 Tissue section preparation 
Spleens were removed from sacrificed mice, and after carefully taking away excess fat, 
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they were immediately snap frozen in liquid nitrogen (N2). The tissues were stored in a 
-80°C freezer until use. When ready for use, the tissues were mounted in pre-cooled 
O.C.T. Compound and quickly freeze-sprayed. 5µm sections were cut using a cryostat 
(Bright Instruments, Huntingdon, UK), and picked onto multispot glass slides. The 
sections were air-dried under fan at room temperature for 1 hour, and then the air-dried 
sections were fixed in cold acetone (4°C) for further 20 min. Fixed slides were again 
air-dried for 10 min before finally being stored at -20°C for later use. 
2.4.2 Immunohistochemistry staining 
Frozen sections were warmed to room temperature under fan for 10 min, and then 
rehydrated by immersing in Tris buffer (pH 7.6). After rehydration the sections should not 
be dried-out and were made sure covered by solution. Rehydrated sections were covered 
with appropriately diluted primary antibodies (concentrations and details shown in Table 
2.4), and incubated for 1 hour at room temperature. Secondary antibodies were absorbed 
30 minutes before use in 10% normal mouse serum to eliminate anti-mouse 
cross-reactivity. At the end of the first incubation slides were washed for 5 minutes. 
Secondary antibodies (concentrations and details shown in Table 2.5) were added to 
corresponding sections, and left to react with sections for 45 minutes. Excess antibodies 
were washed away in Tris buffer (pH 7.6), when staining with biotinylated secondary 
antibodies. Tertiary stains were used when necessary. Streptavidin complex (Vector, UK), 
prepared 30 minutes before use, was added to sections and left to react for 30 minutes. 
After washing, stains were developed using first the peroxidase substrate solution for 
horseradish peroxidase (PX) conjugated to secondary antibodies, and then alkaline 
phosphate substrate solution for biotinylated antibodies (with five minutes washing 
between adding two substrate solutions, and substrate solution have to make fresh before 
using). Developed slides were washed twice in dH2O and left to dry (minimum 
30minutes) before being mounted in immunomount (Thermo, Basingstoke, UK).  
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Table 2.4: Primary antibodies 
Target  Isotype Dilution Clone Manufacturer 
CD3 Rat anti Ms  1/2500 17A2 Got from P. Lane lab 
IgD Shp anti Ms 1/1500 Polyclonal abcam 
IgD Rat anti Ms 1/1000 11-26C.2a BD PharMingen 
IgG1 Rat anti Ms 1/300 LO-MG1-2 Serotec 
IgG Rat anti Ms 1/200 COCKTAIL Serotec 
IgG3 Rat anti Ms 1/200 LO-MG1-13 Serotec 
IgM Rat anti Ms 1/500 LO-MM-9 Serotec  
Caspase3 Rb anti act. Casp.3 1/100 C92-605 BD PharMingen 
NP NP conjugated Shp 1/3000  Got from P.Lane Lab 
CXCR4 Rat anti Ms 1/100 2B11 BD PharMingen 
IRF4 Goat anti Ms 1/400 M-17 Santa Cruz 
CD138 Rat anti-Ms 1/200 281-2 BD PharMingen 
PNA biotin  1/200  Vector 
IgMa FITC  C57BL/6 1/200 DS-1 BD PharMingen 
IgMb Biotin BALB/c 1/100 AF6-78 BD PharMingen 
Bcl-6 Rb anti-Ms 1/30 N-3 Santa Cruz 
 
Table 2.5: Secondary and Tertiary antibodies 
Target Dilution Manufacturer 
Rb anti Rt biotin 1/600 Dako 
Rb anti Rt PX 1/50  Dako 
Dnky anti Shp biotin 1/100 The Binding Site 
Dnky anti Shp PX 1/100 The Binding Site 
Swine anti Rb biotin 1/400 The Binding Site 
Rb anti FITC 1/300 Dako 
Swine anti Rb Immunogloblins 1/100 Dako 
Rabbit PAP 1/100 Dako 
 
Table 2.6: the receipts of buffer and substrate solution 
Tris buffer pH7.6 
 
1.5L Physiological NaCl (7.5G/L) 
1.5L 0.1 M Hcl 
1.0L 0.2M Tris  
Tris buffer pH9.2 As above but pH made up to 9.2  
Peroxidase 
substrate solution 
 
Dissolve 1 tablet (10mg) of 3,3’- Diaminobensidine 
tetrahydrochloride (DAB) (Sigma) in 15 ml Tris buffer (PH7.6), 
and the solution is filtered to 10 ml. One drop of 30% hydrogen 
peroxide (Sigma) was added to the solution to activate the 
enzyme 
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Alkaline 
phosphate 
substrate solution 
 
Dissolve 8mg of levanisole (Sigma) in 10 ml of Tris buffer (pH 
9.2). 4mg of Naphthol AS-MS phosphate (Sigma) was dissolved 
in 380µl of dimethyl formamide in a glass bijox, and this 
solution was added into the middle of the levanisole solution. 
Finally add 10 mg of Fast Blue salt (Sigma) to that mix, filter. 
 
 
2.4.3. Immunohistology for confocal microscope   
Normal frozen tissue section was cut at 5µm, and picked on normal multispot glass. 
EYFP spleen tissue was fixed in 4% formaline + 10% sucrose in PBS for 4 hours at 4˚C, 
and then snapped frozen in liquid N2 (Kusser KL 2003). This tissue was cut at 5µm, and 
picked on Super Frost@ plus glass slide. Antibodies were incubated at room temperature 
in a dark shaking chamber. Sections were washed by PBS for 5 min, and were firstly 
adsorbed with PBS supplemented with 5% horse serum for 10 mins. Primary antibodies 
were incubated for 1 hour at room temperature in PBS supplemented with 10% BSA, 
then washed for 5 mins in PBS. Subsequent antibodies were incubated for 30 mins. 
Sections were immersed in Hoechst 33258 (Sigma) for 1 mins for nuclear staining, then 
mounted using Prolong@ gold antifade reagent (Invitrogen), cure for 24 hours in dark at 
room temperature and finally kept in the dark at -20˚C. A Zeiss confocal LSM 510 
microscope (Zeiss, Germany) was used to visualise staining with images captured and 
processed using Zeiss LSM Image Examiner software (Zeiss).  
Table 2.7: Primary Antibody not listed in the normal histological staining 
Target  Isotype Dilution Clone Manufacturer 
CD3 Hs anti Ms  1/200 145-2C11 BD PharMingen 
IgD alexa@ 647 Rt anti Ms 1/100 11-26c BD PharMingen 
IgG1 alexa@ 633 Gt anti Ms 1/400 Polyclonal Mol. Prob. Invitrogen 
GL-7  Rt anti Ms 1/100 GL-7 BD PharMingen 
Fas Hs anti Ms 1/100 Jo2 BD PharMingen 
CXCR5  Rt ant Ms 1/100 2G8 BD PharMingen 
Ki67 Rb anti Ms 1/400  J. Gerdes, Germany 
BP3 Rt ant Ms 1/500 KT157 Cedarlane Lab  
B220 FITC Rt anti Ms 1/100 RA3-6B2 BD PharMingen 
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Table 2.8: Secondary Antibody 
Target Dilution Manufacturer 
Gt anti-FITC alexa@ 488 1/100 Molecular Prob Invitrogen 
Gt anti Hs Cy5 1/100  Jackson ImmuoResearch 
Dnky anti Rt Cy3 /Cy5 1/300 Jackson ImmuoResearch 
Dnky anti Shp Cy3/Cy5 1/300 Jackson ImmuoResearch 
Gt anti-Rb Cy3/Cy5 1/300 Jackson ImmuoResearch 
Str Alexa @ 405 1/50 Molecular Prob Invitrogen 
Str.Cy3 1/400 Jackson ImmuoResearch 
Rb anti Gt biotin 1/200 Dako 
 
2.4.4 Flow cytometry staining 
Cells were prepared from freshly collected spleens. The cells in RPMI-1640 (Sigma), 
supplemented with 10% fetal calf serum (GIBCO) and 1% penicillin/streptomycin 
(Invitrogen), were spun down again and resuspended in FACS buffer (1% fetal calf serum 
and 5mM EDTA in sterile PBS). All procedures were carried out at 4°C or on ice to 
eliminate cell death and stop the cell cycle. Approximately 1×106 cells were used for each 
staining, and they were kept in 100µl FACS buffer. The appropriate type and amount of 
antibodies (Table 2.9) were added to each cell sample, and incubated for 20-30 minutes. 
At the end of this incubation the cells were washed two times with FACS buffer by 
pelleting at 1,200 rpm for 4 min. When biotinylated antibodies were used, a second 
incubation was carried out. Cells were incubated for 20 min and washed as previously 
described. IRF4 was detected after cells were permeabilizated and fixated with BD 
cytofix/cytoperm buffer (APC BrdU Flow Kit, BD Pharmingen) by first using Goat 
anti-mouse IRF4 (1/200 Santa Cruz), and followed by donkey anti-goat Cy5 (1/500 
Jackson ImmuoResearch). Data acquisition was performed on a Becton Dickinson FACS 
Cyan, and analysed using FlowJo software (FlowJo, Ashland). 
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Table 2.9: Antibodies used in FACS 
Reagents Dilution  Clone Source 
CD16/32 purified 1/200 24g2 BD PharMingen 
B220 Pacific Blue 1/50 RA3-6B2 BD PharMingen 
NP PE 1/2000  Got from P.Lane Lab 
CD4 PE 1/500 GK1.5 BD PharMingen 
CD3 PE 1/50 145-2C11 BD PharMingen 
Fas PE-Cy7 1/100 Jo2 BD Pharmingen 
CD138 Biotin 1/100 281-2 BD Pharmingen 
Str. Per CP-Cy5.5  1/200  BD PharMingen 
 
2.5 Assessment GC size and Quantitation of antigen- (NP) specific B cells 
and plasma cells 
We used slides that carry four stained serial sections. Germinal centres were identified as 
IgD- areas surrounded by IgD+ follicular mantle. To quantify the GC area, we counted the 
number of intercepts on a 100mm2 eyepiece graticule for total GC or NP specific GC at a 
magnification of ×25. The total spleen section was measured by counting intercepts on a 
100mm2 acetate overlay at a magnification of ×4 (Weibel 1963). The concentration of 
some specific cells (e.g. NP+) was expressed as the number of cells counted per 100mm2 
acetate at a magnification of ×25.  
 
To quantify the number of IRF4+ cells at the GC-T zone interface, cells were counted in 
the area of 1× acetate wide at a magnification of ×25 (Fig 2.2), and the sum adjusted for 
the spleen size, the final data was presented by related to the spleen size or the whole GC 
size. The concentration of IRF4+ cells in the follicle was measured as the number of cells 
counted in follicles on the whole spleen section, presented by related to the spleen size.  
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Figure 2.2: Quantification of IRF4+ at 
the GC-T zone interface 
The IRF4+ cells in the GC-T zone 
interface of  1 × acetate wide under the 
a magnification of ×25 were counted.  
The GC-T zone interface size from the 
picture: 3 (long) × 1 (wide). 
 
 
 
 
 
2.6 Technique of quantifying brown/blue staining of immune complex in GC 
To measure the appearance and disappearance of IgMa immune complex (IC) in GCs, we 
used the ImageJ software (Rasband 1997-2009) to quantify the DAB derived brown and 
the Fastblue derived blue immunohistological staining for IC on FDCs. IgMa was usually 
stained brown, while IgMb was stained in blue. At early stages of the response IgMa-IC 
clearly presents in GC LZ (Fig 2.2 A). To separate brown from blue staining, ImageJ was 
used to do colour deconvolution using inbuilt vectors for FastBlue and DAB. This 
procedure converts the image into a dual channel image (Fig 2.2 B) (Ruifrok AC 2001) or 
the detail function instrument on the website). Regions of interest were drawn around 
areas representing IC on the FDC network (Fig 2.2 C). The mean pixel values in the 
channel representing brown and blue staining were measured (Fig 2.2D). From this, the 
ratio of brown/blue is calculated. One or two areas of interest per GC were chosen, and in 
total 10-20 regions of interest per individual tissue section.   
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Figure 2.3: Technique of quantifying blue and brown staining 
ImageJ was used to separate these colours using colour deconvolution, which converts 
brown and blue to a red/green dual channel image (B). Then regions of interest are drawn 
on the FDC network (C), and mean red and green pixel values are determined for this 
area (D). A: Original staining, B: Colour deconvolution, D: Colour intensity value of 
brown and blue 
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2.6.1 Technique of quantifying IRF4 blue staining on spleen section 
ImageJ software was used to assess the IRF4 expression on tissue section at the time 
points after immunization. This is the similar technique to quantify brown/blue staining 
of immune complex in the GC. This procedure converts the image into a dual channel 
image. The areas of interest were selected by drawing at the same size in the different 
sites such as the marginal zone, follicle, outer T zone, middle T zone, GC, IRF4+ plasma 
cell area, and IRF4 low/negative red pulp as negiative control. The mean pixel values in 
the channel representing blue staining were measured. 5 or 6 areas per site/white pulp 
were chosen, and in total 10-30 regions of interest per individual tissue section.     
 
2. 7 Detection of serum antibody levels 
2.7.1 Serum preparation 
Blood was taken from the heart while the mice were under anaesthesia with CO2. The 
blood samples were left in 37°C water bath for 60 minutes, and spun at 13,000 rpm for 5 
minutes. The clear supernatants were collected and stored at -20°C.  
2.7.2 ELISA 
This technique was used to detect serum antibody level specific for antigen. 96 well 
flat-bottomed plates (Nunc) were coated overnight at 4°C with 100µl of some antigen in 
coating buffer (Table 2.10). For detection of high-affinity NP-specific antibodies (IgG), 
NP2-bovine serum albumin (NP2-BSA; 5µg/ml) was coated onto plates. As for total titre 
of NP-specific abs (IgG and IgM), NP15-BSA (5µg/ml) was used. All NP conjugated 
proteins were prepared by Mrs C. Rayundalia. The plates were washed with wash buffer, 
and blocked for 1 hour at 37°C with 200µl blocking buffer per well. The blocking buffer 
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was tipped of and washed three times with wash buffer. Sera (1/30 or 1/100 dilution at 
start) were added into wells and serial tripling dilutions were made using dilution buffer. 
This incubation was for 1hour at 37°C. At the end of the incubation period, the serum was 
carefully washed away with wash buffer for three times. Anti-Ig antibodies were diluted 
into appropriate concentrations (Table 2.11) with dilution buffer, and 100µl of the diluted 
antibody was added into each well. After one hour of incubation the plates were washed 
for three times, and 100µl of substrate solution was added into each well. The 
development took approximately 20 min in a 37°C incubator or 2 hours for weak reaction 
such as high-affinity IgG1. The absorbance of the developed substrate solution was read 
at a wavelength of 405 nm. Standard calibration curves were plotted from the positive 
control sera and the test serum titres calculated as a relative value of these standard 
controls. 
 
Table 2.10: Reagents used in ELISA 
Reagents  Recipe 
Coating buffer Na2CO3 1.95g, NaHCO3 2.93g in 1L dH2O, pH=9.6 
Wash buffer 0.1M PBS (pH=6.8)+ 0.05% Tween (Sigma) 
Blocking buffer 0.1M PBS + 1% BSA (Sigma) 
Dilution buffer 0.1M PBS + 0.05% Tween + 1% BSA 
Substrate solution Dissolve substrate NpNN (N2770 Sigma)(one gold and one silver 
tablet) in 20ml dH2O 
 
Table 2.11: AP-conjugated antibodies used in ELISA 
Ab Specificity Coating-Antigen  Dilution  Source  
Goat anti Ms IgM (AP) * NP2-BSA 1/2000 Southern Biotech 
Goat anti Ms IgG (AP) NP15-BSA, NP2-BSA 1/1000 Southern Biotech 
Mouse anti Ms IgMb biotin # NP15-BSA 1/500 BD PharMingen 
*: Because IgM is multi (deka)-valent, the titre was just measured on NP2-BSA coated 
plates. 
#: Mouse anti-Ms IgMb: monoclonal antibody, and one more step (Alkaline Phosphatase 
Streptavidin Vector) to detect IgMb production by comparing to normal method. So the 
results were much weaker, only NP15-BSA coating plate was used.   
PS: Goat anti-Ms IgM/IgG AP antibodies are polyclonal. IgMb clone: AF6-78 
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2.8 mRNA detection 
2.8.1 Total mRNA extraction 
5µm spleen section was taken and saved in -80°C until use. RNA was extracted by using 
the RNeasy Mini kit (Qiagen, UK), incorpotating the use of QIAshredder columns 
(Qiagen), according to the manufacturers instructions to ensure complete homogenization 
of the tissue. The resulting RNA was eluted in 30µl of RNAse free water and stored at 
-80°C until needed.   
2.8.2 Production of cDNA 
10µl of RNA solution was mixed with 1ul of random oligo-dH6 (0.5µg/ul) (Roche, 
Lewes,UK) and denatured at 70°C for 10 mins. This was shock cooled on ice and 9ul of 
reverse transcription mix was added. The following reagents were added to each sample: 
 10µl RNA sample 
0.5µl dH2O (Gibco-BRL) 
  4µl 
5×first strand buffer (Invitrogen, Paisley, UK) 
  2µl 0.1M DDT 
  1µl dNTP (10Mm) 
0.5µl RNAse Inhibitor (RNAguard, Pharmacia) 
  1µl Moloney murine leukemia virus (M-MLV ) reverse transcriptase (Gibco-BRL) 
This was mixed and heated for 1h at 41°C, and then for 10 minutes at 90°C to inactivate 
RT. The cDNA was stored at -20°C. 
2.8.3 Semiquantitative real time PCR 
This is to quantify in cDNA the expression of the gene of interest such as switch 
transcripts, transcription factors, chemokines, or cytrokins. PCR was performed by 
adding 1μl of cDNA prep to each well of a 384 well plate (Applied Biosystems) followed 
by the required primers and probe mixtures (For sequences see Appendix table 3), and 
TaqMan Universal PCR master Mix (Applied Biosystems). The plate was then covered 
with clear adhesive foil (Applied Biosystems) and centrifuged to remove any air bubbles 
(1200rpm, a few seconds). Along with the amplification of the targeted gene, the internal 
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housekeeping gene β-actin or β2-microglobulin was also amplified so that relative 
quantities of gene amplification could be assessed regardless of the number of cells 
harvested to produce each cDNA preparation. The probe for β-actin was VIC-labelled, 
and β2-microglobulin is NED lablled (Applied Biosystems) so as not to interfere with the 
FAM-label. The plate was run in an ABI 7900 Real-Time PCR machine (Applied 
Biosystems) with a cycling programme as follows: 
• 2 minutes at 50oC 
• 10 minutes at 95oC 
Then 40 cycles of  
• 15 seconds at 95oC 
• 1minute 60oC  
Analysis of fluorescence signals was perfomred using SDS 2.2.2 software (Applied 
Biosystems). A threshold was set within the logarithmic phase of the PCR. The cycle 
number (Ct) at which the signals for target gene and house-keeping gene were recorded 
for each sample.  The relative quantity of expressed target gene mRNA was calculated 
by subtracting the Ct for the housekeeping gene from that of the target gene (ΔCt) and 
then calculating 2-ΔCt.   
2.8.4 PCR Arrays 
TaqMan low-density real-time PCR arrays (Applied Biosystems) were designed in a 
96-gene format. Genes chosen were reported to be differentially expressed during early 
plasmablast or germinal centre cell differentiation ((Klein U 2003; Tarte K 2003; 
Underhill GH 2003; Shapiro-Shelef M 2005). RNA was isolated as above and mixed with 
QuantiTect Probe PCR Kit (Qiagen). This was added to the TaqMan Low-Density Array, 
and PCR was performed in a 7900HT Real-Time PCR System (Applied Biosystems) 
according to manufacturer’s recommendations. Array data was analyzed using TMEV 
(http://www.tm4.org) and Applied Biosystems SDS 2.2.2 software. Relative signal per 
cell was calculated as above with β2-microglobulin as the house keeping gene control.  
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2.9 Laser capture Microdissection for qRT-PCR 
For laser capture microdissection (LCM), snap-frozen spleen sections were processed as 
described as for normal slide section (see 2.4.1), but serial sections were collected on 
PALM MembraneSlides NF (PALM) and stained for 3 min with 1% w/v cresyl violet 
(Sigma-Aldrich) in ethanol after hydration in 100%, 70%, and 50% ethanol. Slides were 
then washed again quickly in 50%, 70%, 100% ethanol sequentially and air-dried. Laser 
microcapture was performed using a Microbeam HT microscope (PALM Microlaser 
Technologies). However additional localisation techniques are needed to identify splenic 
compartments with confidence, and GCs themselves cannot be identified by cresyl violet 
staining alone. Two additional sections were thus cut before the sections to be used for 
microdissection, and two additional sections cut after. These four were stained by 
immunohistochemical techniques (IgD/IRF4). Each section was photographed in entirety. 
By cross reference between composite photomicrographs of the immunohistochemically 
stained slides and the cresyl-violet stained sections I identified GC (IgD- area), follicle 
(IgD+), central T zone, the GC-T zone interface (containing IRF4+ cells), 
plasmablast/plasma cell rich extrafollicular foci (IRF4+), and plasma cell sparse areas of 
red pulp (IRF4-IgD-) for microdissection. Finally membrane only was selected as a 
negative control (Fig 2.4).  
 
Spleen tissue was selected from d5 after NP-CGG response in the carried-primed 
C57BL/6 mice, due to the maximum IRF4+ cells appearance on the GC-T zone interface 
at that time point. The 10-20 similar microdissected areas were catapulted into RNeasy 
buffer (Qiagen) in an mRNA free eppendorf and RNA isolation processed by using the 
RNeasy Micro kit (Qiagen, Crawley, UK)(Erickson HS 2009; Mohr E 2009). RNA 
storage and cDNA preparation are describe as before (section 2.6)(For the sequence of 
primers and probes used in this thesis please see Appendix Table3). 
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Figure 2.4: Photomicrographs of two proximate splenic sections from a mouse 
sacrificed 5 days after NP-CGG immunisation in carrier-primed mice 
demonstrating relationship between appearances after cresyl violet staining, and 
after immunohistochemical staining for IgD and IRF4. 
A:  spleen section immunohistochemically stained with cresyl violet, revealing intense 
staining of the B cell follicle, slightly weaker staining of the GC, T zone, and light 
staining of the red pulp. B: Junction section was stained for IgD (brown) and IRF4 (blue). 
This is representative of two individual experiments. 
 
 
B: IRF4/IgDA: Cresyl violet staining tissue
GC
T F
EF
RP
GC-T
Microdissection:
1) GC- T zone border (GC-T)
2) Germinal center (GC)
3) Central T zone (T)
4) Follicle
5) IRF4+plasma cell area (PC)
6) Red pulp without IRF4+ cells (RP)
7) Just membrane as –ve control
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2.10 Mouse Genotype by PCR  
2.10.1. Preparation of genomic DNA from mouse ear tip for PCR 
About 2 mm of ear tip was placed into each of the labelled sterile 1.5 ml Eppendorfs, and 
300 µl of 50 mM NaOH was added to each labelled tube. This was mixed and heated up 
at 98 oC for 30 minutes, and then vortexed for seconds, returned to heat at 98oC for 
another 30 minutes or until sufficiently lysed. The mixture was neutralized with 30 ul of 1 
M Tris (pH8), and mixed by vortexing again. The mixed solution was centrifuged for 6 
min 13,000rpm at room temperature, and finally the supernatant (about 100µl) was 
transferred into a sterile 0.2 ml tubes, stored at -20oC for later use.  
The receipts of Solution 
  1M Tris  (pH8) 
        60.6g Tris Base (Sigma T1503-5kg) 
        500ml ddI H20 
        Autoclave 
  50 nM Sodium Hydroxide 
2g sodium hydroxide (Fisher S318-500) 
1 L ddI H2O 
Autoclave 
 
2.10.2 PCR typing 
The V region gene was amplified by PCR to check whether the daughter mice inherit the 
expected genes when different mouse strains cross in order to producing a right mouse 
model. For example, to study IgG1 switching in Cγ1-Cre mice, we use Cγ1-Cre× 
ROSA26 eYFP to obtain an F1 hybrid (Cγ1-Cre+/-× R26eYFP+/-) strain.  
 
The PCR reaction was made with by 1µl of template, 1µl of primers (20µM), 10µl of 
polymerase and 7µl of water (REDtaq ready mix PCR reaction kit, Sigma UK). The 
solution was mixed by a pipette in an 8-well strip and centrifuged for a few seconds, run 
 57
in a Techne PCR machine, no oil but with a heated lid, calculated temperature. (Genes 
primer sequences see Appendix Table 1 and 2) 
 
2.11 Statistics analysis and presentation of data 
The Wilcoxon Mann-Whitney Test is a nonparametric test for assessing whether two 
samples of observations come from the same distribution. (Details on (Campbell 
2000).We used this to compare the difference of the two independent groups. Figures 
presented were created by Excel 2005 and Powerpoint 2005 (Microsoft).  
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Chapter3 Setting the threshold - On the role of antibody 
for selection of Germinal Centre B cells 
3.1 Introduction 
3.1.1 The role of immune complex and FDCs for the selection of GC B cells  
Follicular dendritic cells (FDCs) are considered to develop from stromal cells of 
mesenchymal origin, or from migratory precursor cells (Cyster JG 2000), or generate 
from the fusion of stromal cells and migratory CD35+B220+ cells (Murakami T 2007). B 
cells are known to be required for FDC development (MacLennan 1994). Tumour 
necrosis factor (TNF) and lymphotoxin (LT) are essential for their generation and 
development (Fu YX 1999; Tumanov AV 2003). 
 
FDCs are present in the central region of the primary follicles, whilst they reside mainly 
in the LZ of secondary follicles, where they have long processes called dendrites. Some 
are also found in the DZ (El Shikh ME 2006). FDCs express a high level of CR1/CR2 
(CD35/CD21) which bind to fragments of C3 (Imai Y 1996; Fang Y 1998). In the LZ 
they upregulate two low affinity Fc receptors: CD23 (FcεRII), the low affinity receptor 
for IgE, and FcγRIIB (CD32), the receptor for IgG (Qin D 2000). Recently identified Fc 
receptor for IgM, known as Fcα/µR, is predominantly expressed on FDCs, MZ B cells 
and follicle B cells in mouse spleen (Shibuya A 2000; Honda S 2009). Deposition of 
immune complex on FDCs is dependent on CR1/CR2 and Fc receptors. Monoclonal 
antibodies for FDC antigens such as FDC-M1 (Kosco MH 1992; Le HM 1996) and 
FDC-M2 (Berney C 1999; Taylor PR 2002) are used as markers for FDCs. The antigen 
bound by FDC-M1 is also present on tingible body macrophages. FDC-M2 binds to the 
complement component C4, present in immune complex. In addition, FDCs in the LZ 
express the adhesion molecules ICAM-1, VCAM-1 and MAdCAM-1 (Maeda K 1995; 
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Imai Y 1996; Szabo MC 1997; Balogh P 2002). FDCs, like other follicular stromal cells, 
produce CXCL13 (Cyster JG 2000). CXCL13 and its receptor CXCR5 are critical for B 
cell migration into follicles and are also required for B cell migration into the LZ (Allen 
CD 2004). SDF-1 produced by FDCs in the DZ has a crucial role in organizing GCs into 
LZ and DZ (Allen CD 2004).  
 
A major role of FDCs is presentation of antigen in the form of immune complex (IC) to 
naïve B cells when they survey primary follicles, and to GC B cells when they test their 
BCRs by binding antigen (MacLennan 1994; Tew JG 1997; Allen CD 2008). Immune 
complexe typically contains antigen–antibody, antigen plus complement. Immune 
complexes are transported to FDCs by naïve B cells from the subcapsular sinus in lymph 
nodes (Phan TG 2007), and by MZ B cells from the MZ in spleens (Cinamon G 2008). 
Both types of B cells can bind ICs through CR1 and CR2. 
 
The classic theory suggests that ICs on FDCs play a major role in selecting high affinity 
B cells and promoting affinity maturation in GC (MacLennan 1994). Immunization with 
IC can increase the repertoire of antigen-active B cells early in the response (Nie X 1997) 
and increase SHM (Song H 1999) within the GC. Tew’s group also found that preformed 
ICs, which would be rapidly trapped by FDCs, stimulated SHM more efficiently than free 
immunogen (Wu Y 2008). Research in vitro demonstrated that some types of IC on FDCs 
can strongly stimulate B cells (Tew JG 2001) to induce expression of AID, leading to 
SHM and CSR, finally promoting the production of high affinity Ig (Aydar Y 2005). TD 
antigens in IC on FDC can cross-link B cell receptors and trigger a TI like immune 
response (El Shikh ME 2009). In addition, recently in vitro and in vivo studies suggested 
that TLR4 signalling modulates FDC activation and maturation, strongly impacting on 
SHM and the generation of Ig class switched high affinity B cells (El Shikh ME 2007; 
Garin A 2010). These findings further support the regulatory role of IC-bearing FDCs on 
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affinity maturation. IC deposition on FDCs may have a role for the differentiation of GC 
B cells into plasma cells or memory B cells. As the immune response progresses, 
antigen-specific IgG will be produced. Engagement of FcγRIIB on GC B cells by 
IgG-ICs and altered engagement of BCR may generate a signal that stimulates 
centrocytes differentiation into memory B cells (Tarlinton DM 2000). 
 
3.1.2 Mathematical modelling GC reaction   
Mathematical modelling of GCs using a combination of state charts and cellular automata 
can create a 3D interaction environment where chemotaxis, cell migration, cell division 
and apoptosis, cell contact and interaction and cell differentiation can take place in-silico. 
Each cell type and physical object is assigned a digital code to describe the cellular 
activation (Iber D 2002; Meyer-Hermann 2002). Mathematical modelling provides a 
quantitative and systematic framework for the verification of hypotheses and theories on 
the GC reaction, and adds a different vantage point to experimental data. For example, 
mathematical modelling of the GC indicated that soluble antibody may have a role in the 
selection of high affinity B cell clones, and therefore affinity maturation (Iber 2002). A 
theoretical study by Meyer-Hermann (2006) leads to the hypothesis that competition for 
helps from TFH cells in GCs is an efficient mechanism for achieving the selection of high 
affinity clones (Meyer-Hermann ME 2006; Allen CD 2007b). 
  
A recently published study used mathematical modelling of the GC reaction with 
cell-based space-resolved methods to reinterpret motility data generated from 
experiments using intravital two-photon microscopy (Figge MT 2008; Meyer-Hermann 
ME 2009). The mathematical analysis found that although GC B cells move via a random 
walk, zones of organisation can be maintained by transient chemotaxis. This is dependent 
on periodic sensitivity and desensitisation of B cells for the chemokines CXCL12 and/or 
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CXCL13 (Figge MT 2008). Therefore, In-silico experiments can help to identify critical 
time points and experimental conditions for conclusive in vivo experiments (Figge MT 
2008, Garin A 2010). 
 
In GCs, B cells proliferate and hypermutate their Ig variable region genes. After this, B 
cells must undergo selection for specificity and affinity of their B cell receptor. This is 
thought to happen by interaction with antigen deposited as IC on FDCs (MacLennan IC 
1997a). As antigen on FDC is present in the form of IC, antibody covering the antigen 
interferes with B cell antigen binding. 
 
In this thesis I am testing the competition model that GC B cells are competing with 
antibody bound on antigen in ICs (Fig 3.1). During the initial phase of an antibody 
response this antibody will be natural antibody or low affinity antibody produced by early 
plasmablasts that have developed in the early extrafollicular response. Therefore initially 
even relatively low affinity centrocytes should be able to compete for access to the 
antigen. However, during the course of an immune response, this antibody may be 
replaced by high affinity antibody produced by plasma cells that are derived from GCs, 
resulting in an increase of antibody affinity in ICs (Tew JG 1997). This may also have 
some impact for the interaction of BCR, and centrocyte selection in the GC as well. In 
silico modelling of the GC response using GC B cells, FDCs and T cells moving and 
interacting on a 3D lattice over two weeks confirmed that a dynamic selection threshold, 
which is dependent on the affinity of antibody, is more efficient in producing output cells 
rapidly and at higher affinity compared to a fixed threshold model (Adam Reynold’s 
thesis 2010, and Michael Meyer-Hermann, personal communication). 
 
The Fig 3.1 presents migration and differentiation of GC B cells and the competition 
model on selection of GC B cells that was tested in this chapter. Activated B cells move 
 62
into the follicle and form proliferating centroblasts. Centroblasts proliferate and 
hypermutate in the DZ, after which they differentiate into centrocytes in the LZ. Here 
they test their mutated BCR by binding antigen on FDC. Antigen is covered with 
antibody as IC present on FDC, and so centrocytes have to compete with this antibody to 
gain access to the antigen. This antibody could provide a threshold, as only B cells with 
higher affinity than antibody already present may be able to gain access to the antigen 
and obtain positive selection signals, whilst others will die by apoptosis. The selected 
centrocytes move back to the DZ to further mutate, or differentiate into plasma cells, 
which produce higher affinity antibody. The question is whether this newly formed 
antibody will move back into the GC to replace the initial low affinity antibody in ICs, a 
process that may increase the selection threshold for subsequent centrocyte selection. 
 
 
 
 
 
 
 
 
Figure 3.1: Germinal centre selection hypothesis: how antibody feedback may 
produce a dynamic selection threshold 
Antibody produced by the GC output binds to antigen on FDC raising the selection 
threshold for subsequent centrocytes. As the reaction progresses the antibody held on 
FDC and therefore the threshold for B cells to access antigen may increase. CB: 
Centroblast, CC: Centrocyte, T: Follicular T helper cell, Ag: antigen, PC: Plasma cell. 
 
The aim of this project is to test whether competition of IC antibody with GC B cells has 
a role in the development and selection of high affinity B cells in GCs. The detailed aims 
of the project are the following: 
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1. Are antibodies inside GCs replaced by antibodies produced outside GC? 
2. Is the affinity of the antibody immobilized on the FDC important for antibody 
replacement? 
3. Does antibody affinity have an impact on centrocyte selection? 
The main approaches used include: immunohistology to investigate the appearance and 
disappearance of ICs, GC development and the production of early plasmablasts, and 
ELISA to detect the antibody affinity in sera after immunization with different affinity 
IgM-IC. 
 
3.2 Results  
3.2.1. Characterisation of the avidity of anti-NP clones 
To provide a tool to be able to test the role of antibody affinity on the selection of B cells 
in germinal centres, several NP-specific hybridoma cell lines producing monoclonal 
anti-NP antibodies with different affinities were developed by immunization of QM, B1-8 
and B1-8high mice with NP-Ficoll (Detail see section 2.3.1).  
 
Antibody binding can be defined by affinity or avidity. As the in vivo antigen-binding 
characteristic of our antibodies is determined by the whole antibody molecule, we sought 
to determine avidity, and not affinity, which is determined by the binding of one Fab 
segment to one epitope. To do this, antibodies were characterised by using surface 
plasmon resonance. This involves measuring their binding to NP15-BSA which should 
have a similar epitope density to NP15-CGG, used in the in vivo experiments. This method 
allows analysis of the direct kinetics of binding interactions in the real time (Fig 3.2) (See 
method review (Adamczyk M 2001). 
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Figure 3.2: High and low avidity NP-specific IgM Clones 
Surface plasmon resonance studies show the NP-specific association and dissociation of 
different antibody clones and the estimated avidity. (A) Clone82 (developed from QM) 
has a very fast off rate and low avidity when binding NP antigen. (B) NP2.315 (B1-8) and 
(C) NP1.298 (B1-8high) have similar association rates, but NP1.298 dissociates 
considerably slower and has a higher avidity at higher dilution. (D) NP1.197 (B1-8high) 
binds with very high avidity. Different lines show different concentrations: from 
2mM,double dilutions to 15.625µM  (Green line to red line). (E): Estimated avidity rises 
mainly with stability (slow off rate). Arrow shows an estimated measure of relative 
avidity.  RU: Response unit. 
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Fig 3.2 shows marked differences in the binding kinetics of these four antibodies at 38oC 
over concentrations ranging from 15.625µM to 2mM in PBS. The data are plotted on a 
linear scale to show differences in avidity more clearly. To measure early and late binding, 
response units were measured at set time points (2500 seconds after antibody injection for 
“stability late” and at 1500 seconds after injection for “binding late”) at the lowest 
antibody dilution of 15.625µM. The antibody concentrations injected into mice are much 
lower than this, for example, 180µg or 90µg of antibody per mouse as used in our 
experiments would dilute to 2×10-4 and 1×10-4 mM, respectively. Stability late and 
binding late provide a good estimate for the relative avidity of all antibodies since the 
binding-late response is related to the association rate of interaction (on-rate), and 
stability–late is inversely related to the dissociation rate (off-rate) (BIACORE 3000 
tech-note) (Fig 3.2E). Batista et al (1998) showed that the off-rate has a major role for 
determining the affinity of BCR/antigen. Anti-NP clone 82 was found to have a high 
on-rate, but also a very high off-rate (Fig. 3.2A), and therefore was classed as having low 
avidity for NP (labelled LoAv). NP1.198 (Fig 3.2 C) has a slightly higher avidity than NP 
2.315 (Fig 3.2 B). NP1.198 was classed as intermediate high avidity (HiMAv), and 
NP2.315 was classed as intermediate low avidity (LoMAv). NP1.197 (Fig 3.2 D) has the 
slowest off-rate, and was used as high avidity NP-specific IgMa (HiAv) in further 
experiments. 
 
3.2.2. The appearance of injected IgMa immune complex in germinal centers 
3.2.2.1 Experiment design 
Experiments were carried out on mice that express endogenous IgMb allotype in order to 
test the competition model, that antibody inside GC would be replaced by antibodies 
produced by GC output cells during an immune response. Mice had been primed with 
CGG, and were then injected with immune complex of NP-CGG plus anti-NP IgMa, 
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which is a low avidity antibody clone82 (LoAv). Carrier priming induces GC 
development within three days by accelerating B cell activation through immediate 
availability of T cell help (Toellner KM 1996). It may also reduce the threshold for B cell 
activation by antigen opsonisation by preforward carrier-specific antibody (Sze DM 2000; 
Sze DM-Y 2002). Immune complex, containing 20µg of NP-CGG, was prepared with a 
ratio of hapten/antibody antigen-binding site of 1, and mixed well 30 min before i.v. 
injection. For 5 days after immunization the replacement of IgMa with IgMb in the IC on 
FDCs, and the GC response were followed (Fig 3.3). 
 
 
 
Figure 3.3: Protocol for the experiment on appearance and disappeaance of 
antibody from germinal centre 
C57BL/6 mice were primed with CGG. 5 weeks later, mice were injected with immune 
complex of NP-CGG+ anti-NP IgMa, the apperance and disapperance of IgMa and IgMb 
from the GC were followed over the next 5 days.  
 
3.2.2.2 Optimisation of IgMa and IgMb 
IgMa and IgMb antibodies were selected to identify the extraneous IC and endogenous 
antibodies in the spleen sections. In preliminary experiments antibody dilutions for 
immunohistochemical staining were optimized. Furthermore, the absence of 
cross-reactivity to the other allotypes was tested by staining splenic tissue from mice with 
allotype IgMa or IgMb.  
 
Frozen spleen sections from IC immunized mice were stained for IgM allotype and IgD. 
GCs were identified as IgD- areas surrounded by an IgD+ follicular mantle. As seen in fig 
3.4A, in non-immunised BALB/c mice (allotype IgHa) IgMa is detected clearly on all 
non-switched B cells and on plasma cells in the extrafollicular foci. IgMb was not 
detectable on others sections from the same animal (Fig 3.4C).  
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Figure 3.4: Optimisation of the IgMa/IgMb specific immunohistology 
A: Spleen sections from BALB/c mice (allotype IgHa) as IgMa positive, B: spleen 
section  from C57BL/6  mice (IgHb) as IgMa negative control. C: BALB/c spleen 
tissue as IgMb negative control, and D: C57BL/6 spleen as IgMb positive control.  E: 
IgMa (brown) IgMb (blue) staining on BALB/c spleen tissue. F: IgMa (brown) IgMb 
(blue) staining on C57BL/6 spleen tissue.   T: T zone; GC: germinal centre; F: follicle; 
PC: plasma cells, MZ: Marginal zone. 
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In C57BL/6 mice, IgMa-specific antibodies did not produce any non-specific staining 
(Fig3.4 B), while IgMb was detectable in a similar pattern to IgMa in BALB/c mice. After 
immunisation of C57BL/6 mice IgMb was strongly positive on plasma cells, FDC 
network, non-switched GC B cells and MZ and follicular B cells (on Fig 3.4D). Double 
immunohistochemical staining for IgMa and IgMb of BALB/c or C57BL/6 spleen 
sections showed only the respectively expressed IgM allotype, while the other one was 
undetectable or showed only weak non-specific cross-reaction in the red pulp (Fig3.4 E 
F). 
 
3.2.2.3 Appearance of IgMa immune complex in Germinal Centres 
Immunohistological staining was used to detect the appearance and disappearance of 
IgMa antibody in IC on spleen sections at different time points. Four serial cryostat 
sections were stained to detect NP-binding cells with IgD, IgMb with IgD, IgMa with IgD, 
and IgMa with IgMb. Fig 3.5A clearly shows the background without any non-specific 
IgMa staining in the follicle of non-immunised mice. IgMa-IC arrives in the MZ and is 
rapidly transported towards the follicle within 2 hours of injection (Fig 3.5B). One day 
after immunization all IgMa-IC localizes on FDC in the GC light zone (Fig 3.5C). 
Immunofluorescent staining using FDC-M2 and FDC-M1 to identify FDC (Kosco MH 
1992; Taylor PR 2002) confirms that IgMa-IC is mainly located on FDC (Fig 3.5D, E), 
and not on GC B cells (Fig 3.5 D-F).   
 
Three days after injection, the injected IgMa antibodies start to disappear from the FDC 
network (Fig 3.6A), and at day 5, IgMa is hardly detectable in the GCs (Fig 3.6B). At the 
same time staining for endogenous IgMb shows that FDCs still display much IC that is 
covered with IgMb antibody with a constant density at both day 3 and day 5 (Fig 3.6C, D). 
NP-specific plasma cells and GC B cells were measured by incubating sections with 
sheep-Ig that had been conjugated with NP. At day 3, only occasional antigen-specific 
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(NP-binding) B cells are detectable in follicles and the red pulp (Fig3.6E). These expand 
in the red pulp within the next two days to form early extrafollicular plasma cells 
(Toellner KM 1996, Sze-DM 2000), or form large GCs filled with NP-specific GC B cells 
(Fig. 3.6F). Comparing IgMa, IgMb and NP-specific staining show that much of the IgMb 
staining in the GC is due to the presence of NP-specific IC on FDCs, which seems to be 
produced by early extrafollicular plasmablasts. The disappearance of IgMa is likely to be 
due to replacement by endogenous NP-specific IgMb, not due to the disappearance of 
NP-specific IC. 
 
3.2.2.4 Quantifying the disappearance of immune complex during an antibody 
response 
To measure the appearance and disappearance of IgMa-IC in GCs, we used the ImageJ 
software to quantify the DAB derived brown and the Fastblue derived blue staining of IC 
on the FDC areas (detailed method see section 2.6). One or two areas of interest per GC 
and in total 10-20 regions of interest per individual tissue section were chosen. Median 
intensities of IgMa and IgMb staining were quantified from different areas from one 
spleen tissue. Median values from one spleen section at an individual time point are 
shown in Fig 3.7 A and B. Each diamond represents one region of interest in the GC. 
 
Immunoenzymatic staining is not ideal for quantifying the presence of antigen densities 
on tissue sections, as staining intensity depends on the timing of enzymatic colour 
development. Furthermore, dye deposition can become too dense for bright-field 
microscopic quantification, and brown and blue dyes have considerable spectral overlap. 
We tried to control this by developing tissue sections at the same time, avoiding 
overdevelopment by microscopic control. Further control experiments were done with 
quantitation of fluorescent staining. These produced similar results, but were of inferior 
sensitivity. 
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Figure 3.5: IgMa immune complex appearing on FDC 
Low avidity NP-specific IgMa antibody (clone 82)– antigen IC was i.v. injected into 
CGG primed mice. A: white pulp area (IgD+) section before injection, B: IgMa-IC 
transported toward follicle from marginal zone 2hr after injection (arrow), C: IgMa-IC 
localized in the FDC area  at 1d after injection. Fluorescent staining by using FDC-M2 
(D) and  FDC-M1(E), B220 (F) confirms IC sitting on FDCs (white arrow)  F: 
Follicle;GC: Germinal centre; T: T zone, RP: Red Pulp, MZ: Marginal zone 
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Figure 3.6: Disappearance of exogenous IgMa 
Three days after injection IgMa-IC starts to disappear from FDCs (A), at day 5, IgMa-IC 
is hard to detect (B), while staining for endogenous IgMb shows that FDC still display 
much IC day3, 5 after immunization (C. D ). Antigen-specific (NP+) B cells are first 
detectable in GC on day 3 (E). On day 5 considerable numbers of plasma cells in the red 
pulp produce NP-specific antibody, and big NP+ GC forms (F). GC: Germinal centre, T: 
T zone, PC: Plasma cell. 
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This method always produces some brown and blue background detected on stained 
sections even though only one antigen was present and only one colour was seen visually. 
Therefore positive control areas were taken that have mainly IgMb-specific FastBlue 
staining, i.e IgMb expressing plasma cells in the extrafollicular regions, and areas that 
have maximum DAB derived IgMa-specific brown staining and contain minimal amounts 
of endogenous Ig, i.e. MZ macrophages containing IgMa-IC shortly after injection. These 
are labelled brown and blue on Fig 3.7 C, D. IgMa (blue) and IgMb (blue) median 
densities from the same GC areas of one section at the different time points are shown in 
Fig 3.7 A and 3.7 B respectively. Ratios of IgMa (brown)/IgMb (blue) densities from 
double staining of IgMa/IgMb on the same GC following the time point are shown on Fig 
3.7 C. Data from different animals are summarized in Fig 3.7 D, showing that the results 
from different animals were highly reproducible.  
 
The figure shows the arrival of IgMa in the MZ and its binding to phagocytes within 2 hr 
(brown diamond). At the same time a clear increase above background level of IgMa is 
detectable on FDC. IgMa on FDC peaks 1 day after immunization. At the same time IgMb 
on FDC seems to be displaced. This probably shows that there is a limit to the amount of 
immune complex that can be stored on FDC. Over the next 4 days IgMa levels on FDC 
decrease and IgMb levels rise again. The IgMa staining on FDC is not significant although 
there is a slight trend to higher levels on day 5 than on day 0. These observations are 
compatible with the hypothesis that extraneous IgMa is deposited on FDC in GCs. Over 
the next few days this disappears due to replacement by IgMb produced by the early 
extrafollicular plasma cells.  
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Figure 3.7: Quantification of relative amount of IgMa and IgMb 
The relative amount of IgMa (blue) and IgMb (blue) of the same interest region in GC 
from  one spleen section at different time point are respectively shown on (A) and (B) 
(Each diamond represents one area interest in GC). Then calculate the ratio of 
IgMa(brown)/IgMb(blue) was calculated from the same area of interest. C: Each 
diamond indicates ratio of IgMa/IgMb for one FDC, all data from 1 spleen; D:Each 
diamond represents average of ratio from one mouse.  
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3.2.3 Impact of antibody avidity in immune complex for B cell response  
Next we decided to investigate what the effect of antibody avidity in IC present on FDC 
has for the kinetics of the replacement of antibodies in ICs on FDC. Further, the effects of 
antibody on selection and affinity development in GC were studied. To do this we studied 
GC output, serum antibody affinity, GC size and lifespan. Mice, primed with CGG 5 wk 
earlier, were challenged with 20µg immune complex of NP-CGG plus anti-NP IgMa of 
intermediate low or intermediate high avidity via i.v. injection. The LoMAv (NP2.315) 
and HiAv (NP1.198) IgMa antibody were developed from B1-8 or B1-8high, as described 
earlier (section 3.2.1).  
 
 
 
 
 
Figure 3.8: Experiment to detect impact of different antibody avidity in IC for B cell 
development and selection in GC  
 
 
3.2.3.1 Intermediate high avidity antibody (HiMAv)  
Initially, LoMAv (NP2.315) and HiMAv (NP1.298) were selected. The appearance and 
disappearance of IgMa-IC in GCs were observed on cryostat spleen sections by 
immunoenzymatic staining. Interestingly, five days after injection of ICs containing 
LoMAv or HiMAv antibody, LoMAv IgMa-IC had almost disappeared from GCs (Fig 
3.9A), while at the same time the higher avidity antibody was still detectable in GCs 
(Fig3. 9B). The quantification of the size of IgMa-containing FDC area in the whole GCs 
shows a significant difference between the two groups at day5 with more of the higher 
avidity IgMa-IC detectable (Fig 3.9E). A similar trend was seen on day 7, although this 
was not significant because of the small number of animals used. This observation of 
LoMAv-IgMa developed from B1-8 mouse
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more HiMAv IgMa-IC seen in GCs at d5 was reproduced in a second independent 
experiment. Big NP specific GCs were formed and high numbers of antigen-specific 
plasma cells were produced in the red pulps in both groups at d5 (Fig 3.9 C D). In the 
LoMAv group, IgMa-IC disappeared, and may be replaced by newly formed antibody 
from the GC output.  
 
It appears that the antibody avidity determines the kinetics of antibody replacement in 
GCs. Therefore we then assessed whether antibody avidity in IC affects GC B cell 
selection by quantifying the number of apoptotic cells in the GC. Caspase-3 is a member 
of the cysteine protease family, which plays a crucial role in executing apoptotic 
pathways by cleaving a variety of key cellular proteins. Antibodies to activated caspase-3 
can be used as a marker for cells that have entered apoptosis irreversibly (Devarajan E 
2002). 
 
Apoptotic cells in the GC were assessed on d5 and d7 when the GC reached a significant 
size. Apoptotic cells were found in GCs (Fig 3.10 A) and were also present in the red pulp 
(data not shown). Although the frequency of apoptotic cells in the samples at day5 after 
injection is quite variable, interestingly, GCs from the mice that received HiMAv IC 
already had more apoptotic cells (p=0.025). This difference trend was apparent at day 7. 
Because of the small group size on day 7 this difference was not significant (p=0.2) (Fig 
3.10 B). According to our competition model centrocytes are expected to enter apoptosis 
if they fail to be selected because their BCR affinity is lower than the antibody affinity on 
FDCs. Higher frequencies of apoptotic cells in GC developing after immunisation with 
HiMAv IC are compatible with our model that centrocytes are in competition with 
antibodies in ICs on FDCs, and this is mainly dependent on antibody avidity for the 
antigen.   
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Figure 3.9: The effect of avidity on the replacement of antibody in immune 
complexes on FDC. 
CGG primed mice were injected with NP-CGG plus anti-NP IgMa of LoMAv or HiMAv antibody. 5 
days after injection LoMAv IgMa had almost disappeared (A), while HiMAv IgMa-IC is still easily 
detectable in GC (B). Antigen specific (NP+) plasma cells in the red pulp produce the antibody and large 
NP+ GCs formed. There is no significant difference in the amount of NP staining in GC induced with 
higher or lower avidity IC (C.D). (E): As a measure for the total amount of injected antibody at the 
different times after immunisation, the percentage of IgMa+ FDC network of the whole GC area was 
measured at d5 and 7 after injection. Each points represents one mouse. p<0.001 between int. low and 
int. high avidity, according to the Wilcoxon Mann-Whitney U test. This is representative of two 
individual experiments. LoMAv: intermediate low avidity (NP2.315), HiMAv: intermediate high 
avidity (NP1.298). 
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Figure 3.10: Effect of antibody affinity for Caspase3+ apoptotic cells in GC, and GC 
outputs. 
The number of apoptotic cells was assessed by staining caspase3 at d5 and d7 after 
immunisation with LoMAv/HiMAv IgMa-IC. A: Caspase3 histological staining in tissue 
section. (B) Density of Caspase3+ apoptotic cells in GC area.C: IRF4 as marker for the 
early GC output was used to stain on tissue section. D: Density of IRF4+ cells on the 
GC-T zone border. Number of cells is expressed as the number per mm2 of GC area on 
tissue section. Each point represents one mouse. p<0.05 between LoMAv and HiMAv 
group, according to the Wilcoxon Mann-Whitney U test. This is one of two individual 
experiments. GC: germinal centre; T: T zone; RP: red pulp. LoMAv: intermediate low 
avidity (NP2.315), HiMAv: intermediate high avidity (NP1.298).IRF4, a transcriptional 
regulator, has been suggested to act upstream of (Sciammas R 2006) or in parallel to 
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(Klein U 2006) Blimp1 in the differentiation of plasma cells. IRF4 mRNA peaks in B 
cells within 1h after immunization with a TI antigen, and IRF4 protein expression also 
becomes detectable within 1h. Therefore, IRF4 can be used as a marker induced 
immediately after activation of B cells (discussed in chapter4). IRF4 expression is lost 
when B blasts move into follicles and differentiate into GC B cells (Cattoretti G 2006a), 
Marshall, Zhang et al, manuscript in preparation), but regain as soon as GC B cells leave 
the GC and form plasma cells. These cells are detected in the GC DZ-T zone interface 
(discussed in chapter4). We used IRF4 expression in this area to detect the plasma cell 
output from GCs. Interestingly, more IRF4 plasmablasts were found on the GC-T zone 
interface at day5 after NP-CGG immunization in the carrier-primed mice (Fig 3.10 C). 
These cells are plasmablasts exiting GCs, as they express plasma cell markers such as 
CD138, and antigen-specific Ig, and at the same time downregulate GC markers such as 
GL-7, Bcl-6, and PNA (Further details about IRF4 are discussed in Chapter 4).  
 
GCs were seen in tissue sections at 5days post immunization. High numbers of IRF4+ 
cells were present at the GC-T zone interface, and significantly more cells on the 
interface when mice received LoMAv IgMa-IC than another group, which were 
immunized with HiMAv IC (p<0.001) (Fig 3.10D). At day7, the number of IRF4+ 
plasmablasts at the GC–T zone interface was lower compared to day5. No significant 
difference was detected between the two groups. This result again reflects the effects on 
the selection threshold in GCs. This data supports the competition model, that higher 
avidity antibody results in a higher selection threshold. Therefore, in the presence of 
higher avidity antibody, less B cells will pass the strict selection process and then 
differentiate into the plasmablast output. Centrocytes may undergo several cycles of 
proliferation and somatic hypermutation to develop competitive BCRs that can compete 
with the high avidity IC deposition on FDCs. Therefore, effects on the selection from 
HiMAv IC immunization will be higher on day5, just 2d after GCs have formed, then on 
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day7. 
 
Mice produce IgM as the primary Ab, followed by production of IgG after Ig class 
switching. ELISA was used to detect the production of new NP-specific serum antibody 
of different classes after immunization. As the IC injected contains IgMa, only IgMb was 
measured to detect endogenous IgM production. An increase above detection level was 
first seen at 5d after injection with IC (Fig 3.11A). This is because newly formed 
plasmablasts do not start antibody production before day3 after immunization (Sze-DM 
2000). There is no significant change in the level of IgMb production between mice which 
got HiMAv and LoMAv IC group. 
 
NP-specific IgG titre and affinity were tested by detecting antibody on NP15-BSA and 
NP2-BSA coated ELISA plates, and comparing the levels. IgG above detection level was 
first observed at day5 after injection with IC. While no significant difference between 
LoMAv and HiMAv in total IgG production was detected (Fig 3.11B), mice challenged 
with HiMAv IC produced higher affinity IgG (p=0.004). At day 7 the difference between 
the groups became smaller with both producing high affinity antibody (Fig 3.11 C.D). 
HiAv IC induced the earlier onset of high affinity antibody production, due to increased 
competition at the early stages of the GC response. Independent in silico modelling 
produced similar results, with an earlier onset of high affinity GC output (unpublished, 
see 3.3.6 Discussion). The difference between LoMAv and HiMAv becomes smaller later 
in the response. This may be due to GCs induced by LoMAv IC adapting a similar 
threshold later in the response, after higher affinity plasma cells have left these GCs and 
produce antibodies.  
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Figure 3.11: Endogenous IgMb and IgG titre after injection of LoMAv and HiAv IC 
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The figure shows the relative IgMb and  IgG titre at 5 and 7 day after 2nd injection with 
LoMAv/HiMAv IgMa-IC. Each spot represents one mouse. A: (NP2) IgMb titres; B: (NP15) IgG 
titres; C: (NP2) IgG titres; D : IgG affinity (RatioNP2/NP15)).          : Detection threshold. IgMb
titre  was measured in ELISA plates coupled with NP2-BSA. B:  IgG was measured in ELISA 
plates coupled with high hapten density (NP15-BSA). C: was measured in ELISA plates 
coupled with low hapten density (NP2-BSA).    : Samples with undetectable NP2IgG, so 
NP2/NP15 ratio is lower than the indicated value. n.s.: non-significance. p<0.05 between int.low 
and int. high avidity antibody group, according to the Wilcoxon Mann-Whitney U test. This is 
one of two independet experiments. LoMAv: intermediate low avidity (NP2.315), HiMAv: 
intermediate high avidity (NP1.298). IC: Immune complex
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The size of NP-specific GC developed similar between the two groups (Fig 3.12A). 
Plasma cell numbers were determined in both responses. The number of NP-specific 
plasma cells peaks on d5. After that plasma cell numbers fall until d7 because 
plasmablasts come out of cell cycle, and disappear due to apoptosis or emigration 
(Sze-DM 2000) (Fig 3.12B). Extrafollicular plasma cell expansion is not significantly 
changed by variations in avidity of antibody in IC (p>0.05) (Fig 3.12 B). This indicates 
that the higher amount of high affinity IgG seen (Fig 3.11C) is not produced by variations 
of the extrafollicular response, but induced by effects of HiMAv IC in GCs. Taken 
together, these results suggest that higher avidity antibody in IC on FDCs may increase 
the selection threshold for centrocytes, enhancing affinity maturation during GC B cell 
development. Therefore, the avidity of the antibody immobilized on the FDCs seems to 
be important in determining the selection threshold in the GC. However, the trend to 
more NP+ plasma cells in the red pulp in the group receiving HiMAv IC, may suggest that 
the antibody in IC may have minimal effects on extrafollicular plasma cell differentiation 
and proliferation as well.  
 
In a further experiment LoAv antibody (clone82) could be used, compared to HiMAv 
antibody (NP1.298). Low avidity IgMa rapidly moved into the FDC areas (Fig 3.5 A-C), 
and but was not detectable in GCs d5 after immunization (Fig 3.6B), while the higher 
avidity antibody was detectable in GCs when injecting NP1.298 (Fig 3.9B). Clone82 has 
a very high dissociation rate. It contains the somatic hypermutation as QM mice with an 
unmutated non-affinity matured antibody from BALB/c (Cascalho M 1996). This 
antibody should have a similar avidity to the natural antibodies cross-reacting with NP in 
non-immunized C57BL/6 mice, providing that the natural endogenous IgHb antibodies of 
C57BL/6 can compete for antigen binding. Around day3 the first extrafollicular 
non-mutated plasmablasts have just formed and start to produce non-mutated low avidity 
antibody (Sze-DM 2000). This antibody may be able to compete with clone 82, but not 
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with the higher avidity clones. This would explain why clone82 started to disappear from 
the FDC area so early. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Effect of antibody avidity on GC size and plasma cell in red pulps. 
Germinal centre size and splenic plasma cells develop normally after immunization of 
LoMAv or HiMAv immune complex. A: the percentage of NP specific GC per spleen 
section. B: the number of NP-specific plasma cells in red pulps. Number of cells is 
expressed as the number per mm2 of spleen area. Each point shows data from one mouse. 
n.s.: non-significance. This is one of two individual experiments. LoMAv: intermediate 
low avidity (NP2.315), HiMAv: intermediate high avidity (NP1.298). 
 
 
3.2.3.2 High avidity antibody  
To test the effects of antibody that have considerably higher avidity than the typical low 
affinity non-mature B cells, we injected IC prepared with HiAv antibody (NP1.197) and 
compared the response to IC prepared with LoMAv (NP2.315) (Fig 3.2). The same 
immunization protocol was used as before (Fig 3.8). Mice, primed with CGG 5 wk earlier, 
were i.v. immunized with 20µg of IC of NP-CGG plus anti-NP IgMa of LoMAv or HiAv. 
The HiAv IgMa antibody was developed from B1-8high mice. 
 
Interestingly, mice that received the HiAv IC developed significantly smaller GCs at d5 
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and d7 when compared to the group that received LoMAv or soluble antigen without 
antibody (p<0.05) (Fig 3.13E). The group that just received LoMAv IC developed 
slightly larger GCs than the group that received soluble antigen. This may be due to an 
adjuvant effect through costimulatory signals such as CD21 (Boackle SA 1998; Boackle 
SA 1998). As in the experiments described above, LoMAv IgMa was just detectable five 
days after immunization with LoMAv IC (Fig3.13 A). If mice received the HiAv IC, IgMa 
staining was easily observed on the FDC network in the LZ (Fig3.13 B). Binding of 
NP-sheep was used to detect the presence of NP-specific IC and NP-specific GC B cells. 
This showed that most GC B cells in the group that received LoMAv IC were binding 
NP-antigen (Fig 3.13 C), while in the group that received HiAv IC most of the GC B cells 
did not appear NP-specific, with individual GC B cells appearing NP-specific (Fig. 3.13 
D). Whether this means, that most GC B cells are specific for other epitopes, e.g. the 
carrier protein, remains to be investigated. At the peak of the extrafollicular response on 
d5, antigen-specific plasma cell number in extrafollicular foci appeared significantly less 
in the HiAv group compared to the groups receiving LoMAv antibody or no antibody 
(p<0.001) (Fig 3.13 F). At d7 the number of plasma cells was reduced compared to d5 in 
all groups, with the group receiving HiAv antibody still significantly lower than the other 
two groups (Fig3.13F). We conclude that immunization with LoMAv IC would produce 
lower selection threshold than HiAv IC, leaving more GC cells alive, and so appearance 
of slightly bigger GCs and the generation of more plasma cells.  
 
HiAv IC induced significantly lower numbers of plasma cells at d5 and 7 after 
immunization compared to LoMAv IC or free antigen. This may be due to the higher 
selection threshold introduced for centrocytes. Most centrocytes with lower affinity BCRs 
could not compete to gain access to antigen in ICs, resulting in increased apoptosis and 
much smaller GC output, leading to fewer plasma cells.  
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Figure 3.13: Effect of antibody affinity on GC size and plasma cell output in red 
pulps 
CGG primed mice were injected with NP-CGG plus anti-NP IgMa with LoMAv (NP2.315) or HiAv 
(NP1.197). 5 days after injection LoMAv IgMa almost disappeared (A), while HiAv IgMa-IC is still easily 
detectable in GC (B). However, mice which received HiAv IgMa-IC developed smaller GC at day5 (C.D). 
Much fewer plasma cells produced in the extrafollicular foci (D). (E):the percentage of NP+ GC per spleen 
area. (F): NP-specific plasma cells in red pulps. Number of cells is expressed as the number per mm2 spleen 
area. p<0.05 between LoMAv and HiAv, according to the Wilcoxon Mann-Whitney U test. *: p=0.03 
between soluble Ag only and HiAv antibody group according to the Wilcoxon Mann-Whitney U test. This is 
one of three independet experiments. LoMAv: intermediate low avidity (NP2.315), HiAv: high avidity 
(NP1.197). 
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To study the effects of IC on selection pressure inside the GC, apoptotic cells in GCs 
were detected by staining for active caspase3. This showed that statistically more 
caspase3+ cells were present when mice were immunized with HiAv IC compared to mice 
that received LoMAv IC or soluble antigen (p=0.03, Fig 3.14A). Mice receiving LoMAv 
IC just had slightly more apoptotic cells in GCs compared to the soluble antigen group. 
At the same time GCs produced more output, reflected by a greater number of IRF4+ 
plasmablasts on the GC-T zone interface (p=0.001 Fig 3.14 B). The results prove that 
LoMAv IC could introduce a lower selection threshold for centrocytes, resulting in 
greater GC B cell survival, leading to enhanced GC output, HiAv IC in comparison 
supplies a strict selection threshold for centrocytes, and leading to apoptosis of more low 
affinity B cells in GCs, with fewer successfully selected plasmablasts.  
 
 
 
 
 
 
 
 
 
Figure 3.14: Effects of antibody avidity for apoptosis in GC and GC output 
The measurement of apoptotic cells in GCs and GC outputs was used to detect selection 
in GC after immunisation with LoMAv or HiAv IC and only soluble antigen. (A) Density 
of Caspase3+ apoptotic cells in GC area. (B) Number of IRF4+ plasmablasts on the GC-T 
zone interface. Each point represents one mouse. P=0.03 between LoMAv and HiAv, 
according to student T test. P=0.001 between LoMAv and HiAv, between no antibody and 
LoMAv, or between no antibody and HiAv, according to the Wilcoxon Mann-Whitney U 
test. This is one of two individual experiments. LoMAv: intermediate low avidity 
(NP2.315), HiAv: high avidity (NP1.197). Ag: Antigen, IC: Immune complex. 
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To study the quality of output from GCs serum antibody measurements were done by 
ELISA. This showed that as in earlier experiments the production of endogenous IgMb 
peaked on d5, and was similar in all groups, whether they received LoMAv, HiAv IC, or 
only soluble antigen (Fig 3.15A). IgG levels increased further in all groups until d7 (Fig 
3.15B), and IgG affinity increased until d7 (Fig3.15 C D). Interestingly, mice that 
received HiAv IC had slightly lower total IgG levels, however, the affinity was 
significantly higher than in mice that received LoMAv IC (p=0.02) (Fig3.15D) or just 
soluble antigen (p=0.001).  
 
As discussed above, HiAv IC seems to induce a stringent selection. This leads to smaller 
GCs, greater apoptosis and fewer plasma cells resulting in lower antibody titres, but 
increased antibody affinity. This effect is only noticed at the early stage day5, and 
disappears at day7. This effect is most prominent at early stages and is the same as the 
effect of HiMAv antibody for antibody response in serum shown as before (Fig3.11 C D). 
Mathematical modelling experiments by Michael Meyer-Hermann (unpublished) found 
similar effects with high avidity antibody injection decreasing GC size and GC output, 
while improving the affinity of the few output cells that are still produced (See section 
3.3.4 Discussion).   
3.2.4 The impact of soluble extraneous antibody for B cell responses 
The experiments described above indicate that extraneous antibody is deposited on FDCs, 
and may affect GC B cell selection threshold depending on the form of antigen-antibody 
IC at the time of immunization. Our competition model predicts that the GC selection 
threshold is determined by the antibody produced by plasma cells, which have developed 
in extrafollicular foci during the ongoing immune response. If this model is correct, then 
systemic antibody should freely diffuse back into the established GC. To test this, we 
injected soluble extraneous antibody injected during ongoing GC responses.  
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Figure 3.15: IgMb titre, IgG titres and affinity in serum 
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The figure shows the relative IgMb and IgG antibody titre at the following time course: d5 
and 7 after injection with LoMAv or HiAv IgMa-IC at the  CGG primed mice. Each point 
represents one mouse. A: (NP2) IgMb titres;  B : (NP15) IgG titres; C: (NP2) IgG titres; D : IgG
affinity (Ratio of NP2/NP15).             : Detection threshold. IgMb titre was measured in 
ELISA plates coupled with NP2-BSA. B:  IgG titre was measured in ELISA plates coupled 
with high hapten density (NP15-BSA). C: IgG  was measured in ELISA plates coupled with 
low hapten density (NP2-BSA).  n.s.: non-significance. P=0.02 between LoMAv and HiAv
antibody group, according to the Wilcoxon Mann-Whitney U test. This is one of three 
individual experiments.LoMAv: intermediate low avidity (NP2.315), HiAv: high avidity 
(NP1.197). Ag: antigen, IC: Immune complex. 
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We used alum-precipitated NP-CGG to induce GC in C57BL6 mice at day10 of the 
primary response and soluble NP-CGG at day 4 after the carrier-priming. In the first 
experiment 20µg of soluble LoAv IgMa (Clone82) was given via i.v.. Interestingly no 
allotype IgMa was detectable on FDCs in GCs at any time point 2hr, 1, 2, and 4d after 
injection. Possibly the dose of antibody used was too low. We injected mice with 80µg, 
200µg and 500µg of LoMAv IgMa (NP2.315) at day10 after primary response with 
NP-CGG. IgMa still was not detectable on FDCs. Clone82 and NP2.315 are low avidity 
antibodies, as demonstrated by BiaCore analysis (Fig 3.2 E). From this we concluded that 
10 days after the primary response or 4 days after 2nd injection in the carrier-primed mcie, 
GC development may be too advanced, with GC derived plasma cells in the red pulp 
already producing considerable amounts of high affinity antibodies. According to the 
antibody competition model this would appear on FDCs, and prevent extraneous antibody 
from entering the GC.  
 
In the next series of experiments, higher avidity soluble antibodies were injected at very 
early stage of GC development. At day3 and day4 after carrier-primed response to 
NP-CGG, 90µg of LoMAv (NP2.315) or HiAv (NP1.197) antibody was given i.v. (Fig 
3.16). Immunohistological staining was used to detect extraneous IgMa on spleen section 
at day5 after immunization.  
 
 
 
 
 
 
Figure 3.16: Soluble int. low or high avidity antibody was introduced at d3 and d4 
after NP-CGG immunization in carried-primed mice, to further detect the impact of 
soluble antibody for B cell selection in GC. 
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Figure 3.17: Soluble LoMAv/HiAv antibody can move into the early developed GC 
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CGG primed mice were injected with NP-CGG, at d5 the spleen tissue were collected as control 
(A). At d3 and 4, i.v. immunized with soluble LoMAv Ab, and at 5, extraneous IgMa was 
detected on section (B and C) . If at d3, mice were received HiAv Ab, d 4 extraneous IgMa was 
detected on section (D). If at d3 and 4, mice were gave HiAv Ab, at d5 extraneous IgMa was 
detected on section (E and F). At the same time. GC and plasma cells were assessed by staining 
with NP. LoMAv: intermediate low avidity (NP2.215). HiAv: high avidity (NP1.197). GC: 
Germinal centre, PC: plasma cell.
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In contrast to the LoAv antibody experiment described above, LoMAv IgMa antibody 
could be seen very clearly in GCs on all sections at day5 after immunization if antibody 
was injected at day3. However, if LoMAv antibody was injected one day later, there was 
less present in GCs on day 5 (Fig 3.17 B.C). This may be explained by affinity of 
endogenous antibody already competing with deposition of this low avidity antibody by 
day 4. When HiAv antibody (NP1.197) was used for injection 3 days after NP-CGG 
immunization, it was found deposited on FDCs in high densities within 24hr (Fig. 3.17 
D). HiAv antibody was still detectable on the FDC network at high amounts two days 
after injection (Fig. 3.17 E). Different from LoMAv, HiAv was injected 4 days after 
NP-CGG was still easily detected on the FDC network 1 day later (Fig. 3.17F). This 
confirms that an affinity dependent process seems to prevent LoMAv antibody from 
entering the GC on day 4, indicating that there may be competition with higher avidity 
endogenous antibodies that have appeared at this stage. 
  
The size of NP-specific GC on day 5 was significantly smaller in the carrier-primed mice 
receiving soluble LoMAv or HiAv antibody at day3 or day4 compared to mice that only 
received soluble antigen (p=0.01 Fig 3.18A). No significant difference was detected 
between LoMAv and HiAv groups, although there was a trend to smaller GC in the HiAv 
group. Accordingly, both affinities of antibody induced a strong rise in the frequency of 
apoptotic cells in GCs, as measured by staining for active caspase3, indicating that these 
antibodies have an affinity-dependent effect on the selection threshold (Fig 3.19A). HiAv 
antibody induces significantly more apoptosis than lower avidity antibody (Fig. 3.19A red 
points). LoMAv induces less apoptosis than HiAv antibody, but significantly increases 
apoptosis compared to the GC, which did not receive extraneous antibody (Fig. 3.19A 
green points). Interestingly, the effect of LoMAv was dependent on the time when this 
antibody was injected. Injecting LoMAv antibody on day 3 resulted in significantly more 
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apoptosis detected on day 5, than when it was given on day 4, indicating that this LoMAv 
antibody is less able to compete with the endogenous antibody, when given on day 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: Effect of antibody avidity on GC size and plasma cell output in the red 
pulps 
CGG primed mice were injected with NP-CGG, at day3 and 4, i.v. immunized with 
soluble LoMAv or HiAv antibody, and at d5, samples were collected called d3d5, and 
d4d5 respectively. Another group of mice did not get soluble antibody as control labeled 
as d5No Ab. (A): the percentage of NP+ GC per spleen section area. (B): NP-specific 
plasma cells in red pulps. Number of cells is expressed as the number per mm2 spleen 
area. P=0.01 between no antibody injection and antibody immunisation group, according 
to the Wilcoxon Mann-Whitney U test. Each point represents one mouse. This is one of 
two individual experiments. LoMAv: intermediate low avidity (NP2.315). HiAv: high 
avidity (NP1.197). 
 
 
 
Appearance of IRF4 positive cells at the GC–T zone interface, a marker for early 
plasmablast output from the GC, showed significantly fewer plasmablasts after mice 
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(p<0.05, Fig 3.19 B), confirming that the selection threshold in the GC is higher, resulting 
in less output. Injection of antibody also resulted in significantly fewer plasma cells in the 
red pulp (p=0.01 Fig 3.18 B). No significant difference was detected between the 
different avidity antibodies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19: Injection of soluble LoMAv/HiAv Ab induces more caspase3+ cells in 
GC, and decreases GC output 
CGG primed mice were injected with NP-CGG, at day3 and 4, i.v. immunized with 
soluble LoMAv or HiAv antibody, and at d5, samples were collected called d3d5, and 
d4d5 respectively. The apoptotic cells in GC and GC outputs were assessed after 
immunisation with int. low/high avidity soluble antibody. (A) Density of Caspase3+ 
apoptotic cells in GCs. (B) Number of IRF4+ plasmablasts on the GC-T zone border. 
Number of cells is expressed as the number per mm2 GC area. p<0.05 between int. low 
and high avidity group, between no antibody injection and antibody immunisation group 
according to the Wilcoxon Mann-Whitney U test. n.s.: non-significance. Each point 
represents one mouse. This is one of two individual experiments. LoMAv: intermediate 
low avidity (NP2.315). HiAv: high avidity (NP1.197) 
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ELISA was used to detect antibody production in blood. This showed production of total 
IgG and high affinity IgG 5d after immunization with NP-CGG (Fig 3.20A, B). 
Interestingly, High avidity antibody induced significantly more higher affinity IgG 
production when injected at day3 and 4 after NP-CGG injection in the CGG-primed mice 
(p<0.05, Fig 3.20 C), even though no significant difference was detected in the total IgG 
and in the high affinity IgG production between groups receiving antibody on day3/4 and 
no antibody injection group.  
 
LoMAv antibody has a smaller effect for the B cell reaction in GC. This is similar to 
results shown earlier (section 3.2.4.2, Fig 3.14), when mice were immunized with 
LoMAv IC. This is compatible with the idea that soluble HiAv antibody moving into GCs 
would increase the selection threshold leading to stringent selection which allows only 
higher affinity B cells to be selected. This leads to higher affinity antibody production. 
The results from injection with soluble antibodies are in line with the results of the 
experiments with IC immunization, and are compatible with the competition model that: 
1) antibody in IC in GCs may be replaced by antibody formed later in the response, 
which then induces the antibody affinity on FDCs to increase during the process of the 
immune response, 2) centrocytes compete with antibodies on FDCs for antigen binding, 3) 
the affinity of antibody immobilised on FDCs is important to determine the selection 
threshold of GC B cells. 
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Figure 3.20: IgG Ab titres and affinity  
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The figure shows the relative IgG antibody titre and affinity at the different  time course. CGG 
primed mice were injected with NP-CGG, at d3 and 4, i.v. immunised with soluble LoMAv or 
HiAv antibody, and at d5, antibody in sera were assessed called d3d5, and d4d5 respectively. 
Another group of mice did not get soluble antibody as control labeled as d5 No Ab. A: (NP15) 
IgG titres; B : (NP2) IgG titres; C: IgG affinity (Ratio of NP2/NP15) ).           : Detection 
threshold. n.s.: non-significance. *: p=0.04, **: p=0. 01 between non antibody injection and 
HiAv injection group, p<0.05 between LoMAv and HiAv, according to the Wilcoxon Mann-
Whitney U test. #: not detectable with NP2BSA, so value is as plotted or lower.     : the same 
two samples shown on Fig B, so the value actually is lower than the plotted. Each point 
represents one mouse. This is the merge of two individual experiments. LoMAv: intermediate 
low avidity (NP2.315). HiAv: high avidity (NP1.197)
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3.2.6 The effect of antibody on the extrafollicular response 
All the experiments described above assume that antibody has effects solely on selection 
events in GCs. B cells initially get activated outside the GC, and there may be effects on 
competition between antibody and B cell at the pre-GC stage. To investigate whether 
antibody avidity of IC could affect the extrafollicular response, we studied the response 
of QMxC57BL/6 mice to the TI antigen (NP-Ficoll), and IC in the form of NP-Ficoll 
covered in either IgD (low avidity heavy chain, similar to clone82 but bivalent. Fig 3.2E) 
or IgM antibody (clone82) (for the preparation see section 2.2). Spleens were harvested at 
day3 after immunization, which is the timepoint when B blasts differentiate into 
plasmablasts in the red pulp, and when the first GC appear in follicles (Vinuesa CG 2000). 
QM mice produce a strong extrafollicular response to NP-Ficoll and develop GCs, but do 
not show hypermutation or affinity maturation ((Vinuesa CG 2000; Toellner KM 2002). 
Thus, at day 3 after immunization all B blasts and plasmablasts have developed outside 
GCs, and there is no extra competition from affinity matured endogenous antibody. 
 
GC developed after mice were immunized with NP-Ficoll alone, or both kinds of ICs (Fig 
3.21A), but in terms of GC size, no significant difference was found in all groups after 
injection (p> 0.05), and this is similar to the results of the effect of LoMAv IC for GC 
(Fig 3.13 E). High population of NP+ plasma cells were produced in red pulps after 
immunization with antigen only or IgD-ICs/IgM-ICs (Fig 3.21B). There were only 
slightly fewer NP-specific B cells in the extrafollicular foci after receiving IgM-IC 
(p>0.05). This result shows that antibody avidity has only a minimal role for the 
development of B cells in the extrafollicular response. In addition, two different avidity 
ICs of IgM plus NP-Ficoll were injected QMxC57BL/6 mice. No significant difference in 
GC size, or in the production of plasma cells and serum antibody were detected in the 
between groups (L. George MSc Thesis, UoB). Taken together, these results show that 
most of the effects seen on GC size, plasma cell numbers and serum antibody affinities in 
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the experiments described above are mainly due to effects inside the GC, and minimum 
effects on early B cell activation in the extrafollicular pathway. The density change of 
antigen-specific plasma cells in red pulps induced by different avidity ICs originates from 
the direct effect of IC for the GC development.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21: Little effect of antibody of different avidity on the extrafollicular 
response 
QMxC57BL/6 mice were immunized with the TI antigen NP-Ficoll, NP-Ficoll plus 
anti-NP IgD or IgM immune complex, at day3, GC size and NP+ cells were quantified on 
spleen sections. A: The percentage of NP+ GC size of whole spleen section, B: NP 
binding plasma cells in the red pulp. Number of cells was accessed per mm2 spleen 
section. NI: Non-immunized. n.s: non-significance. IC: Immune complex. Each point 
represents one animal.  
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3.3 Discussion 
B cells, activated by antigen and T cells, move into follicles and establish the GCs which 
are an important site for the generation and selection of B cells bearing high-affinity 
antibodies (MacLennan 1994). In the classical model of GC function, B cells in the DZ 
undergo rapid rounds of proliferation and somatic hypermutation of their Ig V region 
genes, followed by exit from the cell cycle and movement into the LZ, where they 
undergo selection based on the affinity of their surface antibody for antigen (MacLennan 
1994; Manser 2004; Tarlinton 2006) Selection process is thought to involve competition 
between GC B cells for antigen capture in the form of immune complex displayed on the 
processes of FDCs (Cyster JG 2000; Cyster JG 2000; Kosco-Vilbois 2003). Recent real 
time imaging studies also support this idea (Schwickert TA 2007; Allen CD 2007a; 
Hauser AE 2007b). When antibody from the primary immunization is present, 
antigen-antibody immune complexes form and are trapped by FDCs (Tew JG 1997). 
Deposition of immune complexes on FDCs is strongly dependent on complement and Fc 
receptors (Allen CD 2008). It is widely accepted that immune complex on FDCs play a 
major role in B cell maturation (Song H 1999; Aydar Y 2005) and differentiation 
(Tarlinton DM 2000; Haberman AM 2003). In addition, some studies have indicated an 
important feedback role of early primary antibody such as IgG1 in the regulation of the B 
cell repertoire and activation of somatic hypermutation in GC B cells (Nie X 1997; Song 
H 1999). Here we sought to determine whether antibody in immune complex on FDC is 
involved in B cell selection by competing with centrocytes for access to antigen in GCs. 
 
As the affinity of the BCR for GC B cells increases with time, it should become easier 
and easier for B cells to compete with antibody in IC on FDCs. A mechanism based on 
increase in the stringency of selection through the replacement of the initial antibody by 
external antibody would overcome this problem. This external antibody is produced by 
 98
GC derived plasma cells, and would warrant efficient selection while higher affinity B 
cell clones develop. A theoretical study that was done in parallel to the experiments 
described here showed that a dynamic selection threshold dependent on antibody affinity 
in IC, is a more efficient mechanism to achieve selection of high-affinity clones (Adam 
Reynolds 2010, thesis UoB, submitted). This study led us to investigate whether the 
affinity of antibody immobilized on FDCs is an important factor for germinal centre B 
cell selection.  
 
3.3.1 Appearance of immune complex in follicles 
The first experiments described here tested the speed of transportation of IC into follicles. 
To help visualize the migration of IC containing extraneous antibody by 
immunohistology, different allotype (a/b) of the same isotype antibody was used. 
Immunohistological staining shows that extraneous IgMa-IC is quickly transported 
towards the follicles from the marginal zone within 2h after i.v. injection. Within a day all 
IgMa-IC localizes on FDC in the light zone.  
 
The marginal zone is considered to screen the systemic circulation for antigens and 
pathogens (Mebius RE 2005). Earlier studies of the capture and deposition of systemic 
immune complex in the spleen suggested that some lymphocytes migrate from the 
marginal zone to the follicle (Brown JC 1970; Veerman AJ 1975). MZ B cells were 
reported to have a role in the transport of IC (Ferguson AR 2004). The light zone in the 
GC is proximal to the marginal sinus where blood-borne antigens enter the tissue. 
Antigen enters the spleen via blood draining the marginal sinus, MZ B cells engage TD or 
TI antigen through their BCR, which is further crosslinked by CR2, upon which they are 
then induced to leave the MZ and migrate to the outer T zone at the first stage in a splenic 
antibody response (Liu YJ 1988; Vinuesa CG 2001; MacLennan 2008). When IgM-IC 
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was directly injected i.v., IgM-IC localized firstly at the MZ where IgM-IC bound MZ B 
cells in a complement and complement receptor (CR1/2) dependent process. Then MZ B 
cells transported the IgM-IC into the follicle for deposition onto FDCs (Ferguson AR 
2004). In addition, Cinamon (2008) presents that MZ B cells are not confined to the MZ 
but continuously shuttle between the MZ and follicular areas by up-regulating the 
expression of the chemokine receptor CXCR5 (migration to follicle), or 
sphingosine1-phosphate receptors S1P1 and S1P3 (back to MZ). This continuous shuttle 
provides an efficient mechanism of systemic antigen capture and delivery to FDCs 
(Cinamon G 2008). The same is observed in lymph nodes, where the light zone is 
positioned close to the subcapsular sinus, which receives the afferent lymphatic drainage 
from the skin, mucosa, or viscera. Naïve B cells have been shown to frequently visit the 
follicles, or an ongoing GC reaction (Schwickert TA 2007). Follicular B cells may play a 
transport role in lymph nodes for larger antigens such as IC or viruses in lymph nodes 
(Carrasco YR 2007; Junt T 2007; Phan TG 2007). Phan (2007) indicated that follicular B 
cells captured ICs through a complement receptor-dependent mechanism from 
subcapsular macrophage processes and then carried complexes through the follicle, 
and/or migrated to the T-B zone boundary for delivery to FDCs. 
 
Antigen in the form of IC could last longer (Tew JG 1978), and was reported to be 
typically more potent than free antigen in promoting antibody responses (Heyman 2000). 
Previous studies had suggested that antigen retained in lymphoid follicles remains active 
for prolonged periods, and could maintain and regulate serum antibody levels for months 
or years after immunization (Nossal G. 1968; Tew JG 1973; Tew JG 1978; Tew JG 
1984). 
 
The kinetics of the appearance of IgM-IC in the MZ, followed by the follicle, described 
here during a carrier-primed response, was similar to antigen trapping in the subcapsular 
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sinus and then transport into the follicles in lymph nodes, when antigen was injected into 
animals primed with the same antigen (Szakal AK 1989), or phycoerythrin (PE) was 
immunized into mice primed with polyclonal antibodies specific for PE (Phan TG 2007). 
Immune complex rapidly formed after injection, or directly injected IC was captured by 
antigen-transporting cells and subsequently accumulated in the FDC area.  
 
Recent studies using two-photon microscopy reported that small molecular soluble 
antigens could gain access to cells in the follicles of lymph nodes through direct diffusion 
through the subcaspular sinus pores (Pape KA 2007) or through follicular conduits 
(Roozendaal R 2009). In our experiments, soluble antibody (particularly high avidity) 
was detected in the FDC area at day1 after immunization during an ongoing GC reaction. 
Therefore in the spleen, the antibody may also rapidly diffuse across the marginal zone 
into the GC, and then be retained on FDCs. Whether soluble antibody enters the follicle 
with increase kinetics has not been tested in this project. However, as a small molecule it 
should be faster. Therefore, internally produced higher affinity soluble antibodies are 
likely to gain access to germinal centres and then provide feedback for the GC B cells 
selection. 
 
3.3.2. The links between FDC, antibodies and antigen 
A range of in vivo investigations provide clear evidence that complement receptor 
CR1/CR2 (Nielsen 2000), FcγRIIB (CD32), and FcεRII (CD23) (Qin D 2000; Ravetch 
JV 2008; Niederer HA 2009) are involved in antigen trapping, particularly the deposition 
and retention of immune complex on FDCs. IgM is a very efficient activator of 
complement (e.g.C1q) (Getahun A 2006). The complement C3 is cleaved into fragments, 
first C3b, and then C3dg and C3d. Bond C3 acts as a costimulator to B cells via CD21 
and CD19 (Fearon DT 2000). FDC binds C3b via the complement receptor CR1 (CD35) 
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and C3d via CR2 (CD21) (Tew JG 2001; Carroll 2004). CR1 and CR2 expressed on FDC 
are important for presentation of antigen to B cells and the induction of immunologic 
memory (Toapanta FR 2006; Speth C 2008). On phagocytes, CR1 cooperates with 
FcγRIIB to bind and ingest foreign material (Ravetch JV 2008). CR2 is thought to 
cooperate with FcεRII, the low affinity receptor for IgE, to regulate the production of IgE 
(Aubry JP 1992). IgG immune complexes bind the low affinity FcγRII (10×106 M-1) on 
FDC (Ravetch JV 2008; Niederer HA 2009). Possibly, IgM-IC deposition on FDC is 
mainly dependent on CR1 and CR2. It has been proposed that this could increase the 
effective concentration of antigen available to stimulate germinal centre B cells (Tew JG 
1997).  
 
Fcα/µR was recently identified as a high affinity Fc receptor for IgM (~3×109 M-1), and 
intermediate affinity receptor for IgA (Shibuya A 2000; Kikuno K 2007; Kubagawa H 
2009). The Fcα/µR gene is localized on chromosome 1 (Shibuya A 2000; Shimizu Y 2001), 
close to other Fc  receptor genes, including FcγRI, II, III, and IV (Daeron 1997; 
Nimmerjahn F 2006), the polymeric IgR, and Fc homologues (Davis RS 2001). Fcα/µR is 
expressed on hematopoietic cells (e.g. B cell and macrophage) and various 
nonhematopoietic organs including liver, kidney, small and large intestines, testis and 
placenta, but not on granulocytes or T cells. In the mouse spleen, Fcα/µR is expressed 
preferentially on FDC, MZ B cells, and follicular B cells (Kikuno K 2007; Honda S 
2009). Recent work in Fcα/µR knock-out mice suggests that the receptor negatively 
regulates antigen retention by FDC, resulting in the suppression of GC responses. This 
was conluded from the presence of germinal centres in responses that develop in the 
absence of Fcα/µR to TI-II antigen (Honda S 2009). Fcα/µR is believed to function by 
trapping IgM immune complexes and presenting the intact antigen to B cells in germinal 
centres (Kikuno K 2007; Kubagawa H 2009; Czajkowsky AM 2010). During the early 
immune response, IgM is the predominant Ig isotype, therefore Fcα/µR may have more 
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pronounced effects than FcγRII for the presentation of immune complex on the FDC 
network in the early germinal centres.  
 
Antigen opsonized by IgM and complement as immune complex may be captured on 
FDC by binding to CR1/CR2 and/or Fcα/µR (Fig 3.22). The binding of CR2 to C3d is 
complex, possibly involving bivalent interactions (Sarrias MR 2001). The association of 
C3d with CR2 is of electrostatic nature and therefore reversible (Morikis D 2004; 
Toapanta FR 2006). The affinity of this interaction is relatively low (KD: ~5×107 M-1) 
(Sarrias MR 2001). Interaction of CR1 with complement is also reversible. As mentioned 
above Fcα/µR binds IgM with relatively high affinity, but this is thought to be a 
monovalent interaction (Shibuya A 2000). This means that, apart of the interaction of C3 
with antibody/antigen, all bonds between FDC and antigen are reversible. More 
importantly, all interactions are in the range of the avidities of the multimeric IgM 
antibody present in the early immune complex, making it possible that IgM is released 
from the immune complexes on FDCs as soon as the IgM – antigen bond is broken due to 
competitive binding of higher avidity endogenous antibody (Fig. 3.22).  
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Figure 3.22: The proposed binding mechanism of immune complex on FDC 
Antigens opsonized by IgM and complement as immune complex are captured on FDC 
by binding to CR1/2 and/or Fcα/µR. The affinity of C3d with CR2 interaction is 
relatively low, and reversible (green circle). Interaction of CR1 with complement is also 
reversible (green circle). Fcα/µR binds IgM with relatively high affinity, but this is 
thought to be a monovalent interaction (Green circle). Apart of the interaction of C3 with 
antibody/antigen, all bonds between FDC and antigen are reversible. All interactions are 
in the range of the avidities of the multimeric IgM antibody present in early immune 
complex. Possibly IgM is released from the ICs on FDC as soon as the IgM – antigen 
bond is broken due to competitive binding of higher avidity endogenous antibody.  
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3.3.3. Is antibody replacement dependent on antibody avidity? 
Our hypothesis of an antibody avidity dependent selection threshold in GCs predicts that 
antibody inside the GC is in a dynamic equilibrium with antibody outside the GC. 
Antigen has been shown to be retained on FDCs for extended period of time (Mandel T 
1980). Antibody in IC should be replaced by higher avidity antibody, as the GC reaction 
proceeds. If this process is dependent on avidity, antibodies in GCs of different avidity 
should have different half-lives. Testing this gave two results. At the time when the 
highest amount of extraneous IgMa was seen on FDCs, there seemed to be a loss of 
endogenous IgMb at the same locations. Conversely, at later stages, IgMa-IC seen in GCs 
started to disappear, and was hardly detectable in GCs by day5. During the same time, 
high amounts of endogenous IgMb-IC were seen on FDCs. GCs contained few 
antigen-specific (NP+) B cells at day3, and by day5, large NP-specific GCs were 
established, while considerable numbers of plasma cells in the extrafollicular foci 
produced amount of NP-specific antibody. Antigen specific B cells that are activated 
during the first 2 days after NP-CGG immunization in CGG-primed mice, undergo 
extensive proliferation either in extrafollicular foci or as a part of the GC reaction 
(Toellner KM 1996). Antibody production from new NP+ plasmablasts starts after day3, 
coinciding with the time when sporadic NP-specific cells and small antigen-specific GCs 
were seen. The number of NP+ plasma cells in the red pulp peaks at day5 when most of 
the cells come out of cell cycle and GCs reach their peak size at around day4. Some of 
the NP+ plasma cells in the red pulps at day5 were found to have mutated V region 
sequence and therefore appear to be early emigrants from GCs (Sze DM 2000). Here, we 
found high numbers of NP+ plasma cells produced in extrafollicular foci, a fraction of 
these are likely to have developed from large antigen-specific GCs, where they may have 
acquired mutations, producing higher affinity B cell receptor that led to their positive 
selection. These cells would produce higher affinity antibody. It seems likely that these 
higher avidity IgMb antibodies generated from new plasma cells could diffuse back to 
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replace the low avidity IgMa in IC, leading to changes in the selection threshold. Even 
though this experiment did not directly observe the replacement process in the tissue, it 
seems likely that antibody retained on FDCs is dynamic and capable of being replaced 
during an immune response. 
 
The LoAv antibody clone82 was shown by BiaCore to be the lowest avidity antibody 
used in this experiment. It has a very fast on-rate and also a very fast off-rate 
(dissociation rate). Avidity (and affinity) is a factor derived from association and 
dissociation rate, although a slow dissociation rate is considered to be the primary 
determinant for antibody affinity (Andersson K 1998; Batista FD 1998). This explains 
why clone82 quickly disappeared from IC on FDCs. 
 
Soluble antibody injected rapidly moved into the FDC network during an ongoing GC 
response. This result may imply that the replacement of antibody in immune complexes is 
a passive transport. To provide further evidence for this, new experiment should be 
designed to detect high and low avidity antibodies. This could be done by marking 
antibodies of different affinities, e.g. FITC or biotin, and following their deposition on 
FDCs.  
 
HiMAv IgMa-IC was still easily detectable in GC at day5 after injection while LoMAv 
IgMa-IC had almost disappeared. This suggests that avidity could influence replacement 
in IC, so there must be on-off binding of the antibody to the antigen, particularly dynamic 
equilibrium of antibody from outside GCs and inside. This means that antibodies are not 
fixed in immune complexes on FDCs, e.g. hidden behind cell membranes as iccosomes or 
covalently linked via complement receptors, although a proteinase dependent process 
could release even covalently fixed antibodies (Andersson K 1998).   
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3.3.4 The impact of different avidity immune complex in GC B cell selection 
IC can facilitate rapid activation of lymphocytes, indeed captured and deposition by 
antigen-presenting cells (APCs) can induce faster and/or stronger GC development 
compared to immunisation with antigen alone (Kunkl A 1981; Ehrenstein MR 1998; 
Ferguson AR 2004; Corley RB 2005). IgM-IC is deposited on FDCs, dependent on their 
expression of complement receptor CR1/CR2 (CD35/CD21) and may thereby increase 
the effective concentration of antigen available to stimulate B cells (Tew JG 1997). 
Physical association between CD21with CD19 and CD81 (TAPA-1) on the surface of B 
cells, lowers the threshold for B cell activation (Boackle SA 1998). This may explain our 
finding that immunization with IgM-IC can improve the GC B cell responses. A recent 
study reported that IgM may have function in concentrating antigens in secondary 
lymphoid organs and stimulating both CD4 T cells and B cells, efficiently facilitating GC 
formation (Corley RB 2005). 
 
In line with this, IgMa-IC rapidly promoted GC formation during the carrier-primed 
response to NP-CGG. Furthermore, the avidity of antibody in IC could affect the selection 
of GC B cells. ELISA data showed that although no difference in the total amount of 
endogenous IgMb production was seen in between the HiMAv and LoMAv groups, higher 
affinity Ig was detected at day5 after mice received higher avidity IC at the early stage of 
GC development. GC B cells scan antigen trapped on FDCs (Schwickert TA 2007). If 
avidity dependent competition for antigen access is important, HiMAv IgMa-IC may give 
higher avidity GC B cells a selection advantage. These B cells may expand better 
compared to an environment with a low selection threshold, producing a greater plasma 
cell output, resulting in the early onset of high avidity antibody.  
 
There are several possible mechanisms how B cells may compete for antigen-derived 
signals. GC B cells are prone to apoptosis. Isolated GC B cells will die within hours, 
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unless survival signals such as BCR stimulation and CD40 dependent signals are received 
(Liu YJ 1989). BCR mediated signals are dependent on access to antigen. Signals from 
BCRs without high enough affinity for antigen will just receive a small or brief signal, 
and will die (Tarlinton DM 2000). Selection may be due to direct competition between B 
cells due to limited access to the antigen because of spatial restrictions (Meyer-Hermann 
ME 2006), or affinity dependent access to antigen. Competition for space is not affinity 
dependent, therefore a further selection process on T cells is necessary (Meyer-Hermann 
ME 2006; Allen CD 2007a; Allen CD 2007b). A single GC T cell is suggested to only 
form a stable interaction with GC B cells that present the highest number of antigen 
peptide-MHC class II complexes compared with neighbouring cells (Allen CD 2007b). 
Therefore high affinity GC B cells would gain an advantage in obtaining T cell help. 
Direct competition between B cells may also be dependent on the affinity of the BCR 
(Andersson K 1998). Because GC B cells are in close proximity, higher-affinity cells 
might be able to pick up antigen from the surface of lower-affinity cells in direct cell-cell 
competition, prior to antigen internalization (Allen CD 2007b). Higher-affinity cells 
might be able to capture more antigens during rapid movement past the FDC processes. 
Furthermore, B cells may compete with antibody for access to antigens in IC on FDCs. 
This antibody initially will be natural antibody of low affinity. Later, this may be replaced 
by higher affinity antibody, raising the selection threshold. The higher affinity antibody 
may be either antibody arriving from outside the GC (Tew JG 1997), which is the 
hypothesis that has been tested in this thesis, or it may be antibody that is shed from 
centrocytes that have passed over and been selected on IC (Andersson K 1998). A further 
study recently showed that low affinity B cells in GC may have an intrinsically higher 
death rate (Anderson SM 2009), and so high affinity antibody in GC may act as a 
threshold and directly induce the relative low affinity B cells in the GC to undergo 
apoptosis. 
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To further prove the influence of different avidity IC for GC B cell selection, higher 
avidity IC was used. As expected, HiAv IgMa-IC was apparent in GCs at day5 after 
immunization compared with LoMAv IC, confirming that avidity is a major factor for the 
antibody replacement in GCs. More interestingly, mice which received higher avidity 
IgMa IC developed much smaller GC at d5 and d7, and fewer plasma cells in 
extrafollicular foci. It can be assumed, that the mutations introduced during the Ig 
hypermutation in centroblasts will lead to only limited variations in affinity. Raising the 
selection threshold too much in a short time will lead to negative selection of the vast 
majority of GC B cells. This may in the extreme case lead to complete abolition of the 
GC reaction, due to induction of apoptosis in most GC B cells. Mathematical modelling 
experiments, done in parallel to our experiments, lead to the same results (discussed 
later). 
 
It has been noted previously that duration of the GC response and the availability of high 
affinity antibody or free antigen correlate. Bleeding of animals during an antibody 
response leads to a prolonged GC response (Tew JG 1980). According to the antibody 
feedback selection model this could be explained by the absence of antibody feedback in 
GCs leading to low selection pressure, resulting in a prolonged GC reaction. In a similar 
way, giving specific antibody during an immune response has been shown to dampen the 
immune response, which may be due to raising the GC selection threshold (Tew JG 1973). 
Therefore, antibody feedback may terminate the germinal centre reaction.   
 
The response of anti-hapten in carrier-primed mice will be of low titre and affinity 
compared to a primary response, due to reduced thresholds of B cell activation during the 
recruitment of B cells into the responses, and free hapten in carrier-primed responses 
resulting in relaxed selection of centrocytes in GCs (Sze DM-Y 2002). This is the reason 
that soluble LoMAv antibody was detected in the GC after NP-CGG response in the 
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carrier-primed mice, not in the GC after the primary response to NP-CGG. As ELISA data 
has showed, LoMAv IC in the carrier priming will finally induce the same high affinity 
response as HiMAv IC and HiAV IC. So the carrier priming could expand the repertoire 
of B cells recruited, enabling them to respond faster upon encountering further variations 
of the pathogen, and the high finally antibodies in response will develop later. Conjugate 
vaccines are increasingly being used to raise immunity to bacterial capsule 
polysaccharide in infants, such as tetanus and diphtheria toxoids (Anderson 1983; 
Schneerson R 1983). The significant effects of carrier priming should be considered when 
designing immunization strategies. 
 
3.3.5 Mathematical modelling of Ab production and GC reaction 
The data described here reproduce predictions from in silico experiments of GC 
responses that were done in parallel studies. These experiments (M. Meyer-Hermann, A. 
Reynolds) were done by modelling 3D interactions and movements of GC B cells. 
Models were developed with or without a positive selection step where B cells have to 
compete with antibody in IC on FDCs. Furthermore this antibody was replaced over time 
with antibody of a similar affinity to GC output cells. Experiments were done where the 
affinity of the competing antibody in IC on FDCs at the beginning of the experiment were 
either low or high from the beginning (similar to our experiments described here).  
 
The results from these in silico experiments showed that GC B cell affinity increased 
over time under all conditions. However, introducing a selection step that makes B cells 
compete with antibody on IC accelerated the appearance of positively selected high 
affinity mutant clones. The development of high affinity was further accelerated, if the 
affinity of antibody in IC varied over time and represented the affinity of clones leaving 
the GC after positive selection (A Reynolds unpublished). Varying the affinity of the 
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extraneous antibody present at the onset of the response had the effect that high affinity 
clones appeared earlier (around day 5 after the simulation), but this effect was lost during 
the next days (M Meyer-Hermann, unpublished) (Fig 3.22). These in silico studies were 
done to simulate what was done by us in vivo. High affinity antibody induces the earlier 
onset of high affinity GC output.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23: In silico simulation confirms that a dynamic increasing selection 
threshold is more efficient in producing high affinity antibodies 
Independent in silico modelling study showing the effects of a dynamic selection 
threshold which is dependent on the affinity of antibody produced by plasma cells 
generated earlier in this GC.  
- GCs with dynamic threshold produce high affinity output cells quicker and at higher 
affinity (compare coloured to black curve).  
- High affinity antibody leads to higher affinity GC output, but this effect is strongest at 
the early stages of the response (compare red and green at day 5) 
 
 
In silico experiments also modelled the size of GC reaction. In all simulations B cell 
number peaks at approximately 108 hours (about 4-5 days), and then reduces. The 
kinetics are quite similar to NP-CGG immunization of carrier-primed mice or primary TD 
antigens if immediate T cell help is available (Liu YJ 1991; Toellner KM 1996; Sze DM 
2000). After low affinity antibody simulations, GCs remain until 360 hours. This 
response suddenly reduces and is truncated to 180 hours in the simulations containing 
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very high affinity antibody (Fig 3.23 A). The experiments have also shown that mutation 
rates are minimal when high affinity antibody is injected and that endogenous high 
affinity antibody does not develop significantly. The fraction of high affinity output cells 
and mutations per output cell is highest when an intermediated affinity antibody is 
injected. The highest rate of apoptosis per GC volume is predicted to occur when high 
affinity antibody is used for immunization (Fig 3.23 B) (Meyer-Hermann, unpublished). 
Finally Meyer-Hermman et al predicted that low affinity antibody would have minor 
effects on the kinetic of GC development, but very high affinity antibody injection would 
dramatically decrease the size of the GC reaction, and raise apoptosis levels. GC outputs 
would be very small, however, these outputs would be of higher affinity. This is exactly 
matched by what we found in our in vivo experiments. Smaller GCs and less fewer 
plasma cells in the red pulps were detected after injection with HiAv IgM-IC. In addition, 
the total titre of IgG was low, and the titre of high affinity IgG did not increase 
significantly, but the fraction of high affinity IgG was significantly higher (Fig3.14). The 
parallel mathematical modelling experiments further confirm that a dynamic selection 
threshold produces stringent selection for GC B cells, and induces more efficient affinity 
maturation early in the response. 
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Figure 3.24: In silico simulation confirms that a dynamic increasing selection 
threshold is more efficient in producing high affinity antibodies  
Germinal centers are not considerably affected by the injection of low to medium affinity 
antibody. However, injection of high affinity antibody stops the GC reaction by a strong 
induction of apoptosis. A: the kinetic of total number of B cells following the time, and 
(B) the kinetics of apoptotic cells at the same time point. 
 
 
3.3.6. Effects of immune complex on the extrafollicular response 
BCR affinity for antigen may control the B cell terminal differentiation pathways: 
activated B cells with low affinity BCR move preferentially into follicles to become GC 
B cells, whereas modest affinity clones become short-lived plasma cells (O'Connor BP 
2006; Paus D 2006; Benson MJ 2007). The recent in vivo GC imaging reveals that GC 
seeding is an ongoing process and that only B cells with a competitive advantage in 
antigen binding can join a preexisting GC reaction (Schwickert TA 2007). A recent study 
showed that Fcα/µR, the Fc receptor for IgM on B220+ spleenic cells, could mediate 
endocytosis of IgM-coated antigen by B cells (Shibuya A 2006). Therefore LoMAv 
IgMa-IC may help increase the antigen-binding capacity of B cells, resulting in more 
activated B cells in response.  
 
Some studies have provided evidence for affinity-independent cell entry into GCs. Where 
clonal competition occurs and higher affinity clones preferentially differentiate to plasma 
cells and memory B cells (Dal Porto JM 1998; Dal Porto JM 2002; Phan TG 2003; Paus 
D 2006). 
 
Our experiments about the effects of antibody avidity on the extrafollicular response did 
not detect significant differences between groups after they received free NP-Ficoll or 
NP-Ficoll in the form of IgD/IgM-IC. This confirms that ICs mainly affect the GC 
response. Ehrenstein (1998) has compared the follicular response to protein antigen to the 
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extrafollicular response to TI-II antigen in mice that cannot make soluble antibody 
(sIgM). While the GC response is inhibited in the absence of sIgM, the extrafollicular 
response is increased when the epitopes are kept free (Ehrenstein MR 1998). Further the 
previous research reported that the administration of IgM complexed with T-independent 
antigens had no effect on antibody titre, duration or affinity maturation, despite increased 
antigen deposition in lymphoid follicles (Corley RB 2005). These results support the 
finding that antibody affinity in IC has a minimal effect for the extrafollicular response. 
 
Haberman’s review (2003) discussed the hypothesis that immune complex retention by 
FDCs is not required for germinal centre development. It is difficult to imagine how 
evolution of high affinity clones can happen without repeated contact with antigen. 
However, the role of antigen is not disputed in this review. Hannum (2000) shows that 
there is less antigen presented in GC, but there is also less antibody to cover epitopes, 
therefore the two effects may cancel out each other. Further, Germinal centres in mTg 
mice are much bigger than normal (Hannum LG 2000). Possibly there is less positive 
selection, and therefore bigger GC, as GC B cells are not leaving GCs, similar to that 
reported in AID-/- mice (Muramatsu M 2000).  
 
3.3.7. Final outlook 
Studies on hypermutation in germinal centres could be done to more directly show that 
the effects on antibody affinity observed are due to changes in GC selection during 
affinity maturation. EYFP expression in GC B cell of Cg1-Cre × ROSA eYFP mice can 
be used as a marker to easily FACS sort GC B cells. Germinal centres with less stringent 
B cell selection would be expected to show clonal relationships between individual GC B 
cells that produce genealogical trees that are less “bushy” than sequences GC B cells that 
have developed in under high stringency selection, while genealogical trees from GCs 
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with high selection pressure would have ‘pruned’ genealogical trees (Banerjee M 2002; 
Dunn-Walters DK 2002). 
 
IgMa-IC deposit on FDC may increase the GC B cell activation and affinity maturation 
by fixing complement and bridging BCR with complement receptor (CR1/CR2). Mice 
deficient in CR1/CR2 (Molina H 1996) can be used to study the role of different CRs 
compare to Fc-receptors for development of germinal centres. Specific complement 
receptors can be blocked with soluble CRs. We have recently received Ig-CR2 and will 
block C3 interaction to address this. Specific for antibodies to different variants of C3 and 
different CRs on FDC may be used to detect on FDC during different stages of the GC 
reaction, and the role for entry of immune complex into the spleen (van den Berg TK 
1992). We can selectively inhibit immune complex trapping by FDC with monoclonal 
antibodies against C3. The role of Fcα/µR expressed on FDC may be tested by using 
F(ab’)2 fragment of different affinity during immunization.  
 
An important aspect that has not been addressed is the role of Ig class switching for the 
regulation of the germinal centre reaction. Ig class switching produces a dramatic 
decrease in antibody avidity. At the same time IgG inhibits B cells activation binding 
inhibitory Fcγ receptors on B cells. The interaction between FDC, B cells, IgG and 
antigen are expected to be complex, but they may provide another mechanism to prolong 
the germinal centre reaction producing a lower selection threshold, once high affinity 
switched plasma cell clones have emerged from the germinal centre. Others have shown 
that pre-formed antigen-IgG1 complex can have effects on GC formation, clonotypic 
repertoire and stimulate somatic mutation in GC B cells (Nie X 1997; Song H 1998; Song 
H 1999). We have several NP-specific IgG hybridoma clones of different affinity and 
subclass (e.g. IgG3, IgG1) available to investigate their effect for B cell response.    
 
 115
Manipulating immune responses with affinity antibodies may be a useful way to 
accelerate affinity maturation in vaccine responses, either in situations, where a very fast 
onset of high affinity antibody production is desirable, or in aged individuals. Aged 
individuals have lower germinal center responses and problems with B cell selection in 
germinal centers, leading to reduced affinity maturation (Gibson KL 2009). The exact 
reasons are not clear, but if it is due to defects in production of antibody from germinal 
centre emigrant plasma cells, manipulation antibody responses in aged individuals with 
antibody competition would be a good way to increase GC selelction pressure and 
affinity maturation. Preliminary experiments on aged mice indicate that our immunization 
protocol may accelerate and improve affinity maturation in aged individuals. We will do 
further experiment to confirm this, and then plan to expand this to real pathogens. Targets 
would be vaccine antigens with little variation, where the production of such a complex 
and highly specific agent such as an antibody would make economical sense, and to 
provide fast acting vaccines for situations, where a very fast onset of affinity maturation 
is desired, as is the case after the onset of an epidemic.  
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Chapter 4 Plasmablast differentiation from Germinal Centres 
4.1 Introduction 
Antigen-activated B cells enter cell cycle in the T zone, and these B blasts subsequently 
differentiate into either plasmablasts that form extrafollicular foci at the junction between 
the red pulp and T zone, or GC founding cells in follicles (Liu YJ 1989; Jacob J 1991; 
Toellner KM 1996). A recent study from our group (Marshall, Zhang et al submitted for 
publication) analysed the gene expression associated with B blast differentiation by 
sorting single responding B cells on the basis of molecules expressed on the cell surface 
in QMxC57BL/6 mice after NP-Ficoll immunization at the different time points. The 
study showed that Bcl6 mRNA, but not protein, is expressed in naïve B cells. Bcl6 
mRNA is repressed while B blasts move through the T zone 24-48h after immunization. 
At the same time Aicda mRNA is induced. This is lost 3 days after immunization when B 
blasts have moved into the red pulp, and express CD138. Transcription factors inducing 
plasma cell differentiation such as Blimp-1 and Xbp-1, and the mRNA for the 
downstream transcription factor Bob-1 are strongly induced. Finally Ig protein is 
produced in these CD138+ plasmablasts. At the same time, GC founding cells appear in 
follicles, and re-express Bcl6 mRNA (and protein) and Bach2. Plasmablasts at this time 
completely lose expression of Bcl6, Bach2 and Pax5 mRNA (Fig 4.1).   
 
IRF4 is a transcription factor that positively regulates the gene expression of Aicda and 
Prdm1 (which encodes the Blimp-1), and also represses Bcl-6 to terminate the GC 
transcriptional programme (Sciammas R 2006; Teng Y 2007). It is not clear whether IRF4 
acts as upstream of (Sciammas R 2006), in parallel to (Klein U 2006), or downstream of 
(Kallies A 2007a) Blimp1 in the generation of plasma cells. So far, all studies agree that 
IRF4 and Blimp-1 can increase XBP-1 transcription (Shaffer AL 2002; Klein U 2006), 
and so coordinate expression of Blimp1, IRF4, and XBP-1 regulates plasma cell 
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differentiation (Kallies A 2007b). Recent studies from our lab have shown that IRF4 is 
expressed at low levels in naïve B cells, and intermediately expressed in activated B cells 
when they enter the T zone after stimulation by NP-Ficoll in QMxC57BL/6 mouse. IRF-4 
expression is lost when B blasts move into follicles and differentiate into proliferating 
centroblats. IRF4 can be found in a fraction of centrocytes which have been committed to 
differentiate into plasma cells, and is highly expressed in plasma cells (Falini B 2000; 
Marshall 2009) Thesis UoB). Low level expression of IRF4 may activate Aicda gene 
combining with Pax5 (Gonda H 2003), and Pax5 at this stage prevents Blimp-1 induction 
by promoting Bcl6 expression (Nera KP 2006). Increased IRF4 expression can inhibit 
Bcl-6 and induce Prdm1, and in turn, Prdm1 could feed back to enhance the IRF4 gene 
expression (Sciammas R 2006) (Fig 4.1). Theoretical studies suggest that low level of 
transcription factors like IRF4 could be critical for cells going through a phase of 
multilineage transcriptional priming (Laslo P 2006). IRF4 is required for the generation 
of plasma cells from both GC and memory cells (Klein U 2006; Jourdan M 2009). Even 
though it probably isn’t critical for the generation and proliferation of memory B cells, 
IRF4 is expressed on memory cells (Cattoretti G 2006a), and may maintain memory cell 
pool (Klein U 2006). 
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Figure 4.1: Plasma cell and memory B cell differentiation.  
Changes in transcription programs that promote GC B cell differentiation towards plasma 
cell or memory B cell fate. Activated B cells move into the outer T zone, and then move 
back into follicles to form GCs, and then differentiate into plasmablasts. Alternatively 
they may directly differentiate into plasmablasts to form the early extrafollicular response. 
Int.: Intermediate. Act. B cell: Activated B cells. 
 
In the classic model, activated B cells travel into follicles and form the GC. Germinal 
centre B cells will proliferate and undergo hypermutation in the dark zone, then move 
into the light zone, where they test the specificity of BCR by binding antigen in immune 
complex on FDC. This is followed by interaction with follicular T helper (TFH) cells, 
which may lead to class switch recombination (Liu YJ 1996b) and to differentiation of 
high affinity antibody producing plasma cells or memory B cells (MacLennan 1994). It is 
not clear how successfully selected GC B cells move out from the GC: via the LZ, DZ, or 
from both (Fig 4.2).  
 
In recent in vivo studies by multiphoton microscopy it was observed that cells in both 
light and dark zones have similar morphology and velocities, and transit occurs between 
dark and light zones in both directions in an apparently random way (Schwickert TA 2007; 
Allen CD 2007a; Hauser AE 2007a). These observations challenged the classical model 
in which GC B cells preferentially migrate from the dark zone to the light zone with 
recirculation back to the light zone, and have led to the proposal of alternative models of 
migration.  
 
Studies on GCs from human tonsils had led to the conclusion that proliferation in GCs 
mainly occurs in the DZ. However, the recent work has shown that in murine GCs cells 
progress through the cell cycle in both DZ and LZ (Wang Y 2005; Allen CD 2007a; 
Hauser AE 2007a). Within both zones cells can be found going into S phase, with a 
higher frequency of cells in G2/M phase in the DZ (Allen CD 2007a; Hauser AE 2007a). 
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Figure 4.2: the B cell migration in Germinal Centre 
In the classical GC model, centroblasts proliferate and  undergo hypermutation in the 
DZ, and they then move into the LZ, differentiating into centrocytes. Centrocytes test 
their BCR by binging antigen on FDCs, followed by competing for signals from helper T 
cells. Cells will do apoptosis if they can’t get signals from FDC or T help cells. Finally, 
successfully selected cells will move back into the DZ and do further recycling, or 
differentiate into plasma cells or long lived memory cells. The path, where selected cells 
take when leaving the GC, is not clear. LZ: Light zone, DZ: Dark zone. CB: Centroblast, 
CC: centrocytes, FDC: Follicular dendritic cell, T: follicle T helper cell. 
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Dependent on the time of immunization, proliferation and apoptosis can be seen in 
different zones of the GC. Early GCs can be seen as a focus of proliferating blasts inside 
follicles (MacLennan IC 1988). Separation into clear dark and light zone occurs later, 
with proliferating B cells in both (Fig. 4.3 A). Apoptotic cells and tingible-body 
macrophages are detected in dark and light zones (Fig 4.3B). Hauser et al (2007b) 
suggested that successive rounds of selection and mutation may occur within each zone, 
and also proposed the ‘intra-zonal circulation model’ where multiple rounds of selection 
and proliferation are required for the generation of high-affinity antibodies. Currently, it 
is not clear how these intravital studies should be interpreted and what the exact 
migratory processes in GCs are. A theoretical study reinterpreting intravital data showed 
that the observation periods of the intravital experiments are currently not long enough. 
So far the available intravital data does not exclude the traditional dark–light zone 
re-entry model (Meyer-Hermann ME 2006; Figge MT 2008). 
 
Figure 4.3: Proliferation and apoptosis happen in both light and dark zones 
A: Spleen section from C57BL/6 mouse was stained with BrdU. The animal was 
immunized with SRBC, d5 it received BrdU 2hr before sacrifice. The light zone can be 
defined by the presence of T cells (Blue), and immune complex on FDC (light brown 
staining). Cells in both zones are undergoing proliferation (BrdU+). B: spleen section, 
from d5 after NP-CGG response in the carrier-primed mouse, was stained for active 
Caspase3. Apoptotic cells appear in both zones. F: Follicle, T; T zone, GC: Germinal 
centre. 
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Follicle T helper cells and FDCs in the light zone may provide signals for cell division 
and selection. Further cells proposed to be important for selection are accessible for dark 
zone B cells either at the GC periphery or at the T-B zone interface (Lindhout E 1993; 
Fischer MB 1998; Haberman AM 2003). T-B zone interfaces are portions of the dark 
zone base in direct contact with T zone. The outer T zone contains activated T cells and 
DCs during the TD response (Grouard  G 1996; Pape KA 2003; Okada T 2005). DCs in 
the T-B zone interface are theoretically capable of providing signals similar to those 
thought to be provided by FDCs, including presentation of retained, undegraded antigen 
(Wykes M 1998; Bergtold A 2005; Qi H 2006; Hauser AE 2007b). Low numbers of T 
cells can also be found in the dark zone (Arnold CN 2007; Haynes NM 2007). Studies in 
human tonsil found that T cells in the GC–T area interface express preformed CD40L 
similar to TFH cells (Casamayor-Palleja M 1995). T cells in this area could play a role in 
GC B cell selection, providing that GC B cells would enter the T zone in this area. 
Real-time imaging observed the movement of GC B cells toward and away from the GC 
at the dark zone-T zone interface (Hauser AE 2007a). 
 
The aim of this part of the project was to study the development and migration of 
plasmablasts leaving the germinal centre:  
1) To determine the timing of IRF4 expression on B cells after stimulation 
2) To identify the expression of IRF4 cells in different zones of the GC. 
3) To confirm whether IRF4+ cells on the GC-T zone interface are plasmablasts and 
whether they are derived from the adjacent GC. 
4) To detect which costimulatory signals or cytokines may affect the generation of the 
early IRF4+ plasmablasts on the GC-T zone interface by working on mice deficient 
costimulatory signals or cytokines. 
5) To determine which signals are important for the production of the early plasmablasts 
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and locate sites of these signals on spleen section. 
 
The main approach used was immunohistology to investigate the location and time of 
early IRF4+ cells, and define the expression of these cells. Furthermore, mice deficient 
for cytokines and costimulatory molecules which may be involved in GC B cell selection 
were used to follow plasmablasts exiting from GCs. Histology, microdissection and 
RT-PCR were used in combination to define these signals and locate the site of their 
production. 
 
4.2 Results 
4.2.1 IRF4 is induced rapidly after B cell activation 
To test the timing of IRF4 induction in B cells, QMxC57BL6 mice were immunized with 
NP-Ficoll. Surprisingly, IRF4 is induced rapidly after B cell activation. Using real time 
RT-PCR to detect IRF4 mRNA from whole frozen spleen sections shows that IRF4 
mRNA levels peak within 1h after immunization and then quickly fall again, keeping at 
the intermediate level (Fig 4.4 A). FACS sorted B cells were analysed for their IRF4 
mRNA expression. In naive B220+ B cells low levels of IRF4 mRNA were found. IRF4 
was strongly upregulated on B220+NP+FITC+ (antigen binding) cells at 1h after 
immunization with NP-FITC-Ficoll (Fig 4.4B). Over the next hours mRNA expression 
levels fell again, and stabilized at intermediate expression levels at 4 hours. Finally, it was 
highly expressed when plasmablasts started to express CD138+. The high expression level 
of IRF4 mRNA on activated B cells at 1h corresponds to the expression levels in 
plasmablasts.   
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Figure 4.4: IRF4 mRNA expression after NP-Ficoll immunization 
A: IRF4 mRNA level was measured in the whole frozen spleen section at the different 
time points after NP-Ficoll immunization in QMxC57BL/6 mice. B: Responding B cell 
populations from spleen sections were analysed for their expression of IRF4 mRNA at 
different time points after NP-Ficoll immunization. Each diamond represents one animal.  
 
 
NP-Ficoll primarily activates MZ B cells and follicular cells via BCR, and upon activatin, 
B cells then move into T zone (Bajpai UD 2000; Vinuesa CG 2001). In non-immunized 
spleen sections, background NP specific plasma cells can be found in the red pulp. Naive 
NP binding B cells sit in the MZ and follicles (Fig 4.5 A). IRF4 staining shows that the 
same NP+ plasma cells are IRF4 high, whilst MZ B cells are IRF4 low. Only a few 
individual IRF4+ naïve cells travel in follicles. IRF4 protein is detectable in MZ B cells 
within 1h after NP-Ficoll injection (Fig 4.5 B). After 4h NP specific B blasts can be seen 
moving through the follicle, and some already appear in outer T zone, these B blasts 
express intermediate levels of IRF4 protein (Fig 4.5 C). 8h later, the outer T zone is filled 
with IRF4int B blasts, and these B cells express lower level of antigen binding (NP+) than 
naïve MZ B cells, probably due to receptor blocking or internalization. 
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Figure 4.5: IRF4 protein induced shortly after B cell activation 
Serial spleen sections from QMxC57BL/6 mice at the different time points after 
NP-Ficoll immunization were stained with NP/IgD (left) and IRF4/IgD (right). A: 
non-immunized section, B: 1hour, C: 4hour, and D: 8hour. F: Follicle. T: T zone, MZ: 
Marginal zone. 
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ImageJ software was used to quantify the IRF4 staining intensity on the tissue section at 
the different times after immunization (a detailed method is described in section 2.6.1). 
Usually more than 10 areas of the same size were chosen per individual tissue section. 
The mean IRF4 values (blue immunohistological staining) in different areas from one 
spleen section are shown in Fig 4.6 A (marginal zone), C (Follicle) and E (Outer of T 
zone) with the data from several mice in Fig B, D and F. IRF4 protein is detectable at 
very low levels in non-activated marginal and follicular B cells and at all times, 
expression levels were lower than in red pulp plasma cells. IRF4 protein increased above 
background levels within 1h after immunization in the areas, where NP-binding cells are 
found, particularly the marginal zones and follicles, and IRF4 expression reached peak 
levels in 2 hours, and then decreased (Fig 4.5 A B). Within the first 2 hours, the IRF4 
expression level in the outer T zone was low, In the T zone IRF4 was seen from 4 hours 
after immunization, coincident with a reduction of the IRF4 level in marginal zones and 
follicles. This suggests that B blasts have arrived in the T zone. Double staining for 
NP-binding and IRF4 expression shows that all antigen-specific B blasts express 
intermediate levels of IRF4 protein (data not shown). Intermediate levels of IRF4 were 
maintained over the next 2 days on B blasts which reside in the T zone (data not shown). 
Three days after immunization, some B blasts differentiate into plasma cells expressing 
high level of IRF4, and some move into follicles to become GC founding cells that 
become IRF4 negative. Fig 4.7 shows a summary, comparing IRF4 expression in B cells 
of the MZ, T zone, red pulp and follicular location over the time course after NP-Ficoll 
activation.  
 
These results strongly suggest that IRF4 can be used as a general marker for activated B 
cells. As IRF4 is involved in the regulation of AID expression, class switching and 
plasma cell differentiation (Klein U 2006; Sciammas R 2006), we chose IRF4 as a marker 
to investigate GC B cell activation and differentiation.  
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Figure 4.6: Quantification of IRF4 staining colour intensity 
The amounts of IRF4 staining intensity in the marginal zone (A, B), follicle (C,D) and in 
the outer of T zone (E,F) at the different time point were shown.  Each point in Fig 
A.C.E represents one interest region in the marginal zone, follicle, and outer T zone 
respectively. In Fig B. D. F. each point represents media data from one mouse. d0: 
non-immunization. 1h, 2h,4h, 8h, 24h, 96h: hours after NP-Ficoll immunization in 
QMxC57BL/6 mice.  
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A: IRF4 staining in Marginal Zone
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B: IRF4 staining in Marginal Zone
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E: IRF4 staining in Outer T zone
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F: IRF4 staining in Outer T zone
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Figure 4.7: Summary of quantifying IRF4 staining colour intensityThe amounts of 
IRF4 staining intensity in the marginal zone and in the outer  T zone at the different time 
point were shown.  Each point in Fig A represents one region in one spleen section. In 
Fig B each point represents media data from one mouse. d0: non-immunization. 1h, 2h,4h, 
8h, 24h, 96h: hours after NP-Ficoll immunization in QMxC57BL/6 mice.  
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4.2.2 Appearance of IRF4+ cells in the TD primary response 
Firstly, to investigate the timing of IRF4 cells appearing in GCs in C57BL/6 mouse 
spleens, sheep red blood cell (SRBC) was selected as the antigen to induce GCs in 
primary antibody response. Injection SRBC in C57BL/6 mice induces a fast primary 
immune response in spleens. The kinetics are quite similar to the response in lymph 
nodes after footpad immunization with alum-precipitated NP-CGG (Toellner KM 1998). 
T cell priming starts around day 2, when IL-4 mRNA and IgG1 switch transcript above 
increase above background levels, this occurs slightly faster to what has been described 
for other TD responses (Luther SA 1997; Toellner KM 1998). IL-4 and IgG1 switch 
transcripts peak around d3 after immunization (Fig 4.8) before GCs have developed.  
 
We used immunohistological staining to detect the timing of IRF4 expressing cells by 
studying the time course of the primary response. In non-immunized mice we found only 
very few cells expressing intermediate levels of IRF4 in follicles and T zones (Fig 4.9A).  
Apart from B blasts IRF4 is also known to be expressed in mature T cells, and it is 
upregulated upon CD3 stimulation (Matsuyama T 1995). IRF4 detected in the T zone of 
non-challenged spleens may be due to expression on occasionally activated T cells, 
similar to what is seen when naive lymph nodes are stained for BrdU (Luther SA 1997). 
Some background plasma cells expressing high level of IRF4 are seen in the red pulp.  
 
At day3 after immunization, IRF4+ cells were mainly clustered at the outer edge of the T 
zone (Fig 4.9 B). No GC or occasional small GCs are present in follicles. Cells in the T 
zone with IRF4 staining represent activated B cells and T cells. Immunofluoresence 
staining shows that IRF4+ cells at the T zone-follicle interface represent both B cells and 
T cells (Fig 4.10B). Flow cytometry confirms that T cells upregulate IRF4 at day3 after 
immunization. This is reduced at later days (Fig 4.10A). This confirms that T blasts may 
interact with B blasts at this stage in the outer T zone, possibly via expression of CD40L 
 129
as proposed earlier (Casamayor-Palleja M 1995).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: IL-4 mRNA and IgG1 switch transcript expression after SRBC 
immunization 
(A) IL-4 mRNA and (B) IgG1 switch transcript expression level were measured in the 
whole frozen spleen section at the different time point after SRBC immunization in 
C57BL/6 mice. Each point represents one animal. 
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Figure 4.9: Timing of IRF4 cells in outer of T zone at the primary TD response  
C57BL/6 mice were immunized with SRBC. A: d0 tissue section shows the IRF4 staining 
background. B: At day3, IRF4 expressing cells in the outer T zone. C: The quantification 
of IRF4 staining intensity  shows that the maximum of  IRF4  expressing cells 
accumulate at the outer of T zone at day3 after injection, and then reduce. Each point 
represents one area interest in one spleen section at each time point. D: a summary of 
IRF4 staining intensity in the outer of T zone, each point represents one animal. T: T zone, 
F: Follicle 
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Figure 4.10: Activated T and B cells express intermediate level IRF4 at day3 after 
SRBC immunization 
C57BL/6 mice were immunized with SRBC. A: At day3 FACS shows the upregulation of 
IRF4 on T cells, and downregulation at d5 and 8. B: Fluorescent staining further confirms 
that both activated T cells (small white arrow)and B cells (big yellow arrow) express 
IRF4 at the follicle- T zone interface.  F: Follicle, T: T zone. This is representative of 
two individual experiment.  
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The quantification of staining intensity using ImageJ confirms the migration of small 
numbers of activated lymphocytes to the follicle-T zone interface at day2. By day3, IRF4 
cells accumulated in this region, and then became fewer after day4 (Fig 4.9 C.D). This, 
together with data shown in Fig 4.10, confirms that, as shown in previous studies 
(Toellner KM 1998), the onset of T cell priming, and cognate interaction between 
activated B cells and helper T cells at this location occurs 3 days post-immunization.  
 
Germinal centres were clearly seen at day 4 post-immunization. Surprisingly, IRF4+ cells 
were first seen at the GC-T zone interface (Fig 4.11A). At day 5, maximal numbers of 
IRF4+ cells were found in the GC–T zone interface (Fig 4.11B). These cells are usually 
located within the IgD- areas that constitute the GC. The fluorescent staining on spleen 
section at day5 after NP-CGG immunization in the carrier-primed mice further shows that 
plenty of IRF4+ cells at the GC-T zone interface already express CD138 and high levels 
of Ag-specific (NP+) Ig. These cells therefore appear to be plasmablasts (Fig 4.11C-E). 
At this stage IRF4 is mainly expressed in B blasts and plasmablasts, not in T cells (Fig 
4.11C). This is confirmed by flow cytometry staining (Fig 4.10A).  
 
Around 6 to 7 days after immunization, germinal centre has reached maximal size and the 
numbers of IRF4+ cells seen at the GC-T zone interface declined (Fig 4.11E.F). At day9, 
the numbers of IRF4+ cells at the GC-T zone interface appeared to decline further (Fig 
4.11F and H). By day 14, GC size became smaller, and just few IRF4+ cells presented at 
the GC-T zone interface. It seems likely that these IRF4+ cells are early plasmablasts 
leaving the GC at an early stage via the dark zone–T zone interface, and then migrating 
through the outer T zone and develop into plasma cells in the red pulp (Fig. 4.11C-E).  
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Figure 4.11: Timing of appearance of IRF4+ cells at the GC-T zone interface at the 
TD primary response 
C57BL/6 mice were immunized with SRBC and then the GC size and IRF4+ cells at the 
GC-T zone interface were measured by staining IRF4 (blue) and IgD (brown). A: IRF4+ 
cells appear at the GC-T zone interface at d4 just after GCs form. B: Plenty of IRF4+ cells 
present at the GC-T zone interface at d5. Fluorescent staining on the spleen section from 
d5 after NP-CGG response in carrier-primed mice shows that these IRF4+ cells are not T 
cells (C), upregulate CD138 (D) and NP-specific antibody, related to the adjacent NP+ 
GC (E). F: day9 the number of IRF4 cells at the GC-T zone interface reduced. G: the GC 
development during the day time course after immunization, H: the timing of IRF4+ cells 
appeared on the GC-T zone interface after immunization. T: T zone, F: Follicle, GC: 
Germinal centre, PC: Plasma cell. NP-CGG immuzation can help detect antigen-specific 
plasamblasts.  
 
While at day10 the numbers of IRF4+ cells seen at the GC-T zone interface reduced 
further, considerable numbers of IRF4+ cells were found in the LZ (Fig 4.12A). Immune 
complexes on FDC easily produce non-specific staining. Counterstaining with IgM 
confirmed that the IRF4 staining seen in the LZ was specific staining (Fig 4.12B). The 
quantification for the appearance of IRF4 expressing cells in LZ showed that only a few 
IRF4 cells were seen at day5, and more cells appeared at the later response. The number 
of IRF4 cells in LZ reached the peak at day7, and remained until day10 (Fig 4.12C). Four 
colour fluorescent staining of day8 samples showed that while some IRF4+ cells were still 
located on the GC-T zone interface (Fig 4.14 A D: small white arrow), many IRF4+ cells 
now presented in the LZ, particularly in the area adjacent to the follicular mantle where 
the majority of TFH cells localize (Fig 4.13A B C white line). High power magnification 
showed that most IRF4+ B cells were often associated with T cells, possible interacting 
and receiving signals from T cells (Fig 4.13 B C: big white arrows). Additionally, some T 
cells express IRF4 in both LZ and GC-T zone interface. These possibly represent 
antigen-specific activated T cells. IRF4 has been reported to have a function in T helper 
cell differentiation promoting expression of IL-4 and IL-10 (Rengarajan J 2002; Ahyi AN 
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2009), which stimulate B cell differentiation and antibody production (Briere F 1994; 
Toellner KM 1995).  
 
IRF4 expression associated with centrocyte activation in the LZ may be a different 
development phase of B cell differentiation in the GC. It may be associated with memory 
B cell activation or plasma cell differentiation, as some IRF4+ cells in the LZ upregulate 
CD138 (Fig 4.13C and Fig 4.14 D, yellow arrow). Taken together, IRF4 expression cells 
seen in cells in the LZ and GC-T zone interface might indicate that there are two 
pathways of GC B cell leaving GC from either LZ or DZ.  
 
In follicles, two waves of IRF4+ cells were observed at different times after immunization 
(Fig 4.11, Fig. 4.14). Quantification shows that, as mentioned above, naive follicles 
contain considerable numbers of IRF4 expressing cells. IRF4 expressing cells became 
fewer at day2, when activated blasts were seen in the T zone. At day 3, more IRF4 
expressing cells were seen again in follicles. This stage probably corresponds to B blasts 
undergoing rapid clonal expansion at the perimeter of follicles, where they become GC 
feeding cells (Coffey F 2009). At this stage, EBI2 (Epstein-Barr virus–induced gene2) 
expression promotes B cells to move to the outer follicle and inter-follicular regions 
(Gatto D 2009; Pereira JP 2009). By day5, when GCs have formed, IRF4 expressing cells 
reduced in the follicles, but became more abundant after selection of centrocytes in the 
GC light zones had started, around day 8 (Fig. 4.14). This could correspond to the exit of 
the high affinity plasma cells and/or early GC-derived memory B cells, as described. 
Anderson et al showed that memory B cells localize in the outer follicle (Anderson SM 
2007), and IRF4 is known to be expressed on memory B cells (Klein U 2006). The results 
of the timing of IRF4 appearance in the LZ indicate that stable and long-term GC output 
cells may exit from the LZ, though follicles. Also these observations highlight that the 
peripheral GC border may be a substantial component of the migratory route.  
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Figure 4.12: Timing of IRF4+ cells in light zone at the primary TD response 
C57BL/6 mice were immunized with SRBC. A: At day 10, IRF4+ cells clearly presented 
in the light zone. B: IgM as counterstaining further confirmed that these cells in the LZ 
are IRF4+ not non-specific staining on immune complex. C: the quantification data 
shows the timing of IRF4+ cells in the LZ after immunization. Each point represents one 
mouse. GC: Germinal centre, T: T zone.  
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Figure 4.13: IRF4+ B cells in light zone at day 8 after the primary TD response 
Fluorescent staining on the spleen section from C57BL/6 mice d8 after immunization 
with SRBC. A: follicle containing GC and T zone. IRF4+ cells at the  GC-T zone 
interface (small white arrow), and in the LZ close to the follicle mantle (white line). B 
and C with high power magnificent show some IRF4+ cells closely localised with follicle 
T help cells in the LZ (big white arrows). D: IRF4+ B cells at the GC-T zone interface. 
GC: Germinal centre, T: T zone 
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Figure 4.14: Timing of IRF4 expression cells in follicle at the primary TD response  
IRF4 expression cells present in follicles before and after immunization. A: Fluorescent staining shows 
IRF4+ cells in the follicle from d8 after immunization with SRBC in C57BL/6. B, C, D: high power 
magnificent show IRF4+ cells in the follicle, some are CD138+ (big yellow arrow), some are not (white 
arrow). E: The quantification data shows the timing of IRF4 expression cells in follicles. Each point 
represents one animal. GC: Germinal centre, T: T zone, F: Follicle 
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The data of the appearance of IRF4+ cells in different zones and the possible migration 
routes are summarized in figure 4.15. In summary, naïve B cells expressing intermediate 
level of IRF4 recirculate through follicles. After stimulation, B blasts with intermediate 
levels of IRF4 expression start to move to the B-T boundary, where they divide and meet 
antigen-specific T cells. After accumulation in this region, B blasts migrate back to the 
outer follicles, where they may undergo further clonal expansion, and become GC 
founding B cells. By day5 most B cells have joined the GC reaction. Just after GCs have 
formed, early GC-derived plasmablasts with higher levels of IRF4 expression appear at 
the GC-T zone interface. These cells travel through the outer of T zone into the red pulp, 
and differentiate into early GC derived plasma cells. From day6, IRF4 expression is 
detected on the light zone B cells. This may be a different developmental phase, 
involving prolonged hypermutation, and may require a different selection processes on 
FDC and TFH cells. This may lead to the production of long-lived GC-derived high 
affinity plasma cells and memory cells for a long-term humoral response. This should be 
further investigated, for example, by the use of different markers such as CD138 for 
plasma cells, or CD38, CD80 and Pax5 for memory cells. In addition, chemokine 
receptors such as CXCR4 and CXCR5 could be utilise to further identify differentiation 
and migration of IRF4+ cells in the LZ and the follicle mantal at the later stages of the 
response. In this thesis I mainly focus on the characterization of IRF4 expressing cells 
leaving the early GC from the GC-T zone interface.  
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Figure 4.15: Timing of IRF4 expression in different splenic microenvironment 
A: The summary of the timing of IRF4 expression cells in different areas of the white pulp after SRBC 
immunization in C57BL/6 mice. IRF4 expression cells in follicles, the LZ and the GC-T zone interface 
are presented per mm2 spleen area (right scale), IRF4 expression cells in the outer T zone is assessed by 
quantifying staining colour intensity (left scale).  B: After SRBC injection naïve B cells get activation 
and differentiation into B blats expressing intermediate level IRF4 (IRF4+), move into the outer T zone. 
After contract with T cells, they migrate back into the follicle to expand and become GC founding cells 
and lose IRF4 (IRF4-). Just after GC forms,  early plasmablasts expressing high levels of IRF4 
(IRF4++) appear at the GC-T zone interface, whilst in mature GCs, B cells may get preferentially 
selected in the LZ and leave through follicles.  
B: Location of IRF4+ B cells in the white pulp after TD antigen stimulation
T
F
T
F
T
F
T
F
d1-3 d3-4 d5 >d7
Activated B cell
IRF4+
Activated B cell
IRF4+
GC B cell
IRF4-
Early plasmablasts
IRF4++
Memory cells and 
Later plasmablasts
IRF4++
T
F
d4
Dark zone-T zone border
GC light zone
Outer T zone
Follicle
Cells / mm2 Spl (right scale)
Colour intensity (left scale)
Timing of appearance of IRF4 expressionA:
Days after SRBC immunization
0
20
40
60
80
100
120
0
4
8
12
16
20
IR
F4
 c
ol
ou
r i
nt
en
si
ty
IR
F4
 c
el
l s
 p
er
 m
m
2
s p
le
en
d0               d2      d3     d4      d5      d6      d7      d8     d9     d10             d14
Outer T zone
GC-T interface
LZ
Follicle
B blasts: IRF4+
IRF4-
IRF4++
IR
F4
 c
ol
ou
r i
nt
en
si
ty
IR
F4
 c
ol
ou
r i
nt
en
si
ty
IR
F4
 c
ol
ou
r i
nt
en
si
ty
IR
F4
 c
ol
ou
r i
nt
en
si
ty
IR
F4
 c
ol
ou
r i
nt
en
si
ty
 141
4.2.3 Characterization of IRF4 expressing cells on GC-T zone interface 
To identify the differentiation stage of IRF4+ cells at the GC–T zone interface we used a 
selection of markers typical for plasma cell and GC differentiation. All studies were 
performed in early stage GCs, 5-6 days after immunization with SRBC. . 
 
Cg1-Cre xROSA-eYFP mice were used to identify the presence of cells that have 
undergone through induction of IgG1 switching, as B cells which have undergone this 
process, become eYFP positive (Fig. 4.16). Typically, most GC B cells appear yellow, 
and eYFP expression shows that a B cell is likely to be derived from GCs (Casola S 
2006). Three days after SRBC immunization individual eYFP+ cells appear in the outer T 
zone and the inner follicle (Fig 4.16A). This represents extrafollicular T–B cell 
interaction (as discussed above). By day4, activated B cells have already differentiated 
into extrafollicular plasmablasts in the junction between T zone and the red pulp, and into 
GC B cells in follicles (Fig 4.16 B). Around 40% of these plasmablasts, which have 
developed outside follicles, are eYFP positive (data not shown). At day6, large GCs (and 
larger plasma cell foci) have developed. GC B cells express lower levels of eYFP (Fig 
4.18C). Very obviously, cells with high level of eYFP expression have appeared at the 
GC-T zone interface. These cells are CD138+ and IgG1 switched (Fig 4.17 A B). High 
frequency of eYFP expression in extrafollicular foci (data not shown), similar to that seen 
in adjacent GCs, shows that these cells are GC derived.  
 
Blimp-1 acts as a master regulator to drive terminal differentiation of mature B cells into 
plasma cells (Turner CA Jr 1994; Shaffer AL 2002). A Blimp-1EGFP reporter mouse 
(Ohinata 2005) was used to identify Blimp-1 expression after immunisation with SRBC. 
(mouse spleen tissue was kindly donated by Dr. M. Turner Cambridge UK). Interestingly, 
cells expressing Blimp-1 (green) were seen at the GC-T zone interface and in the red pulp 
6 day after immunization, but not in GCs (Fig 4.17C D). At the same time, these 
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Blimp-1EGFP expressing cells also upregulated CD138 and IRF4. Similar results 
showing Blimp-1 expressing cells at the same location have been presented 
(Angelin-Duclos C 2000). Immunostaining showed that most of the IRF4 cells on the 
GC-T interface expressed switched IgG1 and IgG2a, with very few cells still IgM 
positive (Fig 4.17E F), and most cells switched to IgG1. These shows that IRF4+ cells on 
the GC-T zone interface have irreversibly started terminal differentiation to the plasma 
cell phenotype.  
 
Next, we tested markers expressed by GC B cells to study whether IRF4+ cells on the 
GC-T zone interface have lost GC identity. GL7, originally identified as late activation 
antigen on B and T lymphocytes (Laszlo G 1993; Luzina IG 2001), is commonly used as 
a GC B cell marker (Han S 1996). IRF4 expressing cells on the GC-T zone interface are 
completely GL-7 negative, while few IRF4+ cells in the LZ are still GL-7+ (yellow 
arrow)(Fig 4.18A). Intermediate levels of Fas are expressed on GC B cells (Liu YJ 1995; 
Martinez-Valdez H 1996), while many plasma cells express high levels. IRF4+ cells on 
the interface co-express high levels of Fas at a similar frequency to plasma cells in the red 
pulp (Fig 4.18 B). The expression of Bcl6 protein regulates GC development and function 
(Cattoretti G 1995; Allman D 1996). Post-GC B cell development towards plasma cells 
requires Bcl-6 downregulation (Basso K 2004). IRF4 cells on the GC-T zone interface 
are completely Bcl6 negative (Fig 4.18C). PNA binds strongly to B cells in GCs (Jacob J 
1991). Histological staining shows that PNA is strongly expressed on GC B cells, and it 
is absent on IRF4+ cells localized at the G-T zone interface, while IRF4+ centrocytes do 
express PNA (yellow arrow) (Fig 4.18 D). Complement receptors CD21/CD35 are 
expressed primarily on B cells and FDCs (Weis JJ 1984; Molina H 1990), but not on 
immature B cells and plasma cells (Braun M 1998). IRF4+ cells on the GC-T zone 
interface do not express CD21 (Fig 4.18 E). Taken together these data suggests that IRF4+ 
cells on the interface have completely lost GC B cell identity.  
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Figure 4.16: Appearance of activated B cells in Cg1-Cre x ROSA eYFP mouse spleen 
tissue after immunization 
Immunofluorescent analysis of spleen section from day3 (A), day4 (B), and day6 (C) 
after immunisation with SRBC. Day3, just a few activated B cells (eYFP+) at the 
follicle/T zone boundary; at day4, small eYFP+ GC and the extrafollicular foci appeared; 
at day6,  big eYFP+ GC developed, and more high level eYFP expression plasma cells 
produced. F: Follicle, T: T zone, GC: Germinal centre, RP: Red pulp. PC: Plasma cell. 
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Figure 4.17: IRF4+ cells at the GC-T zone interface express typical plasma cell 
markers 
A. B: Iγ1-eYFP cells appear at the GC-T zone interface from Cg1-Cre x ROSA eYFP 
mouse at d6 after immunization with SRBC.They are CD138+ and IgG1 switched. C. D: 
Blimp-1EGFP positive cells appear at the GC-T zone interface from Blimp-1EGCP mice 
at d6. They express both CD138 and IRF4. E.F: Some IRF4+ cells at the GC-T zone 
interface already express switched IgG antibody at d5 after immunization with SRBC in 
C57BL6 mice.  GC: Germinal centre, T: T zone.  
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Figure 4.18: IRF4+ cells at the GC-T zone interface already lose GC identities 
C57BL/6 mice were immunized with SRBC. At d5, IRF4+ cells at the GC-T zone 
interface, already downregulate typical GC markers, such as: A: GL-7, B: Fas, C: Bcl6, D: 
PNA, and E: complement receptor CD21. They are Ki67+ (F), still doing proliferation. 
The downregulation of CXCR5 (G) and high expression of CXCR4 (H) guides IRF4+ 
cells to move out from the DZ-T zone interface, into red pulps.  GC: Germinal centre, T: 
T zone. PC: Plasma cell.  
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The nuclear antigen Ki67 is a proliferation marker expressed only in cycling cells (during 
all phases of cell cycle: G1, S, G2 and mitosis), but not in resting cells (G0) (Scholzen T 
2000). Immunohistology shows that most IRF4+ cells on the GC-T zone interface were 
undergoing proliferation (Ki67+), like plasmablasts in the red pulp (Fig 4.18F), which 
indicates that these cells were still proliferating blasts, not yet differentiated to mature 
plasma cells. 
 
Expression of CXCR5 directs B cells to home into the follicles (Forster R 1996). When B 
cells differentiate into plasma cells, sometime they downregulate CXCR5 and CCR7, and 
upregulate CXCR4, which recruits cells to localize in the red pulp and subsequently 
accumulate in the bone marrow (Hargreaves DC 2001). IRF4 cells on the GC-T zone 
interface were seen to completely downregulate CXCR5, and highly express CXCR4 (Fig 
4.18 G H). Additionally, these cells also were observed to express only low levels of the 
B cell marker B220, which is typical for plasmablasts.  
 
The BP-3 alloantigen is expressed on early B lineage, immature thymocytes, circulating 
neutrophils, peritoneal macrophages, and on subpopulation of stromal cells in the second 
lymphoid organs (McNagny KM 1988; McNagny KM 1991; Kaisho T 1994). Recent 
research suggests the BP-3 expression in lymphoid organs may be involved in 
leukocyte-stromal interactions which support the development, migration and responses 
of leukocytes (Ngo VN 1999). From the fluorescent staining, BP-3 expresses on the 
stromal cells in the white pulp, particularly on FDC areas (Fig 4.19 A). Interestingly, 
IRF4 cells appearing at GC-T zone interface are closely associated with BP-3 expressing 
stromal cells. This indicates that these stromal cells would be candidates for accessory 
cells providing signals to IRF4 expressing cells at the GC–T zone interface.  
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CD3-CD4+ LTi cells play an important role for organising the development and perhaps 
the maintenance of secondary lymphoid organs by the lymphotoxin-lymphotoxin receptor 
interaction (Mebius 2003). Studies from Prof. Lane group have suggested that adult LTi 
cells can mediate survival of TFH cells and memory T cells, and maintain the affinity 
maturation in GCs and memory antibody response by the TNF family ligand OX40L and 
CD30L (Lane PJ 2005; Kim MY 2007; Withers DR 2007). Recently, a role for CD30 and 
OX40 from LTi cell was proposed for B cell activation in T independent responses (Kerry 
Perks, PhD thesis in preparation, UoB). Beside, localising in B follicles and the central T 
zone in spleen, LTi cells also sit at the interface of the B and T cell area, associated with 
the BP-3 positive stromal population (Fig 4.19 B C). Lti cell are identified as 
CD3-CD11C-CD4+IL-7Rα+ (Kim MY 2003). LTi cells close localisation with IRF4+ cells 
in the GC-T zone interface indicates that LTi cells may be involved in the development 
and response of B cells, possibly through OX40/OX40L and CD30/30L interaction.  
 
The summary table 4.1 presents all markers used to characterize the expression of IRF4 
cells at the GC-T zone interface. In summary, IRF4+ cells in this area are spatially very 
closely associated with the dark zone. As with most other GC B cells, they have 
undergone induction of IgG1 switching and have the same specificity as adjacent GCs. At 
the same time, these cells have already lost all GC B cell markers studied: GL-7, Fas, 
Bcl6, PNA, and complement receptor CD21, and have upregulated plasma cell markers, 
such as CD138, Blimp-1, and NP-specific Ig. They are still proliferating which identifies 
them as plasmablasts. High expression of CXCR4 and loss of CXCR5 recruits these 
IRF4+ cells to the outer T zone and then to the red pulp. Therefore, IRF4+ cells at the 
GC-T zone interface are early plasmablasts, exiting from the associated GC.  
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Figure 4.19: IRF4+ Cell associated with stromal cells and LTi cells 
C57BL/6 mice were received SRBC. At d5, high expression of IRF4 cells appear at the 
GC-T zone interface, associated with BP-3+ stromal cells (A). (B) Adult LTi cells also 
localize in the follicle-T zone boundary.  GC: Germinal center, T: T zone, F: Follicle. 
LTi cell:CD3-CD11C-CD4+IL-7R+ 
 
A: IRF4/BP3/IgD
GC
GCT
100µm
B: CD3/CD11c/CD4/IL-7R/B220
F
T GC
100µm
C: CD3-CD11c-CD4+IL-7R+
50µm
LTi
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Table 4.1: Expression of IRF4+ cells on the GC-T zone interface 
Characterization the expression of IRF4+ cell seen at the GC-T zone interface at d5 after 
immunization with SRBC in C57BL/6 mice. These cells upregulate plasma cell markers, 
and lose GC identities at the same time. LZ: light zone, EF: Extrafollicular Foci.  
 
 
 
 
 
 
Marker Name Expression of IRF4 cells on GC-T zone interface
NP-binding Up-regulated
CD138 Positive
Blimp-1 Positive
IgG switched IgG1 switched for Th2 antigen response
GL-7 Negative
PNA IRF4 cells on border is neg, some cells are PNA+ in LZ
Fas Some cells are Fas+, like plasma cells in the EF
Bcl-6 Negative
CD21 Negative
Ki67 Positive
CXCR5 Negative
CXCR4 Positive, like plasma cells in the EF
BP-3 Cells associate with BP-3+ stromal cells
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4.2.4 Appearance of IRF4+ cells in the follicle –T zone interface is T 
dependent 
SRBC are complex and large antigens with repetitive carbohydrate epitopes. To test 
whether the differentiation of IRF4-expressing cells at the follicle–T zone interface is 
dependent on the presence of signals from T cells, CD3ε KO mice (Wang N 1998) were 
immunized with SRBC. Peanut agglutinin (PNA) as a GC B cell marker (Jacob J 1991) to 
stain spleen sections at day5 after immunization shows that no GCs were detected on 
spleen sections (Fig 4.20A). Some plasma cells that expressing IRF4 (Fig 4.20B) and 
CD138 (Fig 4.20C) were produced in the red pulp, showing that SRBC induce some T 
independent B cell activation. SRBC also induces some IgG switching in the 
extrafollicular response (Fig 4.20D), which was mainly switching to IgG2b (Fig 4.20E), 
and a few cells are IgG3 (Fig 4.20F). This type of switching is typical for a TI-1 antigen. 
Importantly, SRBC do not induce GC development, and do not induce the appearance of 
significant numbers of plasmablasts at the follicular–T zone interface 5 days after 
immunization. 
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Figure 4.20: The response for SRBC in CD3ε KO mice 
CD3ε KO mice were immunized with SRBC. At d5, no GC was detected in spleen 
section (A), and less plasma cells produced in the red pulp. (B.C). Mainly these plasma 
cells in the red pulp are IgG2b switched (D.E.F). F: Follicle, RP: red pulp. Scale bar:100 
µm  
A: PNA/IgD B: IRF4/IgD
C: CD138/IgD D: IgG/IgM
F: IgG3/IgDE: IgG2b/IgD
FRP
RP
F
F F
F F
RP RP
RP RP
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4.2.5 The effects of absence of cytokines or costimulatory signals for the 
generation of IRF4 cells on the GC-T zone interface.  
Next we sought to identify signals that may induce differentiation of blasts at the GC–T 
zone interface. A range of cytokines and costimulatory signals produced by T cells, or 
other cells, which could affect GC B cell differentiation and induce differentiation of 
plasma cells, were tested by immunizing mice with targeted deletions for cytokines (IL-4, 
IL6, IL13, IL10, IL21) or constimulatory signals (CD28, OX40, CD30). 
 
IL-4, a key Th2 cytokine, induces differentiation of naïve CD4 T cells into Th2 cells, and 
the generation of Th2-derived cytokines (Chatelain R 1992; Kopf M 1994). For B cells, it 
can stimulate the proliferation of activated B cells, upregulate the production of MHC 
class II, and induce class switching to IgE (Hinton HJ 1999). IL-13, which is closely 
related to IL-4, also affects Th2 development, upregulates MHC class II expression and 
induces the secretion of IgE in activated B cells (McKenzie GJ 1998; McKenzie GJ 
1999). Compared to IL-4, IL-13 is a more central mediator of the physiological changed 
induced by allergy in many tissues (e.g. Asthma) (Wills-Karp M 1999; Wynn 2003). We 
selected pure IL-4-/- BALB/c (Kuhn R 1991; Kopf M 1993) and IL-13-/- BALB/c mice 
(McKenzie GJ 1998a) to detect whether IL-4 or IL-13 could have some role for the 
generation of early plasmablasts exiting from the GC-T zone interface. However no 
significant difference in GC size and the production of IRF4+ cell at the GC-T zone 
interface were detected in single IL-4 or IL-13 deficient mice by comparing to WT at 
day5 and 7 after immunization (data not shown). IL-4 and IL-13 have overlapping 
functions for initiating Th2 cell-driven responses. In the absence of one cytokine the 
other may compensate, resulting in Th2 cell differentiation, B cell activation and 
development (Cunningham AF 2002). 
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IL-4 and IL-13 play key roles in the Th2 immunity, regulate the activation of DCs, and 
they are functionally linked by their requirement for IL-4Rα for signalling (Nelms K 
1999; Webb DC 2007). IL-4Rα-/- mice (BALB/c background) are impaired in IL-4 and 
IL-13 functions (Mohrs M 1999). This helps understand the severely impaired GC 
formation at d5 after SRBC injection, probably due to the impaired functions of CD4+ 
Th2 cells for the development of B cells, so IRF4+ cells on the B-T interface can’t be 
analysed.  
 
CD28, a B7 receptor expressed on T cells, can provide co-stimulatory signals, and is 
required for T cell activation (June 1990). CD4 T cells are essential for the GC formation 
in the TD response (Han 1995b). CD28-/-Balb/c mice have a severely reduced capacity to 
form GC and a diminished humoral immune response (Shahinian A 1993; Reiter R 2002). 
As expected, we found that GCs were undetectable in CD28-/-BALB/c mice after SRBC 
injection (data not show). There also was no appearance of IRF-4+ cells on the T 
zone–follicle interface 5 days after immunization, confirming that this cell population is 
GC derived. 
 
4.2.5.1 The effect of CD30 / OX40 for the IRF4 cells on GC-T zone interface 
CD30 and OX40 (CD134) are members of the tumour necrosis factor receptor (TNFR) 
family, and have costimulatory effects on T and B cells (Watts 2005; Kennedy MK 2006; 
Sabbagh L 2007). CD30 was originally identified in Hodgkin’s lymphoma and 
Reed-Sternberg cells (Stein H 1982b). CD30 is expressed on activated T, B and NK cells 
(Horie R 1998). Its ligand (CD30L) is mainly expressed on resting B cells, activated T 
and B cells, antigen-presenting cells and a subset of accessory cells (such as LTi cells) 
(Kim MY 2003; Watts 2005). Recent research supports that CD30 may have important 
roles in autoimmune diseases, such as asthma (Polte T 2006; Polte T 2009) and diabetes 
(Chakrabarty S 2003). Additionally, CD30 and CD30L engagement downreguates isotype 
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switching in normal human B cells whose differentiation is mediated by CD40L (Cerutti 
A 1998; Cerutti A 2000; Cerutti A 2001). More interestingly, CD30 signal was identified 
to have an important function in effective B/T segregation (Bekiaris V 2007).  
 
OX40 is a secondary costimulatory molecule, mainly expressed on activated T cells, and 
has critical functions for mediating T cell activation (Croft 2003; Croft M 2009). OX40L 
is expressed on a number of cell types such as activated B and T cell, CD40L activated 
DCs (Fillatreau 2003), and accessory cells (e.g. Lti cells) (Kim MY 2003). OX40/OX40L 
has a critical role in maintaining an immune response beyond the first few days, and 
consequently governing the memory response due to determine the memory T cell pool 
(Croft 2003; Croft M 2009; Withers DR 2009). Many studies have reported that 
OX40-OX40L interaction could regulate autoimmune and inflammatory reactions (Watts 
2005). 
 
Recently Lane’s group identified CD4+CD3-CD11c- LTi cells which costimulate primed 
CD4 T cells through OX40 and CD30 at the B:T interface and in follicles (Kim MY 
2003). OX40 and CD30 signals act together to control the development of memory T 
cells to provide help to maintain GC development, and secondary antibody responses 
(Gaspal FM 2005; Sabbagh L 2007; Lane PJ 2008). A recent study showed that LTi 
derived CD30 has an inhibitory effect, while OX40 has stimulatory activity in TI-I/TI-II 
B cell responses (K. Perks, thesis in preparation). OX40 and CD30 double deficient mice 
have been produced by crossing OX40 and CD30 single KO mice, described before 
(Amakawa R 1996; Pippig SD 1999) (Gaspal FM 2005), mice kindly received from Prof. 
Lane, Birmingham UK) 
 
Germinal centres were observed in all mice on day 5 and 7, illustrating that signals absent 
in CD30KO, OX40KO, and dKO mice were not required for the initiation of GC 
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formation. However, there is significant bigger GC development in OX40KO and dKO 
(p<0.01). This effect was only observed on day5, and disappeared on day 7 (Fig 4.21 A B 
C D E).  
 
More IRF4+ cells were observed at the GC-T zone interface in CD30KO mice (p<0.01), 
and IRF4+ plasma cells in red pulps were far more numerous in KO mice (Fig 4.21B, F). 
As a previous study showed no notable effect on B cell responses in CD30KO mice 
(Kennedy MK 2006), we confirmed this phenotype by fluorescent staining to verify that 
IRF4 cells on the GC-T zone interface in KO mice already show a plasma cell phenotype: 
CD138, IgG1 antibody, and chemokine CXCR4 (Fig 4.22).  
 
OX40 deficiency resulted in significantly less IRF4+ cells at the GC-T zone interface 
(p<0.01) (Fig 4.21F), and also much lower numbers of IRF4+ plasma cells in red pulps. 
Therefore, signals from OX40 and CD30, both of which may be derived from LTi, seem 
to have opposite effects not only on TI-I/TI-II B cell activation, but also on the 
appearance of early GC-derived plasmablasts.  
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Figure 4.21: The effect of OX40, CD30 single and double deficiency for production 
of IRF4+ cells at the GC-T zone interface  
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OX40, CD30 single deficient and double deficient mice, C57BL/6 as control  were immunized with 
SRBC. Representative spleen section from control C57BL/6 (A), CD30 single KO (B), OX40 single 
KO (C), CD30OX40 double KO (D), respectively, was stained to reveal the number of IRF4+ cells at 
the GC-T zone interface at day 5. E: the quantification result of GC size per spleen section from 
C57BL/6, CD30-/-, OX40-/-, and OX40CD30 double KO mice, F: the quantification of IRF4+ cells at 
the GC-T zone interface on sections from different species of mice. Cell was assessed per  mm2 GC 
area. Each point represents one animal. P<0.05 according to the Wilcoxon Mann-Whitney U test. 
GC: Germinal centre. T: T zone. 
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Figure 4.22: IRF4+ cells at the GC-T zone interface in CD30KO mice 
Representative spleen section from CD30 single deficiency mice at d5 after immunization 
with SRBC, was stained with (A) CD3/IRF4/IgD, (B) IRF4/CXCR4/IgD, (C) 
CD138/IgD, (D ): IRF4/IgG1/IgD. IRF4+ cells already express low CD3, high level of 
CXCR4, CD138 and IgG1 switched Ig.  GC: Germinal centre, T: T zone; PC: Plasma 
cell 
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4.2.5.2 The effect of IL-6/IL-10 for the IRF4 cells on GC-T zone interface 
IL-6 is an immunomodulatory cytokine with a wide range of biological activities. For B 
cell, IL-6 can act as a growth factor, and regulate plasma cell differentiation and Ig 
secretion (Van Snick 1990; Tanner JE 1992; Kopf M 1994). Furthermore, it has a 
profound effect on T cells, for example stimulating T cells differentiate into cytotoxic T 
cells, and more importantly regulating CD4 T cell proliferation, survival and 
differentiation (Dienz O 2008).  
 
IL-10 is an important immunoregulatory cytokine that suppresses functions of Th1 cell, 
macrophages, DCs and NK cells (Howard M 1992; Moore KW 2001; Mocellin S 2003). 
It is mainly produced by subsets of T-cells e.g. natural Treg, effector CD4 T cells, with 
diverse roles in contribution in T cell-mediated immune response (Maynard CL 2008). In 
addition, IL-10 augments the proliferation and differentiation of B cells (Moore KW 
1993). To investigate the role of IL-6 or IL-10 in the GC response, IL-6 and IL-10 single 
KO mice were immunized with SRBC, the KO mice were described before ((Kopf M 
1994) and (Kühn R 1993), the mice kindly abtained from Dr. A. Cunningham 
Birmingham UK).    
 
Germinal centre development in the absence of IL-6 was delayed, with no or only small 
GC observed at day5 after injection. GC formed at day7 (Fig 4.23 A B), but only half of 
mice had GC comparable in size to WT mice. This confirms that IL-6 regulates the 
initiation of GC formation (Kopf M 1998). The number of IRF4 cells seen at the GC-T 
zone interface was much lower in KO mice at day5 and 7 (p<0.01 Fig 4.23F).  
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Figure 4.23: The effect of IL-6 /IL-10 deficiency for production of IRF4+ cells at the 
GC-T zone interface 
IL-6-/-, IL-10-/- mice, C57BL/6 as control were immunized with SRBC. Representative spleen sections 
from IL-6-/- at day5 (A) and day7 (B), and from IL-10-/- at d5 (C) and d7 (D) were stained to reveal the 
frequency of IRF4+ cells at the GC-T zone interface. E: the quantification result of GC size per spleen 
section from C57BL6, IL-6-/-, IL-10-/- mice. F: IRF4+ cells at the GC-T zone interface were quantified 
on sections from different mice types. Cell was assessed per mm2 GC area.  Each point represents one 
animal. P<0.05 according to the Wilcoxon Mann-Whitney U test. GC: Germinal centre. T: T zone. In 
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IL-10 KO mice, GC developed with normal kinetic, but the GCs were significantly 
smaller compared to WT (Fig4.23 C D E). This result suggests that IL-10 is not as 
important a factor for the initiation of GC formulation as IL-6, but may maintain GC 
development. IRF4+ plasmablasts at the GC-T zone interface were significantly reduced 
compared to WT (p<0.01), similar to IL-6KO (Fig 4.23 F). IL-10 is essential for 
proliferation of B cells and differentiation of GC B cells into plasma cells secreting IgG 
and IgA (Maliszewski CR 1993; Choe J 1998). Therefore IL-10 deficiency may impair 
GC and plasma cell development. 
 
4.2.5.3 The effect of IL-21 for the IRF4 cells on GC-T zone border 
IL-21, secreted by TFH cells, is associated with the growth and differentiation B and T 
cells through IL-21R (Ettinger R 2008). In vitro, IL-21 can increase both Blimp-1 and 
Bcl6 on B cells (Ozaki K 2004; Arguni E 2006). Recent research supports that IL-21 has 
a role in the development of TFH cells, and may augment the formation of TH-17 cells, 
which secrete IL-21 and promote GC formation (Korn T 2007; Zhou L 2007). Latest 
research from Zotos (2010) utilising mice lacking IL-21 or IL-21R (KO mice described in 
(Ozaki K 2002)) further suggests that IL-21 is required for plasma cell formation through 
IL-21R on B cells. Spleen tissue from IL-21 and IL-21R deficient mice was assessed for 
GC formation and the production of IRF4+ cells at the GC-T zone interface after 
immunization with alum precipitated NP-KLH (Tissue kindly provided by Dr. D. 
Tarlinton Australia).  
 
Germinal centre and plasma cell formation were determined by immunohistological 
staining at day7 after immunization. IL-21/IL-21R deficient mice have smaller GCs, but 
higher number of B blasts occurring in follicles (Fig. 4.24 A-C, F, and (Zotos D 2010)). 
This indicates that IL-21 may have a role for migration of antigen-specific B cells before 
GCs form.  
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Figure 4.24: The effect of IL-21/IL-21R deficiency for production of IRF4+ cells at 
the GC-T zone interface 
IL-21-/- and IL-21R-/- mice, C57BL/6 as control were i.p. immunized with NP-KLH in alum precipitated. Representative 
spleen section histological staining reveals the localization of NP-reactive cells (blue) in control (A) and IL-21R-/- (B) 
mice. NP+ cells in EF and follicles are shown by arrows. C: Quantification of NP specific plasmablasts (PB) and plasma 
cells (PC) in the red pulps and NP specific B blasts in follicles from control C57BL/6, IL-21-/- and IL-21R-/- mice at day7 
(A-F data published in Zotos 2010). Histological staining shows the distribution of IRF4 cells on control (D) and 
IL-21R-/-  (E) at day7 . F: Quantification of GC size per spleen section from C57BL6, IL-21-/- and IL-21R-/- mice, G: 
IRF4+ cells at the GC-T zone interface were quantified. Cell was assessed per mm2 GC area. Each point represents one 
animal. P<0.01 according to the Wilcoxon Mann-Whitney U test. GC: Germinal centre. T: T zone. Scale bar: 100 µm 
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IRF4 staining showed less IRF4+ cells appearing at the GC-T zone interface in KO mice, 
even when the number of these cells was related to the GC area (p<0.01 Fig 4.24 G), 
consistent with the deficiency of NP specific plasma cells in red pulps (p<0.01 Fig 4.24 
C). The results suggest that signals from TFH cells have a role in the response and 
differentiation of GC–T zone interface plasmablasts.  
 
4.2.5.4 The effect of IL-22 for the IRF4 cells on GC-T zone interface 
IL-22, another member of IL-10 family, exerts an important mediator in regulate the 
inflammatory response (Dumoutier L 2000; Wolk K 2006). Its receptor (IL-22R) is a 
cell-surface complex composed of IL-10R2 and IL-22R1, which is mainly expressed on 
epithelial cells of organs in respiratory tracts and gut, and the skin, but not on immune 
cells such as B cells (Wolk K 2006; Jones BC 2008). Recent studies support that IL-22 
could mediate early host defense against microbial pathogen, tissue repair, wound healing 
and the homeostasis of epithelia (Wolk K 2006; Zenewicz L 2007; Zheng Y 2008; Pickert 
G 2009). IL-22 is mainly produced by NK cells (NKp44+), TH-17 cells, and LTi-like cells 
in mice (Kreymborg K 2007; Colonna 2009; Takatori H 2009; Vivier E 2009). As IL-10 
has a role for the production of GC-T zone interface plasmablasts, we tested this member 
of the IL-10 family for similar effects.  
 
IL-22-/-BALB/c mice (Zheng Y 2008), kindly received from Prof. C. Buckley 
Birmingham UK) were immunized with SRBC as before. No difference in GC size and 
plasma cell numbers were observed between KO and WT mice (Fig 4.24 G). Interestingly, 
more T cells were seen in GCs of KO mice at day5 (Fig 4.25 A B). SRBC induce bigger 
GC in BALB/c mice compared to C57BL/6, and far less IRF4 cells localizing at the 
GC-T zone interface (data not shown). GC developed to normal sizes compare to wt 
controls (Fig 4.25 C D). Surprisingly, more IRF4 cells appeared at the GC-T zone 
interface in KO mice (Fig 4.25 E F).  
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Figure 4.25: The effect of IL-22 deficiency for production of IRF4+ cells on GC-T 
zone interface 
IL-22-/- and BALB/c as control  were immunized with SRBC. Representative spleen histological staining with CD3 
reveals the frequency of T cells  in control (A) and IL-22-/- (B) mice at day5.   Staining with IgG and IRF4 at the serial 
sections is going to compare the  IRF4+ cells at the GC-T zone interface between control (C, D) and IL-22-/-   mice 
(E.F) at day5. F: Quantification of GC size per spleen section from Balb/c and IL-22-/- mice, G: IRF4+ cells at the GC-T 
zone interface were quantified. Cell was assessed per mm2 GC area.  Each point represents one animal. P<0.01 
according to the Wilcoxon Mann-Whitney U test. GC: Germinal centre. T: T zone.  
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Quantification showed a significant difference at day5 compare to wt mice (p<0.01), but 
this effect disappeared at day 7 (Fig 4.25 H). Direct effects of IL-22 on B cells so far have 
not been described. It is possible that deficiency of IL-22 might affect the differentiation 
of CD4 T cells in GCs, resulting in effects on selection of GC B cells, finally resulting in 
higher plasma cells output from GCs. The abnormal function of stromal cells or Lti cells 
due to IL-22 deficiency also might affect the early plasma cell development.  
 
The table 4.2 summarizes the impact of all cytokines and costimulatory signals used so 
far for the generation of IRF4+ plasmablasts localized at the GC-T zone interface.  
 
Table 4.2: Summary of the effect of Cytokines or co-stimulatory signals for IRF4+ 
cells at the GC-T zone interface  
Different cytokine or co-stimulatory signal deficient mice were used to detect which 
signal could be involved in the generation of the IRF4+ plasmablasts at the GC-T zoon 
interface. GC: Germinal centre, WT: wild type mice. 
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4.2.5.5 Appearance of IRF4+ cells in the TI primary response 
To assess whether the presence of these IRF4+ cells on the interface is dependent on TD 
signals, the appearance of IRF4+ cells in TI GC response to NP-Ficoll on spleen tissue 
was studied. TI GCs do not have B-T cell interaction and B selection in GC, which is 
thought to be the reason for the sudden convolution of TI GC by mass apoptosis at day 6 
after immunisation (Vinuesa 2000). This study was carried out via using QMxC57BL/6 
mice carrying high frequencies of NP-specific cells (described in section 2.1.1 Vinuesa 
2000). NP-specific activated B cells appeared in the outer T zone within hours after 
injection, and GC started to appear at day 3 (data not shown). Interestingly, IRF4 
expressing cells were seen at the GC-T zone interface beginning from day3 (Fig 4.26 B), 
and these cells were NP-specific (Fig 4.26 A). By day4, large antigen-specific GC had 
formed, and high levels of NP expressing plasmablasts were seen at the GC-T zone 
interface (Fig 4.26 C), which were IRF4+ (Fig 4.26 D). The quantification showed that 
the numbers of IRF4+ cells at the GC–T zone interface were comparable to response to 
TD antigen (Fig 4.26 E). This result indicates that appearance of IRF4+ plasmablasts at 
this location may be induced by signals or cytokines from stromal cells, DCs, or 
CD4+CD3- LTi cells, which localise at the B/T interface and within follicles, and is not 
related to the B–T cell interaction.  
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Figure 4.26: Appearance of IRF4+ cells at the GC-T zone interface in the TI GC 
response 
The appearance of IRF4+ cell at the GC-T zone interface on spleen sections was assessed 
at the time point after NP-Ficoll immunization in QMxC57BL/6, red arrow. The same 
spleen tissue stained with NP/IgD (A) and IRF4/IgD (B) at day 3 after immunization. The 
same tissue stained with NP/IgD (C) and IRF4/IgD (D) at day4. (E): Quantification of  
the density of IRF4+ cells at the GC-T zone interface at d3 and 4. Cell number was 
assessed by per mm2 GC area. Each point represents one mouse. GC: Germinal centre, T: 
T zone. Represent of two individual experiments. 
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4.2.6 Detecting presence of differentiation signals at the mRNA level by 
microdissection and RT-PCR 
To look for the presence of chemokines and or cytokines that may influence the early 
plasmablasts differentiation or migration in vivo, mRNAs encoding these were assessed 
in different compartments of the spleen. Laser capture microdissection (LCM) was 
performed to cut out the different areas from snap-frozen spleen tissue. Spleen tissue 
from d5 after NP-CGG immunisation in carried primed C57BL/6 mice was used in this 
series of experiments, because this tissue contains the highest numbers of IRF4+ cells in 
the GC–T zone interface. Serial tissue sections were mounted on membrane-slides and 
stained by cresyl violet to show the red pulp and white pulp areas. This staining avoids 
damage of RNA. Adjacent sections to the sections used for microdissection were 
mounted on normal multispot slides, which were stained for IRF4 and IgD to show the 
detailed anatomy of the white pulp and GC-T zone interfaces containing IRF4+ cells. 
10-20 similar areas were microdissected, and saved in the same tube to prepare RNA. 5-6 
different white pulp areas were selected per spleen section (detailed methods in section 
2.7). Gene expression was measured by real-time RT-PCR in multiplex with β2 
microglobulin (β2m) specific primers as a uniformly expressed control gene. 
 
Prior to testing other gene expression, CD3ε and CD19 were chosen as area positive 
controls. As expected, CD3ε is highly expressed in T zones, with less expression in GCs 
and the GC-T zone interfaces. The later contains a mix of B cells and T cells. The lowest 
expression is in plasma cell areas, follicles and red pulps which containing few T cells. 
High expression of CD19 was seen in GCs, follicles and red pulps, with intermediate 
levels in the GC-T zone interfaces, and low level in T zones and plasma cell areas (Fig 
4.27 A).  
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Figure 4.27: Plasmablast associated genes upregulated in IRF4+ cells at the GC-T 
zone interface 
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4.2.6.1 The expression of plasmablast/plasma cell associated genes 
As expected, IRF4 mRNA was mainly detected in cells at the GC-T zone interface and in 
plasma cells. IRF4 expression was also detected in GC cells, and follicle B cells. Low 
levels were seen in the T zone. The relatively high levels of IRF4 mRNA in GC cells may 
be derived from the small numbers of IRF4 positive centrocytes. As expected, other 
plasmablast and plasmablast precursor associated genes, such as the transcriptional 
regulator of the plasma cell secretory phenotype XBP1 (Shaffer AL. 2004), and Blimp1 
(Shapiro-Shelef M 2003) are upregulated at the GC-T zone interface as well (Fig 4.27 B). 
XBP-1 is present in lower levels in GC, follicular and red pulp areas, and at much higher 
level in plasma cells. Blimp-1 is expressed in the T zone and follicle, and at lower levels 
in GC. Blimp-1 has been reported to have roles for T cell function, and is present at high 
levels in antigen-experienced T cells ((Martins G 2008) review).  
 
IgG1 switch transcript were mainly expressed in GC cells, but were not detectable at the 
GC-T zone interface (p<0.001 between GC-T and GC, Fig 4.27C). As the first exon of 
IgG1 ST is excised during switching, absence of expression may reflect successful Ig 
class switching. Accordingly, Iµ-Cγ1 rearranged Ig heavy chain transcripts appear in the 
GC-T zone interface. These indicate that cell successfully switched to IgG1 (Li SC 1994). 
J chain, essential for IgM and IgA polymerisation (Mestecky J 1971; Shaffer AL. 2004), 
was expressed highest in plasma cells. The GC-T zone interface upregulated J chain 
mRNA (p<0.05 between GC-T and GC). Therefore, GC-T zone area mainly includes 
plasmablasts, which have started to secrete switched antibody.  
 
Germinal centre typical genes were expressed at low levels in the GC–T zone interface. 
Bcl-6 was almost undetetectable in the GC-T zone interface, whereas it was highly 
expressed in GC (p<0.001 between GC-T and GC). Bcl-6 was also detected in follicles, 
as described by Allman (1996), reporting that Bcl-6 mRNA is expressed in naïve B cells. 
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AID is highly expressed in GC cells, but expression is lost in GC-T zone interfaces 
(p<0.001 between GC-T and GC). Pax-5 is required for the early B-cell differentiation 
and maintenance of B-cell identity (Horcher M 2001; Nera KP 2006) but it is 
down-regulated in the terminal stages of B-cell differentiation to plasma cells (Souabni A 
2002). As expected, Pax5 expression was lower in plasma cells, and high in follicles and 
GCs. In GC-T zone interfaces, Pax5 expression was lower (p<0.001 between GC-T and 
GC, Fig 4.27 C), reflecting plasmablast differentiation in this area. IRF4 expression in 
this area may repress Bcl-6 (Falini B 2000; Saito M 2007), Pax-5 shutting off further AID 
expression (Sciammas R 2006). Apart from Pax-5 downregulation, Blimp-1 induction 
(Shaffer AL 2002) is a possible mechanism for the termination of AID expression. 
 
4.2.6.2 The expression of chemokines and chemokine receptors 
Chemokines have an important role in guiding cell movement during the initiation of 
adaptive immune responses (Cyster 2005). CXCR5 is involved in the attraction of 
recirculating B cells and MZ cells B cells as well as a subset of primed CD4 T cells into 
B cell follicles (Schaerli P 2002; Ekland EH 2004; Cinamon G 2008). CXCR5 also helps 
direct cells to the light zone (Allen CD 2004). Not surprisingly, CXCR5 is expressed in 
follicles and also in the GC-T zone interface, with slightly lower levels in GCs and 
plasma cell areas (Fig 4.28 A). CXCL13 is highly expressed in follicles, and expressed in 
GCs and GC-T zone interfaces as well.   
 
CXCR4 is expressed on GC B cells, especially on centroblasts (Caron G 2009) and 
plasma cells (Allen CD 2004). It is essential for dark and light zone segregation (Allen 
CD 2004). Further CXCR4 expression is implicated both in migration to the T zone 
(Casamayor-Pallejà M 2002) and from the T zone to the extrafollicular foci (Hargreaves 
DC 2001; Cyster 2003a). Upregulation of this gene was seen in the GC, and at lower 
levels in plasma cell areas and the GC-T zone interface (Fig 4.28 B). CXCR4 protein 
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expression in GC is low compared to the G–T zone interface (Fig. 4.18 H). The higher 
levels of CXCR4 mRNA in GC may be due to a low, but homogenous expression of 
CXCR4 in all cells in the GC.  
 
CXCR4 is critical for normal homing of plasma cells to the red pulp in the spleen. 
Accordingly, the plasma cell area expressed a higher amount of the CXCR4 ligand, 
CXCL12 (SDF-1) (Fig 4.28 B). More importantly, high level of CXCL12 expression was 
detected at GC-T zone interfaces, although lower than that in the red pulp. This gradient 
may favour migration of new CXCR4+ plasmablasts to the GC-T zone interface and then 
towards the CXCL12-rich red pulp. 
 
CXCR7 (RDC1) is a scavenger receptor for CXCL12 (Balabanian K 2005; Thelen M 
2008). In zebrafish it has been shown to produce a CXCL12 gradient needed to direct cell 
migration (Thelen M 2008). Detection of mRNA showed that CXCR7 was expressed 
mainly in follicles and less in GC cells (p<0.05 between GC-T and Follicle), compatible 
with CXCR7 producing a CXCL12 chemokine gradient over the GC with a CXCL12 sink 
towards the follicles (Fig 4.28 B). 
 
Homing of T cells to T zone depends on CCR7 and ligands (CCL19 and CCL21) (Forster 
R 1996; Gunn MD 1999). CCR7 is further required for the localisation to and retention of 
B cells at the follicle-T zone interface following antigen-receptor engagement (Reif K 
2002; Okada T 2005). As predicted, high amounts of CCR7 were seen in T zone, more 
interestingly it was also found in GC-T zone interface and plasma cell areas (p<0.001 
between GC-T and GC, Fig 4.28 B). CCR7 expression has been shown to be important 
for follicular B cell migration (Ekland EH 2004; Okada T 2005), and low levels of CCR7 
were detected in follicles.  
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CCL19 and CCL21, the two CCR7 ligands, are expressed in the T zone by 
radiation-resistant stromal cells. CCL21 is also made by HEV, whereas CCL19 can be 
produced by DC (Cyster 1999; Cyster 2005). High amounts of CCL19 and CCL21 
expression were found in T zones and GC-T zone interfaces (Fig 4.28 B), leading to 
migration of cells to the GC-T zone interface.  
 
CXCR3 is expressed on activated T cells, NK cells, and some antibody forming cells 
(AFC), and most T cells in inflammatory lesion express CXCR3 (Houser 2002). CXCR3 
and the ligands CXCL9 and CXCL10 are expressed on early T zone B blasts (J. Marshall, 
personal communication), and also present on in vivo activated T cells (K. Serre, personal 
communication). To test whether CXCR3 has a role for the movement of IRF4+ 
plasmablasts to the GC-T zone border, CXCR3, and its ligands CXCL9, CXCL10, 
CXCL11 were assessed. CXCR3 expression was present in GC-T zone interfaces, T 
zones and plasma cell areas at similar levels, with slightly lower expression in the 
follicles (Fig 4.28 D). High CXCL9 expression is present in the plasma cell area and T 
zone, and moderate and lower levels were seen in GC-T zone interface and follicle 
respectively. Other ligands CXCL10 and CXCL11 (undetermined) showed similar 
abundances of expression throughout different areas. Whether any of the ligands of 
CXCR3 have a role in B blast or plasmablast migration remains to be studied.  
 
4.2.6.3 The expression of cytokines and receptors 
Most of the cytokines such as IL-6, IL-10, IL-4, IL-13, which can mediate the 
differentiation of GC B cells, were undetectable or present at very low amount in these 
microdissected areas at this time point. This could possibly be due to the low concentration 
of mRNA obtained from microdissected section or the choice of time point being 
suboptimal (data not shown here). IL-10Rα is expressed by a variety of murine cell types 
including B and T cells (Moore KW 2001), so interestingly, high amounts of IL-10Rα 
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expression were found on the whole spleen section, particularly in GC and GC-T zone 
interface areas. IL-10 mediates the development of B cells by signalling via IL-10Rα, and 
stimulates activation of other cell types (i.e. T cells) (Fig 4.29 A). This data helps clarify 
why small GC development and reduced plasma cell generation were detected in IL-10 KO 
mice.  
 
IL-21 is mainly produced by GC T cells (Ettinger R 2008). Interestingly, a high level of 
IL-21 expression was detected in GC areas, and mediate amount at the GC-T zone 
interfaces in comparison to other areas (p<0.001 between GC-T and GC, Fig 4.29 A). Less 
IRF4+ plasmablasts at the GC-T zone interface were found in IL-21/IL-21R deficient mice. 
These together could further indicate that the IRF4+ plasmablasts seen at the GC-T zone 
interfaces mainly derive from GCs, particularly signals from TFH cells in the response to 
the TD antigen. In summary, the selection process happened in the LZ for the final 
differentiation into the early plasmablasts. 
 
4.2.6. 4 The expression of co-stimulatory signals 
CD40L, primarily expressed on activated T cells, can cause activation of the resting B 
cells by directly binding to their CD40 receptor, and then guides the B cells through their 
differentiation programme, including rescue from apoptosis, differentiation into GC cells, 
isotype switching, selection, and maturation into memory cells (van Kooten C 2002). 
CD40L is expressed in the GC and T zone areas, as predicted. These is also low level 
expression at the GC-T zone interface (Fig 4.29 B), this is consistent with CD40L protein 
on T cells in the GC– T area interface in human tonsil (Casamayor-Palleja M 1995).  
 
CD30 and OX40 have role for GC persistence and the generation of the early IRF4+ 
plasmablasts (Fig 4.21), consequently it is not surprising that both CD30 and OX40 were 
detected at the GC-T zone border at lower levels than the expression seen in the T zone 
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(Fig 4.29 B).  
 
4.2.6.5 The expression of survival signals for B cells 
BAFF promotes B cell survival and Ig CSR (Mackay F 2002; Castigli E 2005). BAFF-R, 
one of three known receptors for BAFF, is associated with maintaining survival of 
recirculating and MZ B cells as well as GC B cells (Shulga-Morskaya S 2004; Rodig SJ 
2005; Zhang X 2005). Clearly both BAFF and BAFF-R are highly expressed in GCs and 
follicles with intermediate expression in plasma cell areas. It is not surprising that GC-T 
zone interfaces also contain high amounts of BAFF and intermediate level of BAFF-R 
(Fig 4.29C.D). A proliferation-inducing ligand (APRIL) is critical for the plasmablasts in 
bone marrow (Belnoue E 2008). In comparison to the expression of BAFF and BAFF-R, 
APRIL has lower expression in spleen sections. The median level of APRIL in the red 
pulp area containing less IRF4+ plasma cells, was higher than that in the follicle and 
plasma cell area. More interestingly, it is more strongly expressed at the GC-T zone 
interface than in the GC (p<0.001 between GC-T and GC, Fig 4.29 C).  
 
While only BAFF binds BAFF-R, BAFF and APRIL exert effects through the 
cell-surface receptors including B-cell maturation antigen (BCMA) and transmembrane 
activator and calcium modulator and cyclophilin ligand interactor (TACI) (Xu S 2001; 
Seshasayee D 2003). TACI has been implicated in the early plasmablast differentiation 
(Zhang X 2005; Bossen C 2008) in TD and TI responses (von Bulow GU 2001). BCMA 
is reported to maintain plasma cells in the bone marrow (O'Connor BP 2006). While 
BCMA and TACI mRNA were absent from GCs, there was considerable expression of 
BCMA and TACI in plasma cell areas. Interestingly TACI is consistently expressed at 
the GC-T zone interface (p<0.001, Fig 4.29 D). This confirms published data on the role 
of these receptors in the plasmablast differentiation. Taken together, these data provide 
evidence that there may be a role for APRIL, and probably BAFF, via TACI and BAFF-R 
play a role in plasmablast differentiation at the GC–T zone interface.  
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Figure 4.28: Gene expression of chemokines receptors and ligands at different areas 
of the spleen  
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Figure 4.29: Assessment of more genes which may have roles for the production of 
IRF4+ cells at the GC-T zone interface 
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4.3 Discussion 
4.3.1 IRF4 is expressed shortly after B cell activation 
The up-regulation of IRF4 is likely to be key in directing both CSR and commitment to 
differentiation to plasma cells, as absence of IRF4 is associated with the failure of both 
processes (Klein U 2006; Sciammas R 2006; Shaffer AL 2008). High level expression 
induces Blimp-1 and plasma cell differentiation, while intermediate levels are supposed 
to permit Ig class switching (Sciammas R 2006), a process that has been connected with 
GC B cell development (Cattoretti G 2006a). Surprisingly, IRF4 mRNA is significantly 
upregulated rapidly after activation in all B cells after immunization of QMxC57BL/6 
mice with NP-Ficoll. mRNA expression peaks within 1h , and then quickly falls again. 
Further, IRF4 protein starts to be detectable on MZ B cells within 1h of immunization 
before they arrive in the outer T zone, however, the level of expression on B blasts is 
lower than that on plasmablasts. IRF4 is completely lost when B blasts differentiate into 
GC B cells, and highly upregulated in plasma cells. Similar data of low level expression 
of IRF4 in developing B blasts have been produced in vitro by the lab of Roger Sciammas 
(Keystone meeting B cells in context, Taos 2009). The early intermediate level IRF4 
expression in the outer T zone is associated with Aicda mRNA expression in some B 
blasts 48 h after NP-Ficoll stimulation. Interestingly, these B blasts do not express Bcl-6 
mRNA. Therefore, the regulation of Ig class switching may be fundamentally different in 
these cells than in GC B cells (Marshall J, Zhang Y et al., submitted for publication).  
 
Differentiation towards two different cells types may be directed by bistable (switch-like) 
regulatory networks (Laslo P 2006). Both bistable and graded behaviour of IRF4 
expression may control the onset and resolution of mixed lineage patterns during cell fate 
determination (Sciammas R 2006). IRF4 at low level expression may synergize with 
Pax-5 to induce AID (Gonda H 2003), while if expressed at higher levels it inhibits Bcl-6 
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(Falini B 2000; Saito M 2007) and induces Blimp-1 expression, suppressing Pax-5 and 
shutting off further AID expression (Sciammas R 2006). This expression of IRF4 may be 
due to NF-κB1 and STAT activation following BCR and CD40 signalling (Grumont RJ 
2000; Saito M 2007; Lu 2008). While in response to NP-Ficoll, IRF4 is probably 
activated through continued BCR stimulation, which may induce other pathways than 
NF-κB1 (Bajpai UD 2000).  
 
Furthermore, the immediate upregulation of IRF4 mRNA after stimulation suggests that 
IRF4 not only plays a key factor for post-GC plasma cell differentiation, but also has an 
important function for B cell activation. One direct target gene of IRF4 in activated B 
cells is MYC (Shaffer AL 2008), which is a key coordinator of cellular growth, 
metabolism and proliferation (Dang CV 2006). IRF4 and MYC mutually reinforce the 
expression of each other (Shaffer AL 2008; Shaffer AL 2009). A sharp increase in IRF4 
binding to the MYC promoter was also detected after 3 and 20h of phorbol myristate 
acetate and ionomycin activation in human B cells (Shaffer AL 2008). GC cells need 
IRF4 for terminal differentiation to plasma cells (Cattoretti G 2006a). Function of IRF4 is 
associated with a change in interacting partners or with reduced interaction with 
transcriptional coactivator PU.1 (Mittrücker HW 1997; Tamura T 2005; Cattoretti G 
2006a) in regulating B cell development and differentiation.  
 
BCR interaction with NP-Ficoll may quickly activate upregulation of IRF4 in B cells 
reacting to NP-Ficoll in QMxC57BL6 mice. Similar data from genome-wide analysis of 
mouse B cells (in vitro) shows that genes have changed expression within 3 hours of 
BCR stimulation, particularly down-regulation of Pax-5, Bcl6, SpiB, and MITF, and 
activation of IRF4 (Hauser J 2009 in 2nd Eur. Cong. Immunol. Berlin). IRF4 contains 
several potential microRNA binding sites (Malumbres R 2009), and so miRNAs may 
have a role for the quick loss of IRF4. Microarray assays have revealed that several 
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miRNAs are differentially regulated upon stimulation with LPS or a combination of 
anti-IgM, anti-CD40 and IL-4 in the primary splenic B cells. IRF4 transcript was 
identified as a target whose expression is fine-turned by some miRNA that is induced 
upon antigen stimulation (Brandl 2009 7th B cell Forum Salzburg Austria). These studies 
together suggest that IRF4 immediately increased 1-2 hr after B cell activation, with 
subsequent reduction of expression maintained through the activation of miRNA. 
 
miRNA-155, encoded within a region known as bic (B cell integration cluster) 
(Lagos-Quintana 2002), also shows greatly increased expression in activated B cells, 
because it is induced upon B cell receptor (BCR) ligation (van den Berg A 2003) or 
antigenic stimulation (Rodriguez A 2007; Tili E 2007). A further study reported that BCR 
activation induced miRNA-155 expression though a conserved AP-1 element (Yin Q 
2008). miRNA155 was found to attenuate NF-κB signalling in EBV infected cells (Lu 
2008). The NF-κB signalling pathway may mediate IRF4 activation via BCR, CD40 and 
cytokine stimulation (Saito M 2007; Lu 2008). Loss of NF-κB signalling may also be 
responsible for the loss of IRF4 expression. 
 
Different phases of IRF-4 induction may be activated by different signal transduction 
pathways. When NF-κB1 deficient B cells were transferred into normal hosts and 
challenged with NP-Ficoll, low level IRF4 expressions was undisturbed in the transferred 
B cells that arrived in the outer of T zone 1d after immunization. Plasma cell 
differentiation was strongly disturbed and so less plasmablasts were developing in 
bridging channels (L. George, unpublished). The results indicate that NF-κB1 activation 
is not the only way to induce IRF4 up-regulation in activated B cells in response to 
NP-Ficoll. Continued BCR stimulation may directly induce IRF4, other signalling 
pathways may exist. Nevertheless, NF-κB1 signalling may be essential for IRF4 high 
expression in the terminal differentiation of extrafollicular or post-GC plasmablasts 
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(Fig4.30).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.30: IRF4 regulatory network in activated B cells 
IRF4 rapidly increases expression on B cells after NP-Ficoll stimulation by BCR, and 
then reduces and stays at low level may be due to some miRNA expression, leading to the 
induction of AID. 
 
 
4.3.2 Plasmablast development in the GC response 
The rapid increase in IRF4 mRNA and protein expression after stimulation suggests that 
IRF4 may be a good marker to detect B cell activation. Taking advantage of this, spleen 
sections were stained at different times after immunization, to identify the location of 
activated B cells in different areas of the splenic white pulp. 
  
The experiments showed a distinctive distribution of IRF4 positive cells at different 
stages of the immune response (Fig. 4.15): Surprisingly IRF4 expression was already 
seen in some follicular naïve B cells and in T cells in the T zone. Occasional proliferation 
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in naïve T cells in the T zone has been described before (Luther SA 1997), possibly 
indicating homeostatic proliferation in naïve T cells. Similarly, naïve B cells have been 
shown to need occasional signals via their B cell receptor (Kraus M 2004). It is possible 
that IRF4 occasionally seen in follicular B cells corresponds to this process. 
  
2-3 days after immunization, cells expressing IRF4 were mainly clustered at the outer 
edge of the T zone. Some, but not all, of these were T cells. In primary responses T cell 
priming is apparent around day 3 (Luther SA 2007), and IRF4 expression in T cells in the 
T zone is likely to represent this phase of T cell activation. Within several hours of 
encountering TD antigens, antigen-engaged B cells migrate to the B-T boundary area by 
rapidly upregulating CCR7 while keeping CXCR5 expression unchanged (Reif K 2002). 
Other chemokine signals and/or adhesion molecules may be also involved to guide and 
retain cells into the place for encounter with primed T cells (Okada T 2006). Primed T 
cells in the T zone can interact with B cells, exchanging cytokines such as IL-4 and 
induce B cell proliferation and Ig class switch recombination (Toellner KM 1998). In 
addition, in the outer T zone CD11b+ DCs have been shown to be involved in B cell 
priming (MacPherson G 1999; Huang NN 2005). As discussed above, IRF4 is important 
for the regulation of B blast activation and Ig class switching (Huang NN 2005; 
Sciammas R 2006), Marshall, Zhang et al), and the intermediate level expression of IRF4 
in B cells 3 days after immunization are likely to reflect IRF4 activating these processes. 
 
After expression of IRF4 in B cells in the outer T zone, a wave of IRF4+ cells was 
observed in follicles 3–4 days after immunization. Others recently showed that activated 
B cells move to the outer follicles, before the formation of GCs (Coffey F 2009; Gatto D 
2009; Pereira JP 2009). The role of this differentiation phase is not clear.  
 
Germinal centre B cells typically lose expression of IRF4 (Falini B 2000; Cattoretti G 
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2006a; Klein U 2008), and the transcription factors IRF8, Bcl6, and HoxC4 (Park SR 
2009), cooperating with Oct2 are known to regulate the GC phenotype (Lee CH 2006; Lu 
2008). IRF4+ cells were seen at the GC-T zone interface at day4 post-immunization, just 
after GC formed. This population increased rapidly, reached peak levels at day5, and was 
lost after day5, even though GC still kept on developing for one more week. IRF4+ B 
cells in the GC–T zone interface lost all GC markers investigated. The cells express high 
levels of IRF4, and this seems to induce the plasmablast differentiation program: The 
cells at the GC–T zone interface have acquired several plasma cell markers, such as 
Blimp-1 and CD138, showing that these cells are terminally differentiating plasmablasts 
(Turner CA Jr 1994; Shaffer AL 2002).  
 
Recent experiments from our lab from lymph nodes 6-7 days after primary immunization 
with alum-precipitated NP-CGG could also identify an IRF4high plasmablast population in 
the GC–T zone interface. Microdissection and DNA sequencing could identify identical 
V186.2-DFL16.1-JH2 sequences with identical CDR3 shared between GC B cells and 
plasmablasts from the adjacent GC–T zone interface (Yeo, MRe Thesis, UoB 2008). The 
clonal relation of these cells suggests that plasmablasts at the GC-T zone interface are 
descendants of B cells in adjacent GCs. This raises the question whether the GC-T zone 
interface is a pathway for B cells differentiating to plasmablasts exiting from immature 
GCs. The current model of GC differentiation proposes the exit of cells after T cell 
interaction from the light zone (MacLennan 1994). However, occasional exit of GC cells 
via the dark zone has been observed in intravital studies (Hauser AE 2007a). 
 
Mature GCs from day 7 after immunization have few plasmablasts at the GC–T zone 
interface. Interestingly, IRF4+ cells after day 8 clearly presented in the GC light zone. 
These cells expressed intermediated levels of IRF4 and were in close contact with FDCs 
and TFH cells. IRF4 is absent from proliferating GC centroblasts and the majority of 
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centrocytes. Intermediate level IRF4 expression in the light zone may reflect the presence 
of several alternative, but not exclusive, differentiation processes occurring in the light 
zone B cells. The proximity of IRF4+ cells to T cells suggests that they may have recently 
received T cell signals. IRF4 expression in the light zone may reflect plasmablast 
differentiation from selected light zone B cells (Angelin-Duclos C 2000; Klein U 2006; 
Cattoretti G 2006a). The differentiation to plasmablast cells from light zone selected GC 
B cells may reflect the appearance of a more stable long-term surviving GC output. 
However, few of these cells express high levels of IRF4 or Blimp-1. Therefore, the 
majority of IRF4 positive cells observed in light zones of mature GCs were either 
observed just before high level expression of IRF4 was reached, which is unlikely, or are 
involved in other differentiation processes. Alternatively these cells may have been 
selected to recirculate within the GC. Intravital studies using IRF4 reporter mice would 
be a way to test this. Finally, IRF4int cells may be precursors of memory B cells, as IRF-4 
has been shown to be involved in the maturation of memory (Klein U 2006). The final 
wave of IRF4int B cells seen in follicles from day 8 after immunization may reflect the 
exit of these memory B cells from GCs. Memory B cells localization at the outer follicle 
have been detected in the recent research (Anderson SM 2007). Intravital studies have 
shown exit of GC B cells via this pathway (Schwickert TA 2007; Hauser AE 2007b). 
 
Differentiation and activation of B cells seen in both LZ and GC-T zone interface indicate 
that there seem to be two pathways of successfully selected GC B cell exiting GC:  
1) Early plasmablasts leaving via the dark zone-T zone interface rapidly producing GC 
derived plasma cells,  
2) High affinity plasmablasts and memory cells being selected in the GC light zone and 
recruit to long-term responses that efficiently clear antigens.  
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How is the appearance of cells in these two microenvironments regulated? Differences in 
the selection threshold between immature and mature GCs may be responsible for the 
different migration patterns. Furthermore, availability of mature accessory cells may play 
a role. 
 
As discussed in chapter 3, over the first days of the GC response the selection threshold 
changes dramatically. Appearance of plasmablasts at the basal part of the GC may be due 
to the low selection threshold in the early phase of the GC response. At this time antigens 
are already present on FDCs, but covered with very low affinity antibody. The high 
concentration of antigen in immune complex may be sufficient to induce T independent 
BCR stimulation in GCs. That the appearance of these cells may be independent from T 
cell signals can be concluded from the experiments, where T cell independent GCs were 
induced in QM mice after NP-Ficoll injection. On the other hand, significantly reduced 
IRF4+ plasmablasts were seen at the GC-T zone interface after injection with high avidity 
immune complex, indicating that competition with antibody in immune complex on 
FDCs is important for the appearance of these cells. This would support the suggestion 
that rare static centrocyte-FDC contacts are sufficient to drive affinity maturation and 
antibody production (Figge MT 2008). Later in the response strong competition with high 
affinity antibody may mean that GC B cells receive little signal from antigens on FDCs. 
At this stage T cell help may become important, and therefore B cell activation events 
move to the light zone, where the maximum of TFH cells are available (Gulbranson-Judge 
A 1996). These cells will provide signals that may induce different GC B cell 
differentiation outcomes (Butch AW 1993; Toellner KM 1995).  
 
Different sites of B cell activation may be linked to different accessory cells. Whilst in 
the light zone signals will be provided by FDCs and T cells (MacLennan 1994; Liu YJ 
1997a), the identity of cells providing signals for plasmablast differentiation in the GC–T 
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zone interface is not clear. In the red pulp plasmablasts differentiate into plasma cells, 
which are in close association with CD11c+ DCs (de Vinuesa CG 1999; MacLennan IC 
2003) and VCAM-1+ stromal cells expressing CXCL12 and/or BAFF (Cassese G 2003; 
Cyster 2003a). These are critical for survival and homing of plasmablasts /plasma cells. 
The B-T zone boundary also contains many CD11c+ DCs (Lindquist RL 2004), which 
were found to create tightly packed clusters with T and B lymphocytes in TD immune 
responses (Liu YJ 1991; Okada T 2006). They may be involved in the plasmablast 
differentiation similar their functions in red pulps. 
 
Studies in human tonsil found that T cells in the GC–T area interface express preformed 
CD40L, similar to expression by TFH cells (Casamayor-Palleja M 1995). CD40 ligation 
on B cells, via interaction with CD40L expressed on TFH cells, has been shown to 
downregulate Bcl6 through NF-kB activation and consequent activation of IRF4 (Saito M 
2007). The peak number of antigen specific T cells appears in the edge of T zone at the 
immature GC stage (Gulbranson-Judge A 1996). These CD4+ T cells in the GC-T zone 
interface may provide similar functions as TFH cells in light zones. This remains to be 
investigated by adoptive transfer and activation of labelled antigen specific T cells. 
Immunofluorescent staining further showed IRF4+ cells were associated with BP-3+ 
stromal cells and CD3-CD4+ Lti cells at the GC-T zone interface. Defects in the immune 
response to TI-2 antigens in BP3-/- mice suggested that BP-3 cells may contribute to 
splenic plasma cell niches even though the detailed mechanism was not clear (Itoh M 
1998). CD4+ Lti cells constitutively express a diverse set of TNF ligands (TRANCE, 
TNF-α, and lymphotoxins α and β, OX40L, and CD30L) (Kim MY 2003). Former work 
from the Lane group supports an important role for CD30L and OX40L from CD3-CD4+ 
Lti cells, enabling T cells to activate B cells during memory responses (Gaspal FM 2005; 
Lane PJ 2005; Lane PJ 2008; Withers DR 2009). We suggest that Lti cells may also 
mediate immune response of B cells by direct co-stimulatory signals to B cells (K. Perk, 
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Thesis UoB in preparation). In vitro research implied that TNF-α may enhance plasma 
cell survival (Cassese G 2003). In the B/T zone interface CD3-CD4+ LTi cells associate 
closely with CD3+CD4+ T cells, CD11c+ DCs and VCAM-1 stroma cells which may be 
important in directing the migration of lymphocytes via chemokines (Kim MY 2003; 
Bekiaris V 2007; Kim MY 2007). Taken together, all these cells (DCs, BP3 cells, LTi 
cells) are possibly involved in the generation of the IRF4+ plasmablasts at the GC-T zone 
interface by providing cytokines, co-stimulatory signals, and chemokines. 
 
4.3.3 Effects of cytokines, co-stimulatory molecules and chemokines on the 
appearance of GC–T zone interface plasmablasts. 
To study effects of factors inducing differentiation and migration of B cells into 
plasmablasts in the GC–T zone interface, two approaches were used. Firstly, animals with 
targeted deletions available in Birmingham or from collaborating partners were used. 
This approach allows the study of the deficiencies occurring in the absence of cofactors, 
but it can be difficult to conclude whether a cofactor is necessary during stages of the 
immune response, or much earlier in the development of the environment, in which the 
immune response occurs. Furthermore, it is not clear which cell type the defect is 
occurring in. For example, IL-6 deficiency has a large effect on appearance of GCs and 
delays onset of GC development, but it is not clear which cell is essential for production 
of IL-6, and whether IL-6 has effects directly on B cells, or on the differentiation of some 
accessory cell.  
 
Therefore, to obtain information on the spatial relationships, and where cofactors are 
produced, laser microdissection followed by quantitative RT-PCR was used. This 
technique provides good information about the location of cytokines and chemokines at a 
certain time after immunization. Due to time constraints it was not possible to perform 
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time courses and get information about the temporal appearance of these factors, but this 
is a refinement to our experiments that may be pursued in the future. The problem with 
microdissection is that information of the location of a factor can be gained, but the 
spatial resolution is quite limited, probably 10-20µm. The subcellular resolution of 
immunohistology cannot be reached, and there is no connection between gene expression 
and individual cells. This is a problem if an area contains a mix of cells, as it is the case 
for the GC-T zone interface. A good example is CXCR4, which has been shown to be 
highly expressed in all GC–T zone interface plasmablasts. However, because the GC–T 
zone interface is a mix of plasmablasts and many T cells, the PCR signal from this area is 
weaker than that from GCs, where every cell expresses this receptor, but at lower levels. 
CD3ε and CD19 were used as controls to estimate the cellular composition in different 
microdissected areas. Still, microdissection has advantages over immunohistology, as 
soluble factors i.e. chemokines and RNAs, for which no antibodies are available, such as 
switch transcripts can be detected. 
 
4.3.3.1 Cytokines and costimulatory molecules 
IL-4 and IL-13 are likely to have effects on the interaction of GC T cells and B cells, and 
are know to have effects on Ig class switching (Cunningham AF 2002). However, both 
cytokines are able to replace each other in single gene deficient animals (Cunningham AF 
2004a), and therefore effects on plasmablast differentiation in single gene deficient 
animals were not seen. Using IL-4Rα deficient animals overcome this problem, here GC 
onset is delayed, and plasmablast output from GCs 5 d after immunization is negligible. 
mRNAs for IL-4 and IL-13 are produced at very low levels in Th2 differentiated cells 
(Serre K 2009), and therefore they are not detectable by microdissection.  
 
As mentioned above IL-6 has various effects on B cell differentiation. GC differentiation 
was delayed, and GC plasmablast output was strongly suppressed. IL-6 has been reported 
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to directly stimulate activated B cells to secret antibody (Randall TD 1993). In addition, a 
recently study from Wu et al found that IL-6 derived from immune complex-activated 
FDC could promote the GC reaction, somatic hypermutaion and IgG production(Wu Y 
2009). In vitro, IL-6 can stimulate IL-6 deficient GC cells isolated from KO mice into 
cell cycle progression, and increase antibody production (Kopf M 1998). IL-6 mainly 
acted on GC B cell directly via IL-6R and gp130, and indirectly by promoting the C3 
production in the local environment (Kopf 1998). In addition, IL-6 has also a profound 
effect on survival and proliferation of CD4 T cells and Th17 differentiation (Dienz O 
2008), and in this way may reduce T cell help for B cells, further declining the GC 
reaction and plasma cell production.  
 
IL-10 has a broad effect in regulating the T cell-mediated immune response (Moore KW 
2001; Maynard CL 2008). As for IL-6, the GC response was reduced, and output of 
IRF4+ plasmblasts at the GC-T zone interface significantly reduced. For some time IL-10 
has been known as a factor that can induce plasma cell differentiation. IL-10 has been 
reported to enhance proliferation and differentiation of B cells (Moore KW 1993). It was 
originally known as plasma cell differentiation factor (Maliszewski CR 1993; Arpin C 
1995; Choe J 1998). IL-10 is produced by GC T cells (Butch AW 1993; Toellner KM 
1995), and can lead to differentiation of GC B blasts to plasma cells. The defect in IL-10 
KO mice possibly suggests a role of GC T cell–centrocyte interactions for the 
differentiation of GC-derived plasmablasts.  
 
Similar to IL-10, IL-21 is produced by TFH cells. IL-21 has a minimal effect for TFH 
expansion, and development, but is important to regulate growth and differentiation of T 
and B cells directly (Ettinger R 2008; Zotos D 2010). Particularly IL-21 is required for 
the efficient formation of plasma cells (Ozaki K 2002; Odegard JM 2008). IL21 from GC 
T cells controls the expression levels of Blimp-1 and Bcl-6 via STAT3 (Ozaki K 2004; 
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Calame 2008; Haynes 2008; Kwon H 2009). IL-21/IL-21R KO mice have fewer NP+ 
plasmablasts/plasma cells in red pulps after NP-KLH injection (Zotos D 2010). The result 
that far fewer GC-derived IRF4+ plasmablasts develop at the GC-T zone interface 
supports the idea that TFH cell - GC B cell interaction has a role in the differentiation of 
the IRF4+ plasmablats at the GC-T zone interface.  
 
The IL-10 family member IL-22 has been mainly described as having roles in the early 
host defense against microbial pathogen, tissue repair, wound healing and the 
homeostasis of epithelia (Wolk K 2006; Zenewicz L 2007; Zheng Y 2007; Zheng Y 2008; 
Pickert G 2009). IL-22 receptor expression has been described so far on epithelial cells, 
but not on B cells (Wolk K 2004; Jones BC 2008). IL-22 deficiency resulted in increased 
numbers of GC associated plasmablasts. IL-22 mRNA was amplified from GCs and in 
the GC–T zone interface. IL-22 is not only produced by T helper cells (Kreymborg K 
2007; Colonna 2009), but also is produced by adult lymphoid tissue inducer (Lti) cells, 
which are located in the GC-T zone interface (Takatori H 2009). As adult Lti cells express 
further signals (e.g.CD30L, OX40L) that influence B cell differentiation (K. Perks, 
Thesis UoB), both GC T cells and Lti are candidates as producers of this cytokine. IL-22 
deficiency also resulted in increased numbers of T cells in LZ. Therefore, the increased 
production of plasmablasts may be also due to an indirect effect, as increased numbers of 
T cells may increase availability of positive selection signals.  
 
BAFF and APRIL and their receptors play important roles in the differentiation of B cells 
and plasmablast (Moisini I 2009). BAFF is also important for the formation of follicular 
dendritic cells, and can influence Ig hypermutation (Kalled 2006). APRIL has been shown 
to be associated with plasma cell differentiation and loss of proliferation (Mohr E 2009). 
Interestingly, TACI was strongly upregulated at the GC–T zone interface. TACI interacts 
with APRIL, which is produced by Lti cells (Kim MY 2008). And APRIL was detected at 
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the mRNA level in the GC–T zone interface. Plasmablasts leaving from this area and then 
migrating to the red pulp express further TACI and seemingly upregulate BCMA, which 
may interact with APRIL, produced in the same area. BAFF and BAFF-R seem to be more 
important in the GC, and lost after cells leave the GC. 
 
Adult CD4+CD3- LTi cells also express CD30L and OX40L, mediating T cell memory. 
Signals through CD30 and OX40 have been shown to be important for long term 
development of GCs, and B cell memory (Gaspal FM 2005; Lane PJ 2006). CD30 is 
expressed on activated murine T and B cells, and stromal cells in murine lymphoid 
tissues (Seko Y 1999; Bekiaris V 2007). CD30 has complex functions, depending on the 
cell type, stage of development, and presence of other stimuli (Review on Kennedy 2006). 
For B cells, CD30L expressing cells in the presence of cytokines (IL-2, IL-4 and/or IL-5) 
induce B cells to proliferate, differentiate and produce antibodies in vitro (Shanebeck KD 
1995). CD30 co-engagement may downreguate isotype switching in human B cells 
(Jumper MD 1995; Cerutti A 1998). OX40, initially identified as T-cell activation marker, 
can promote effector T-cell expansion and survival, and enhance cytokine production, and 
but not control initial activation and proliferation (Watts 2005; Croft M 2009). 
OX40/OX40L can augment the accumulation of T cells in B cell follicles (Brocker T 
1999; Fillatreau S 2003). OX40 can have roles in the maintenance of follicular T cells 
(Gaspal FM 2005). A study in our lab on effects on CD30 and OX40 deficiency on 
responses to TI-II antigens (e.g. NP-Ficoll) showed that B cell expressed CD30 and 
OX40, possibly interacting with CD30L and OX40L on LTi cells, have opposite effects 
on plasmablast differentiation: whilst CD30 deficiency resulted in faster onset of 
plasmablast responses, OX40 deficiency resulted in lower and delayed responses (K. 
Perks, thesis UoB, in preparation). Our experiments showed similar effects of CD30 and 
OX40 deficiencies on the appearance from plasmablasts from GCs, which would be 
compatible with a role of Lti cells located in the GC–T zone interface for differentiation 
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of GC-derived plasmablasts.  
 
Germinal centre was found to form in OX40 KO mice, but significantly bigger than WT 
after SRBC stimulation. B cells are activated at the same speed as T cells are primed 
(Toellner KM 1996), and so activated B cells could establish a GC reaction with follicular 
T cells at the beginning. OX40 deficiency impaired the late proliferation of effective 
CD4+ T cells and shortened T cell survival, and so GC B cells just did abnormal 
expansion without effective follicular T cell help, resulting in less GC B cells than could 
normally developed, differentiation into plasmablasts. As prediction, much less IRF4+ 
cells were detected at the GC-T zone interface in OX40 deficient mice. Less output 
further helps explain the larger GC size. Possibly, the data will support the suggestion that 
IRF4+ plasmablasts mainly derive from GC B cells, which need contact with TFH cells for 
proliferation and selection in response for TD antigens.   
 
More severe impairment of the B/T segregation and much smaller T zones were detected 
in CD30OX40 dKO mice. Abnormal and bigger GC formed, and much less IRF4+ 
plasmablats at GC-T zone interface, and IRF4+ plasma cells in the red pulp, were detected. 
Both OX40 and CD30 were not required for the GC initiation and plasma cell production. 
OX40 and CD30 could have overlapping functions in the maintaining of CD4 T cells via 
OX40L and CD30L expressed on LTi cells in the light zone and the B/T interface (Lane 
PJ 2005). CD30 signals are essential for podoplainin expression on T zone VCAM-1+ 
stroma cells in maintaining the B/T segregation (Bekiaris V 2007), and so CD30 
deficiency impaired the functions of VCAM+ stroma for T cell homing. CD11c+ DC 
expressing OX4OL, could lead CD4 T cells to accumulate in the follicle (Brocker T 
1999). Therefore CD30OX40 dKO could directly affect the normal development of CD4 
T cell, and reduce the functions of LTi cells, DCs, and stromal cells for T cells via 
ligation with OX40L and CD30L. These factors together aggravate the impairment of B 
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cell responses.   
 
In conclusion, cytokines IL-10 and IL21, possibly derived from GC T cells, seem to have 
a role for the differentiation of GC-derived plasmablasts. Lti cells in the GC–T zone 
interface, are stronger candidates for a role for providing signals directly in the GC–T 
zone interface. They are known to produce APRIL, IL-22, OX40L, CD30L (Kim MY 
2008) (summary on Fig 4.31). An argument for T cells not being directly involved in the 
differentiation of these cells is that AID mRNA and IgG1 switch transcript production 
was very low. Therefore the GC associated plasmablasts do not seem to be under the 
influence of T cell derived Ig class switch inducing cytokines, such as IL-4 and IL-13, 
although a high proportion is Ig class switched, as seen by the high levels of Iµ-Cγ1 
recombined heavy chain transcripts.  
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Figure 4.31: The expression of cytokines, co-stimulatory signals for B cell 
differentiation and survival at the different areas of the murine spleen at the stage1 
of GC development 
GC B cells get helps from TFH cells by co-stimulatory signal such as CD40L, and 
cytokines i.e. IL-21 and IL-10, for the survival and differentiation. BAFF high expression 
in GCs promote B cells survival and Ig CSR, and provide the survival signal plasma cells 
in the red pulp. Particularly, LTi cells produce OX40L and CD30L in the GC-T zone 
interface, which are important for the proliferation of GC B cells and differentiation into 
plasmablasts. APRIL expressed by LTi cells may  provide the similar functions for  
IRF4+ plasmablasts at the GC-T zone interface as in the red pulp.  TACI also expresses 
at the detected level at this area.  
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4.3.3.2 Chemokines  
Chemokines and their receptors play important roles for the cell activation and migration. 
Within secondary lymph organs the majority of B cells and a fraction of primed CD4 T 
cells localize to follicles dependent on their expression of CXCR5 and the localized 
expression of its ligand CXCL13 by follicular stromal cells (Müller G 2003; Cyster 2005). 
Interestingly, CXCR5 and CXCL13 mRNA were found in high concentrations in the 
GC–T zone interface, indicating that plasmablasts exiting from the GC is not mediated by 
loss of sensitivity to this chemokine. IRF4 can promote expression of CXCR4 (Johnson 
K 2008). CXCR4 is a significant chemotactic factor for plasma cell precursors to home in 
the red pulp and subsequently in bone marrow. Its ligand CXCL12 is strongly expressed 
by VCAM-1+ stromal cells, and also was reported to enhance plasma cell survival in vitro 
(Cassese G 2003). The scavenger receptor binding CXCL11 and CXCL12 (Balabanian K 
2005; Burns JM 2006; Thelen M 2008) can remove soluble CXCL12 without signalling, 
this way producing a CXCL12 gradient (Naumann U 2010). Accordingly, CXCR7 was 
found in all microdissected follicular areas, and CXCL12 was found to be strongly 
expressed in the GC–T zone interface, with little expression in the GC. A CXCR7 
induced sink in the follicle may produce a strong CXCL12 gradient, which would induce 
a quick transfer of CXCR4 high plasmablasts towards the T zone. Increased CCR7 
expression on cells (such as naive T cells, some B cells, DCs) favours them to localize in 
T zone, and CCL19 and CCL21 are the only ligands for CCR7, expressed in T zone 
(Cyster 2005). CCR7 and CCL21 are not produced in the GC environment, but strongly 
expressed in the GC–T zone interface. A summary of the chemokine data is given in Fig. 
4.32 
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Figure 4.32: The expression of main chemokines and their receptors at the different 
areas of the murine spleen at the stage1 of GC development 
The expression of CXCL13 and CXCR5 in follicles and GCs lead B cells to localize in 
GCs. The upregulation of CXCR4 on the IRF4+ plasamblasts guild cells move into the 
CXCL12 rich area. CCR7 expression also helps the homing of IRF4+ plasmablasts at the 
GC-T zone interface. GC-T: GC-T zone interface. GC: Germinal centre. LTi: Adult 
lymphoid inducer cells 
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Conclusion 
 
T-cell dependent responses are initiated when naïve B cells encounter antigen and migrate 
to the outer T zone (Cyster JG 2002; Campbell DJ 2003), where they become fully 
activated by interacting with antigen-specific CD4+ T helper cells and antigen-presenting 
cells. 
 
Activated B cells may adopt one of two fates: either migration into the extrafollicular foci 
to differentiate into short-lived plasma cells, or movement into the follicles to form 
germinal centres in the primary follicle (Jacob J 1991; Liu YJ 1991). After initial phase in 
which B blasts expand in-between FDC in follicles, mature germinal centres develop 
which consist of two histologically distinct zones: the dark zone and the light zone (Stage 
2) (MacLennan IC 1990). In the dark zone, centroblasts proliferate and diversify their Ig 
variable genes by the process of somatic hypermutation (SHM). B cells then test their 
modified antibodies for improved antigen binding in the light zone. The data presented 
here are compatible with centrocytes having to compete for antigens with antibody in 
immune complexes on FDCs to receive survival signals. There may be additional 
competition between B blasts with processed antigen for help from TFH cells 
(Meyer-Hermann ME 2006; Allen CD 2007b). B cells that are unsuccessful die by 
apoptosis (Liu YJ 1997a) and are taken up by macrophages. Centrocytes that are selected 
are thought to migrate back to the dark zone where they undergo further proliferation and 
SHM (MacLennan 1994). Alternatively, selected centrocytes differentiate into plasma 
cells or memory cells (MacLennan 1994). 
.  
Germinal centres have been described to develop in stages: Whilst stage 1 germinal 
centres developing in the first week after immunization mainly contain germinal centre 
founding blasts, which proliferate in FDC networks in secondary follicles, stage 2 
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germinal centres have separated into dark zones with highly proliferative centroblasts and 
light zones containing centrocytes, FDCs and apoptotic bodies (MacLennan IC 1990) 
(Fig. 5.1).  
 
Initially the B blasts in early germinal centres will only be competing with low affinity 
antibody, which is either natural antibody cross-reacting with the antigen, or antibody 
produced from non-affinity-matured plasma cells from the early extrafollicular response 
(Tew JG 1997). Therefore, many B blasts will easily receive positive selection signals 
even after short contact with antigen on FDCs (Allen 2007a, Schwickert TA 2007, Figge 
2008), and may be less dependent on the help from TFH cells in the light zone. The 
migration of primed T helper cells from the T zone to follicles is only complete 3 days 
after the onset of germinal centre development (Gulbranson-Judge A 1996). More T cell 
help may be available at the GC–T zone interface (Fig. 5.1 A). Other accessory cells 
providing signals for the development, migration and survival of the early GC derived 
plasmablasts may be adult LTi cells, located in close contact with stromal cells in the 
GC-T zone interface. Selected cells may rapidly differentiate into early plasmablasts 
upregulating IRF4 at the GC-T zone interface. From there they will leave along the outer 
T zone, and finally into the red pulp (Fig. 5.1A). Selected cells may also do recycling and 
affinity maturation, which will lead to an increasing affinity of the plasma cell population 
outside germinal centres. This high affinity antibody will produce a positive feedback by 
replacing the low affinity antibody in the GC (Tew JG 1997), resulting in raising the the 
selection threshold for centrocytes (Fig. 5.1 B). As antigen-derived signals from FDC at 
later stages will be more difficult to obtain, T cell help may become more important 
(Meyer-Hermann ME 2006; Allen CD 2007b). More TFH cells appear in GCs at this stage 
(Gulbranson-Judge A 1996; Ansel KM 1999). This will reduce plasmablast output from 
the GC (Fig. 5.2). Because B cells need more time to acquire appropriate selection signals 
from FDCs and TFH cells, a wave of light zone emigrant develops. Light zones are 
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characterized by centrocytes that less proliferate, apoptotic cells and TFH cells 
(MacLennan IC 1990). Recent intravital studies have shown that germinal centres 
develop in stages. Initial two-photo imaging experiments showed that GC B cells travel 
between FDC, and GC B cells transit between the dark and light zone evenly in both 
directions (Schwickert TA 2007; Allen CD 2007a; Hauser AE 2007a). Recent studies at 
later stages after immunization show that B cells migrate preferentially from the dark 
zone to the light zone, and fewer cells move back (Schwickert TA 2009), showing that in 
mature germinal centres the light zone represents a sink with a net loss of cells, indicating 
a higher selection pressure at later stages of the response. Latest intravital studies have 
shown that the speed of GC B cell migration changes considerably over the course of a 
GC response: whilst GC B cells in immature GC move slowly, mature GC B cells show 
rapid movement between FDCs and T cells (A. Hauser, DRFZ, Berlin, personal 
communication). This may be explained by changes in the availability of antigen and the 
need for additional signals from other cell types (i.e. FDC and T cells). The rise in 
antibody affinity will ultimately lead to a non-sustainable selection threshold, which may 
end the germinal centre reaction or lead to stage 3 germinal centres, which consist of 
small foci of proliferating cells (MacLennan IC 1990). These may be sustained through 
repeated restimulation of recirculating memory B cells on high affinity immune 
complexes deposited on FDC.  
 
A positive feedback loop, where the germinal centre selection threshold is controlled by 
antibody from germinal centre derived plasma cells will stabilize and prolong the 
germinal centre reaction, as the slow increase in selection threshold will lead to efficient 
centrocyte selection over a longer period. This may result in a more efficient affinity 
increase at the beginning of the response, but also lead to higher final affinities. 
Furthermore, antibody feedback may lead to competition between unrelated germinal 
centres. Ultimately, this mechanism may abort the germinal centre reaction at the time 
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when hypermutation and Darwinian selection have led to optimal affinity, and no further 
affinity improvement can be gained by further mutation. 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Development of germinal centres (adapted from MacLennan, I.C. et al 
(1990). The evolution of B-cell clones) 
A: Immature germinal centres consist of proliferating B blasts the fill the FDC network. 
At this stage antigen is deposited in the form of immune complex with low affinity 
antibody. B blasts at this stage may have easy antigen access, and FDC – B blast 
interaction may be sufficient to produce positive selection. Accessory signals may be 
provided by adult LTi in the GC – T zone interface and by primed antigen-specific T cells, 
which may be available in high numbers in the outer T zone. B: Mature germinal centres 
suffer from a high selection threshold controlled by antibody produced by germinal 
centre derived plasma cells. This will lead to the stringent selection on FDC. As signals 
from FDC will be less easy to obtain, T cell help may become more important, which 
may induce different selection outcomes, such as differentiation of memory B cells, high 
affinity long-lived plasma cells or further recirculation. BB: B Blast; CC: Centorcyte. Ag: 
antigen; FDC: Follicular dendritic cell; PB: Plasmablast, LTi: Adult Lymphoid tissue 
inducer cell; T: CD4+ T helper cell, CB: Centroblast, PC: Plasma cell. 
 
 
 200
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: The antibody affinity in ICs in the GC and GC emigrants during the GC 
reaction 
At the beginning of GC development, low affinity antibody in immune complexes (ICs) 
on FDCs is natural antibody produced from the early extrafollicular response (blue line). 
B blasts in germinal centres easily gain access to antigen, and are successfully selected to 
recycle or differentiate into the early IRF4+ plasmablasts that exit from the GC-T zone 
interface (black line). As the antibody affinity from GC output increases, higher affinity 
antibody will positively feedback on the GC selection threshold (blue line). This will lead 
to reduce plasmablast output from the GC, and induce stringent selection of B cells, 
involving interaction with TFH cells in the germinal centre light zone (red line).  
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Appendix 
 
Table1: Primers for genotyping QMxB6 
Primer Sequence 
Fwd GTGGGGCGCTCTAGGCACCA β-actin  
Rev CGGTTGGCCTTAGGGTTCAGGGGGG 
Fwd TTCAGAGGTTCAGCTGCAGCAGT NP 
Rev CTYACCTGAGGAGACDGTGA 
Fwd TCGCCTTCTATCGCCTTCTT Jh 
Rev GCCCCAACTATCCCTCCA 
Fwd AGCTCCCATACTTCATGGCCA JhWT 
Rev TTGGTCCTGAAGGCCCAGAAT 
Fwd CTGGTGCTTTACGGTATCGC Kappa 
Rev GTAGAAGGCTCAAGGTTGTG 
Fwd TGCTGCACCAACTGTATCCA Kappa WT 
Rev CAGGACGCCATTTTGTCGT 
 
 
Table2: primers for genetyping Cγ1-Cre+/-× R26 eYFP+/- 
 
Primers for Cγ1-Cre+/- 
Primer A: IgG1 Kpn1Fw: TGTTGGGACAAACGAGCAATC 
Primer B: Cg1-cre Fw: GGTGGCTGGACCAATGTAAATA 
Primer C: IgG1 Rev3: GTCATGGCAATGCCAAGGTCGCTAG 
Cg1-Cre allele using primers: Cg1-cre fw+ IgG1-Rev3: 455 bps 
Cg1 wild-type allele using primers IgG1 Kpn1 fw+ IgG1-Rev3: 240 bps 
 
Primers for R26eYFP+/- 
Primer1: oIMR0883: AAAGTCGCTCTGAGTTGTTAT 
Primer2: oIMR0316: GGGGCGGGAGAAATGGATATG 
Primer3: oIMR4982: AAGACCGCGAAGAGTTTG TC 
Wildtype using primer1+Primer2: 600bps 
Mutant using Primer1+ Primer3: 320bps 
 
 
 
 
 
 
 
Table3: Sequence of primers and probes used for RT-PCR 
Primers Forward primer sequence Reverse Primer Sequence Probe sequence 
IRF4 GGAGGACGCTGCCCTCTT TCTGGCTTGTCGATCCCTTCT FAM  AGGCTTGGGCATTGTTTAAAGGCAAGTTC  BHQ1 
Blimp-1 CAAGAATGCCAACAGGAAGTATTTT CCATCAATGAAGTGGTGGAACTC FAM  TCTCTGGAATAGATCCGCCA   MGB 
XBP-1 GGTGCAGGCCCAGTTGTC CAAAAGGATATCAGACTCAGAATCTGAA FAM  TCCCATGGACTCTGACACTGTTGCCTC  MethRed 
AID GTCCGGCTAACCAGACAACTTC GCTTTCAAAATCCCAACATACGA TET  GCTTTCAAAATCCCAACATACGA  BHQ1 
Bcl-6 CAGACGCACAGTGACAAACCA ACTGCGCTCCACAAATGTTACA CalFlour 560  ACTGCGCTCCACAAATGTTACA   BHQ1 
PAX 5 GCTGTTGGCAGAGCGAGTCT AGCTGGGACCGGCTGATT FAM  ACACTGTGCCCAGCGTCAGCTCC  MethRed 
IgG1 ST CGAGAAGCCTGAGGAATGTGT GGAGTTAGTTTGGGCAGCAGAT FAM  TGGTTCTCTCAACCTGTAGTCCATGCCA   BHQ1 
IuCu TCTGGACCTCTCCGAAACCA CCAGGGTCACCATGGAGTTAGT FAM  TGCCAAAACGACACCCCCATCTGT MethRed 
J Chain GTCCTGGCCATTTTTGTTAAGG ACATGCATTTGTTGTCAGCAAGA FAM  TGGTCGCTTCGTCGTCACCTGTTACA  MethRed 
CXCR5 GCTCTGCACAAGATCAATTTCTACTG CCGTGCAGGTGATGTGGAT FAM  CCATCGTCCATGCTGTTCACGCC   BHQ1 
CXCL12 CAAGCATCTGAAAATCCTCAACAC CACTTTAATTTCGGGTCAATGCA FAM  TGCACGGCTGAAGAACAACAACAGACAA   BHQ1 
IL-4 GATCATCGGCATTTTGAACGA AGGACGTTTGGCACATCCAT FAM  TGCATGGCGTCCCTTCTCCTGTG  MethRed 
IL-21 ACACCCAAAGAATTCCTAGAAAGACTAA TGCATTCGTGAGCGTCTATAGTG FAM  AGCATCTCTCCTAGAACACATAGGACCCGAAGAT  BHQ1 
CD40L CTCAAATTGCAGCACACGTTGTA TCAAGCATTACCAAGTTGCTTTTC FAM  AGCATCCGTTCTACAGTGGGCCAAGA  BHQ1 
CD30 GATCAGCCACGGCTATATGGTGAG AGCGGCAGGTTCTCCAAGGGTA FAM  CACACCAGCAGTCAATTCCTG   BHQ1 
OX40 AAGATGGCTCAGTGCAACTTCC CAAGGTGGGTGGAGAGGGGCAA FAM  TCTGCAGATGTAGACCAGGCA  BHQ1 
BAFF GAAGTGTGCCATGTGAGTTATGAGA TCACCCAAGGCAAAAAGCA FAM  TCCTTTGCCAACACGCACCGC  dark 
BAFF-R ACTTCAGAAGGAGTCCAGCAAGAG CAGGTAGGAGCTGAGGCATGAG FAM  CCCTGGAAAATGTCTTTGTACCCTCCTCA  BHQ1 
APRIL CGAGTCTGGGACACTGGAATTT AGATACCACCTGACCCATTGTGA FAM  CTGCTCTATAGTCAGGTCCTGTTTCATGATGTGAC  BHQ1 
TACI CATTCTGCCCCAAAGATCAGTAC TGCTCTTTTCGGCAATTGATG FAM  CAGCCAGAGGAGCCAGCGCAC  BHQ1 
BCMA TCCAACCCTCCTGCAACCT CGTGTACGTCCCTTTCACTGAA FAM  TCAGCCTTACTGTGATCCAAGCGTGACC  BHQ1 
CCL19 CCTTCCGCTACCTTCTTAATGAAG, ACAGAGCTGATAGCCCCTTAGTGT FAM  TGCAGGGTGCCTGC  TAMRA 
CCL21 TCCCGGCAATCCTGTTCT-C TTCTGCACCCAGCCTTCCT FAM  CCCCGGAAGCACTCTAAGCCTGAGCTAT  BHQ1 
β2-mglob CTGCAGAGTTAAGCATGCCAGTAT ATCACATGTCTCGATCCCAGTAGA CalFluor560/NED  CGAGCCCAAGACC  (BHQ1/MGB) 
β-actin CGTGAAAAGATGACCCAGATCA TGGTACGACCAGAGGCATACAG Yakima Yellow  TCAACACCCCAGCCATGTACGTAGCC  dark 
*: All primers from MWG erofins (UK), probes from Applied Biosystems (UK) 
**: CD3ε, CD19, CCR7, CXCR3, CXCR4, CXCR7, CXCL9, CXCL10, IL-10Rα TaqMan gene expression assay (Applied Biosystems UK) 
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